Clinical management and 
infection prevention and 
control for mpox 
Living guideline 
May 2025 
 
  
  
Clinical management and 
infection prevention and 
control for mpox 
Living guideline 
May 2025 
 
© World Health Organization 2025 
Some rights reserved. This work is available under the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; 
https://creativecommons.org/licenses/by-nc-sa/3.0/igo).  
Under the terms of this licence, you may copy, redistribute and adapt the work for non-
commercial purposes, provided the work is appropriately cited, as indicated below. In any use 
of this work, there should be no suggestion that WHO endorses any specific organization, 
products or services. The use of the WHO logo is not permitted. If you adapt the work, then 
you must license your work under the same or equivalent Creative Commons licence. If you 
create a translation of this work, you should add the following disclaimer along with the 
suggested citation: “This translation was not created by the World Health Organization 
(WHO). WHO is not responsible for the content or accuracy of this translation. The original 
English edition shall be the binding and authentic edition”.  
Any mediation relating to disputes arising under the licence shall be conducted in 
accordance with the mediation rules of the World Intellectual Property Organization 
(http://www.wipo.int/amc/en/mediation/rules/
). 
Suggested citation. Clinical management and infection prevention and control for mpox: 
living guideline, May 2025. Geneva: World Health Organization; 2025. 
https://doi.org/10.2471/B09434. Licence: CC BY-NC-SA 3.0 IGO. 
Cataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/. 
Sales, rights and licensing. To purchase WHO publications, see 
https://www.who.int/publications/book-orders. To submit requests for commercial use and 
queries on rights and licensing, see https://www.who.int/copyright.  
Third-party materials. If you wish to reuse material from this work that is attributed to a 
third party, such as tables, figures or images, it is your responsibility to determine whether 
permission is needed for that reuse and to obtain permission from the copyright holder. The 
risk of claims resulting from infringement of any third-party-owned component in the work 
rests solely with the user. 
General disclaimers. The designations employed and the presentation of the material in this 
publication do not imply the expression of any opinion whatsoever on the part of WHO 
concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps 
represent approximate border lines for which there may not yet be full agreement 
The mention of specific companies or of certain manufacturers’ products does not imply that 
they are endorsed or recommended by WHO in preference to others of a similar nature that 
are not mentioned. Errors and omissions excepted, the names of proprietary products are 
distinguished by initial capital letters 
All reasonable precautions have been taken by WHO to verify the information contained in 
this publication. However, the published material is being distributed without warranty of any 
kind, either expressed or implied. The responsibility for the interpretation and use of the 
material lies with the reader. In no event shall WHO be liable for damages arising from its 
use. 
 
i 
Contents 
1. Executive summary  ................................................................................ xviii 
1.1 Clinical question: What are the clinical and IPC interventions to use in caring for 
patients with mpox? ......................................................................................................................... xviii 
1.2 New infection prevention and control recommendations .................................................. xviii 
1.3 New clinical management recommendations............................................................................xix 
2. Introduction  ................................................................................................ 1  
2.1 Mpox clades ............................................................................................................................................. 1 
2.1.1 Update of mpox outbreaks by virus clade using of evidence available 
by January 2025 ...................................................................................................................................... 1 
2.1.2 Clade Ia MPXV ...................................................................................................................... 1 
2.1.3 Clade Ib MPXV ..................................................................................................................... 2 
2.1.4 Clade IIa MPXV ..................................................................................................................... 3 
2.1.5 Clade IIb MPXV .................................................................................................................... 3 
2.2 Natural history ........................................................................................................................................ 4 
2.3 Signs and symptoms ............................................................................................................................ 4 
2.3.1 Severe disease and complications ................................................................................. 6 
2.4 Laboratory findings ............................................................................................................................... 6 
2.5 Differential diagnosis ............................................................................................................................ 6 
2.6 Pregnant people and postpartum period ..................................................................................... 7 
2.7 Mid-and-long-term effects................................................................................................................. 8 
2.8 Transmission and viral shedding ...................................................................................................... 8 
2.8.1 Infectious period................................................................................................................ 10 
2.8.2 Children ................................................................................................................................ 11 
2.8.3 Wastewater surveillance ................................................................................................. 11 
3. Who do these recommendations apply to?  ............................................. 12 
3.1 Risk factors for severe disease......................................................................................................... 12 
3.2 Prognosis ................................................................................................................................................ 15 
3.2.1 Risk for adverse outcomes ............................................................................................. 15 
3.3 Rate of complications ......................................................................................................................... 15 
 
 
ii 
3.3.1 Rate of complications ...................................................................................................... 15 
4. Recommendations for the mpox care pathway  ....................................... 17 
4.1 Screening and triage ........................................................................................................................... 17 
4.1.1 Screening ............................................................................................................................. 17 
4.1.2 Triage ..................................................................................................................................... 18 
4.2 Testing for mpox ................................................................................................................................... 20 
5. Recommendations  for patients  with mild or uncomplicated  mpox (home-
based care) ................................................................................................ 21 
5.1 Infection prevention and control (IPC) considerations in home-based care ................. 21 
5.1.1 Infection prevention and control measures............................................................ 22 
5.1.2 Isolation of patients with mpox ................................................................................... 25 
5.1.3 Symptomatic management ........................................................................................... 31 
6. Recommendations for patients at high risk and those with complications 
or severe mpox  ......................................................................................... 37 
6.1 Infection prevention and control in health facilities (New recommendations) ............. 37 
6.1.1 Infection prevention and control considerations ................................................. 39 
6.1.2 Visitors to isolated mpox patients .............................................................................. 46 
6.1.3 Optimized supportive care ............................................................................................ 46 
6.2 Timing of ART initiation in people living with HIV (New recommendation) .................. 48 
6.2.1 Rapid ART initiation as the standard of care ........................................................... 48 
6.2.2 Mpox and ART initiation ................................................................................................. 48 
6.3 Breastfeeding and mpox (New recommendation) ................................................................... 53 
6.3.1 Breastfeeding ..................................................................................................................... 53 
6.3.2 Resuming breastfeeding ................................................................................................ 60 
6.4 Caring for people with mpox during and after pregnancy .................................................. 64 
6.4.1 Place of care during pregnancy................................................................................... 64 
6.4.2 Care during pregnancy ................................................................................................... 64 
6.4.3 Mode of birth ..................................................................................................................... 65 
6.4.4 Pregnancy and postpartum period ............................................................................ 66 
iii 
6.5 Caring for infants and young children with mpox .................................................................. 67 
6.5.1 Monitoring of newborn infants ................................................................................... 67 
6.6 Recommendations for patients with mpox that are sexually active .................................. 68 
6.6.1 Sex and close physical contact .................................................................................... 68 
6.6.2 Use of barrier contraception ........................................................................................ 69 
6.7 Recommendations for caring for mpox patients after acute infection ............................ 70 
6.7.1 Follow-up care ................................................................................................................... 70 
6.8 Recommendations on antiviral and other therapies (under revision) .............................. 70 
6.9 Recommendation on mental and psychosocial support of patients with mpox .......... 70 
6.9.1 Anxiety and depressive symptoms............................................................................. 70 
6.9.2 Sleep problems .................................................................................................................. 73 
6.10 Recommendation of deceased patient management ............................................................ 74 
6.10.1 Handling of human remains ......................................................................................... 74 
6.11 Recommendations for health and care workers with occupational exposure to 
mpox 75 
6.11.1 Occupational exposure to mpox ................................................................................. 75 
7. Methods: how was this guideline created  ............................................... 76 
7.1 Types of statements ............................................................................................................................ 77 
7.1.1 Recommendations ........................................................................................................... 77 
7.1.2 Good practice statements and implementation considerations ...................... 77 
7.2 Step-wise approach - application of GRADE methodology ................................................. 78 
7.2.1 Step 1: Evidence monitoring and mapping and triggering of evidence 
synthesis 78 
7.2.2 Step 2: Convening the GDG .......................................................................................... 79 
7.2.3 Step 3: Evidence synthesis and assessment ............................................................ 80 
7.2.4 Step 4: Recommendations ............................................................................................ 80 
7.2.5 Step 5: External and internal review ........................................................................... 81 
7.3 GDG topic-specific working groups ............................................................................................. 81 
7.3.1 Infection prevention and control technical working group .............................. 82 
7.3.2 Breastfeeding technical working group pre-GDG discussion ........................... 83 
7.3.3 HIV antiretroviral technical working group pre-GDG discussion ..................... 85 
 
 
iv 
7.4 Risk factors for severe disease and prognosis methodology .............................................. 86 
8. How to access  and use this guideline ........................................................ 88 
8.1 How to access the guideline ............................................................................................................ 88 
8.2 How to navigate this guideline ....................................................................................................... 88 
8.3 Additional educational modules and implementation tools for health workers .......... 89 
8.4 Collection of standardized data and the WHO Clinical Platform ....................................... 90 
9. Uncertainties, emerging  evidence and future  research ............................ 91 
9.1 Transmission .......................................................................................................................................... 91 
9.2 Clinical management .......................................................................................................................... 91 
9.3 Infection prevention and control.................................................................................................... 92 
9.4 Methods questions ............................................................................................................................. 92 
10. References  ................................................................................................. 93 
 
Tables 
Table 1. Risk factors and clinical findings described as being associated with severe disease 
and poor outcomes (based on small, uncontrolled observational studies) (Published in 2022)
 ....................................................................................................................................................................................... 12 
Table 2. Risk factors associated with severe disease or hospitalization .............................................. 13 
Table 3. Risk factors associated with mortality ............................................................................................. 14 
Table 4. Baseline risk for adverse outcomes in patients with mpox ..................................................... 15 
Table 5. Baseline risk for complications of mpox ........................................................................................ 15 
Table 6. Readership cues used for statements in the guideline............................................................. 78 
Table 7. Levels of certainty of evidence .......................................................................................................... 80 
 
  
v 
Acknowledgements 
The World Health Organization (WHO) would like to thank the collaborative efforts of 
all those involved in making this process efficient, trustworthy and transparent. The 
following groups contributed to this version of the guideline. 
WHO coordination team 
Janet Diaz, Marta Lado, Jamie Rylance, Julie Viry, Daniel Youkee (Clinical Management 
and Operations, WHO Health Emergencies Programme, WHO Geneva, Switzerland); 
April Baller, Hannah Hamilton Hurwitz, Nosheen Usman, Victoria Willet (Infection 
Prevention and Control and Water Sanitation and Hygiene, WHO Health Emergencies 
Programme, WHO Geneva, Switzerland). 
WHO Steering Committee for mpox 
The Steering Committee for mpox includes representatives from WHO departments 
at regional offices and headquarters, including specialty technical input and is fully 
responsible for decisions about guidance production and convening the Guideline 
Development Group (GDG). Hana Bekele (Nutrition and Physical Activity, WHO 
Regional Office for Africa); Mercedes Bonet Semenas (Sexual and Reproductive 
Health and Research, WHO Geneva, Switzerland); Giorgio Cometto (Health 
Workforce, WHO Geneva, Switzerland); Ana Paula Coutino Rehse (Infection 
Prevention and Control, WHO Regional Office for Europe); Queen Dube (Newborn 
Health, WHO Geneva, Switzerland); Lennox Ebbarnezh (Acute Events, WHO Geneva, 
Switzerland); Fahmy Hanna (Department of Mental Health and Substance Abuse, 
WHO Geneva, Switzerland); Iman Heweidy (Infection Prevention and Control, WHO 
Regional Office for the Eastern Mediterranean); Ana Hoxha (Acute Events, WHO 
Geneva, Switzerland); Landry Kabego (Infection Prevention and Control, WHO 
Regional Office for Africa); Rashidatu Kamara (Clinical Management, WHO Regional 
Office for Africa); Janet Kayita (Child and Adolescent Health, WHO Regional Office for 
Africa); Chiori Kodama (Clinical Management, WHO Regional Office for the Eastern 
Mediterranean); Rosamund Lewis (Global Infectious Hazard Preparedness/Emerging 
Zoonotic Diseases, WHO Geneva, Switzerland); Zhao Li (Infection Prevention and 
Control, WHO Regional Office for Western Pacific); Tamano Matsui (Clinical 
Management, WHO Regional Office for the Western Pacific); Sandra Milena (Infection 
Prevention and Control, Pan American Health Organization [PAHO]); Lorenzo Moja 
(Essentials Medicines, WHO Geneva, Switzerland); Thomas Moran (Risk 
Communication, Community Engagement and Infodemic Management, WHO 
 
 
vi 
Geneva, Switzerland); Dorthy Ngailo (Occupational Health, WHO Geneva, 
Switzerland); Adelheid Onyango (Healthier Populations Cluster, WHO Regional Office 
for Africa); Remco Peters (Global HIV, Hepatitis and STIs Programmes, WHO Geneva, 
Switzerland); Dina Pfeifer (Clinical Management, WHO Regional Office for Europe); 
Angel Rodriguez (Clinical Management, PAHO); Giovanni Satta (Infection Prevention 
and Control Unit and Hub, WHO Geneva, Switzerland); Aparna Shah (Infection 
Prevention and Control, WHO Regional Office for South-East Asia); Nosheen Usman 
(Infection Prevention and Control and Water Sanitation and Hygiene, WHO Geneva, 
Switzerland); Wilson Were (Maternal, Newborn, Child and Adolescent Health, WHO 
Geneva, Switzerland); Pushpa Wijesinghe (Clinical Management, WHO Regional Office 
for South-East Asia). 
Guideline Development Group 
Pierre Abi Hanna (Rafik Hariri University Hospital, Lebanon); Mary Adanma Alex-Wele 
(University of Port Harcourt and University of Port Harcourt Teaching Hospital, 
Nigeria); Meaghen Allen (Canadian Institute of Public Health Inspectors, Canada); 
Bartholomew Boniface Ochonye (Heartland Alliance International, Nigeria); Andre 
Bulabula (Africa Centres for Disease Control and Prevention, Ethiopia); Shama Cash-
Goldwasser (Pox and Rabies Branch, United States Centers for Disease Control and 
Prevention [CDC], United States of America); Mark Cotton (University of Cape Town, 
South Africa); Henry DeVries (Amsterdam University Medical Centre, Kingdom of the 
Netherlands); Jake Dunning (Royal Free London HHS Foundation, United Kingdom of 
Great Britain and Northern Ireland); Carole Fry (UK Health Security Agency, United 
Kingdom); Michelle Giles (University of Melbourne, Australia); Beatriz Grinsztejn 
(Fiocruz, Brazil); Ahmed Hakawi (Ministry of Health, Saudi Arabia); Lisa Hensley 
(United States Department of Agriculture) [participated until 2025]; Prince Imani-
Musimwa (University of Goma, Democratic Republic of the Congo); Yuguo Li 
(Department of Mechanical Engineering, The University of Hong Kong, Hong Kong 
SAR, China); Kushlani Jayatilleke (Sri Jayewardenepura General Hospital, Sri Lanka); 
Nagwa Khamis (Children’s Cancer Hospital of Egypt and Ain Shams University); Jason 
Kindrachuk (University of Manitoba, Canada); Kalisvar Marimuthu (Communicable 
Diseases Agency, Singapore and National Centre for Infectious Diseases, Singapore); 
Geeta Mehta (Journal of Patient Safety and Infection Control, India); Graeme Meintjes 
(University of Cape Town, South Africa); Sharon Nachman (Stony Brook Children’s 
Hospital, United States of America); Grace Ndeezi (Makerere University of Health 
Sciences, Uganda); Chloe Orkin (Queen Mary University, London, United Kingdom); 
Diamantis Plachouras (European Centre for Disease Prevention and Control, Sweden); 
vii 
Priscilla Rupali (Christian Medical College Vellore Tamil Nadu, India); Nadia Sam-
Agudu (Institute of Human Virology, Nigeria); Beate Sander (University Health 
Network, Canada); Mark Sobsey (University of North Carolina at Chapel Hill United 
States of America); Shalini Sri Ranganathan (University of Colombo, Sri Lanka); Joseph 
Tannous (Emirates Health Services, United Arab Emirates); Valdilea Veloso (Fiocruz, 
Brazil); Mija Ververs (Center for Humanitarian Health, Johns Hopkins Bloomberg 
School of Public Health Baltimore, United States of America); Ian Wolley (Monash 
Health, Australia). 
Methodologists: Gordon Guyatt (McMaster University, Canada); Manya Prasad 
(Institute of Liver and Biliary Sciences, India). 
Clinical Chair: Tom Fletcher (Liverpool School of Tropical Medicine, United Kingdom). 
Infection Prevention and Control Chair: Tochi Okwor (Nigeria Centre for Disease 
Control, Nigeria). 
External reviewers: Chedly Azzouz (Infection Control African Network, Tunisia); Amy 
Elizabeth Barrera-Cancedda (Resolve to Save Lives, United States of America); Daniela 
Garone (Médecins Sans Frontières International, Belgium); Richard Kojan (Alliance for 
Internationale Medical Action, Democratic Republic of the Congo). 
Systematic review teams 
Risk factors for severe disease: Ya Gao and Qiukui Hao (McMaster University, 
Canada). 
Breastfeeding of infants of mothers with mpox: Kerry Dwan (Liverpool School of 
Tropical Medicine, United Kingdom). 
Infection prevention and control: WHO Collaborating Centre for Infection 
Prevention and Control and Anti-Microbial Resistance under the supervision of Dr 
Majid Alshamrani (Infection Prevention and Control Department, King Abdulaziz 
Medical City Hospital, Saudi Arabia); with support from: Sarah Alfayez, Maher Alharbi, 
Kholoud Ameer, Wafaa Al Nasser, Mohammed Al Zunitan Mohammed Abalkhail, 
Aiman El-Saed, Fayssal Farahat, Syed Nazeer, Fatmah Othman. 
Technical Working Group on HIV: Andrea Antinori (National Institute for Infectious 
Diseases Lazzaro Spallanzani [IRCCS], Rome, Italy); Alexandre Calmy (University of 
Geneve, Geneve, Switzerland); Mohamed Chakroun (University of Monastir, Monastir, 
Tunisia); Mark Cotton (Stellenbosch University, Cape Town, South Africa); Peter Elyanu 
(Baylor College of Medicine Children’s Foundation, Kampala, Uganda); Beatriz 
 
 
viii 
Grinsztejn (Oswaldo Cruz Foundation [FIOCRUZ], Rio de Janeiro, Brazil); 
Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, India); 
Michael Marks (London School of Hygiene & Tropical Medicine, London, United 
Kingdom of Great Britain and Northern Ireland); Nick Medland (University of New 
South Wales, Sydney, Australia); Graeme Meintjes (University of Cape Town, Cape 
Town, South Africa); Oriol Mitja (Hospital Universitari Germans Trías i Pujol, Badalona, 
Spain); Sharon Nachman (Department of pediatrics, Renaissance School of Medicine, 
New York, USA); Hideta Nakamura (University of the Ryukyus Graduate School of 
Medicine, Nishihara-cho, Japan); Jeremy Nel (University of Witwatersrand, 
Johannesburg, South Africa); Adesola Yinka-Ogunleye (Nigeria Centre for Disease 
Control, Abuja, Nigeria); Chloe Orkin (Queen Mary University of London, London, 
United Kingdom of Great Britain and Northern Ireland); Shama Cash-Goldwasser 
(Centers for Disease Control and Prevention, Atlanta, Georgia, United States of 
America); Marcia Wong (New York City Department of Health and Mental Hygiene, 
New York, United States of America) 
Technical Working Group on Infant feeding: Ebun Adejuyigbe (Obafemi Awolowo 
University Ile-Ife, Nigeria; Najwa Al Dheed (UNICEF, New York, United States of 
America); Brooke Bauer (Save the Children International, United Kingdom of Great 
Britain and Northern Ireland); 
Lars Bode (University of California San Diego, United States of America); Bindi Borg 
(Emergency Nutrition Network [ENN], United Kingdom of Great Britain and Northern 
Ireland); Erin Boyd (Tufts University, Boston, Massachusetts, United States of America); 
Jodine Chase (SafelyFed Canada, Canada); Anne Detjen (UNICEF, New York, United 
States of America); Alessandro Iellamo (FHI 360, Washington DC, United States of 
America); Raoul Kamadjeu (UNICEF, New York, United States of America); Marie 
McGrath (UK Emergency Nutrition Network [ENN], United Kingdom of Great Britain 
and Northern Ireland); Grace Ndeezi (Makerere University College of Health Sciences, 
Uganda); Philippe van de Perre (University of Montpellier, France); Roberta Petrucci 
(Médecins Sans Frontières [MSF], Geneva, Switzerland); Nadia Sam-Agudu (Institute 
of Human Virology Nigeria (IHVN), Nigeria); Fatmata Fatima Sesay (UNICEF, New 
York, United States of America); Mija-Tesse Ververs (Johns Hopkins Bloomberg 
School of Public Health Baltimore, United States of America). 
Additionally, WHO would also like to thank those who contributed to the first 
(interim) guideline development process in 2022 [1]. 
WHO coordination team members (2022) 
ix 
Vanessa Cramond (Clinical Management and Operations, WHO Geneva, Switzerland); 
Kathleen Dunn (Infection Prevention and Controland Water Sanitation and Hygiene, 
WHO Geneva, Switzerland); Krutika Kuppalli (Emerging Diseases and Zoonoses Unit, 
WHO Geneva, Switzerland); Hibak Osman Mahamed (Infection Prevention and 
Control and Water Sanitation and Hygiene, WHO Geneva, Switzerland). 
Steering Committee members (2022) 
Benedetta Allegranzi (Infection Prevention and Control Unit and Hub, WHO Geneva, 
Switzerland); Lisa Askie (Quality Assurance of Norms and Standards Department, 
WHO Geneva, Switzerland); Silvia Bertagnolio (Communicable and Noncommunicable 
Diseases, WHO Geneva, Switzerland); Astrid Chojnacki (Infection Prevention and 
Control, WHO Regional Office for the Western Pacific); Jane A Cunningham (Emerging 
Diseases and Zoonoses Unit, WHO Geneva, Switzerland); Kirrily De Polnay (Food and 
Nutrition Action in Health System); Meg Doherty (Global HIV, Hepatitis and STIs 
Programmes); Marjam Esmail (UNICEF); Melinda Frost (Risk Communication and 
Community Engagement, WHO Geneva, Switzerland); Luca Fontana (Health and 
Technical Logistics, WHO Geneva, Switzerland); Ivan Ivanov (Occupational and 
Workplace Health, WHO Geneva, Switzerland); Kathryn Johnston (Infectious Hazard 
Management, PAHO); Manish Kakkar (WHO Regional Office for South-East Asia); 
Edna Karra (Sexual Reproductive Health and Research); Benjamin Kung (Infection 
Prevention and Control, WHO Regional Office for the Western Pacific); Cleiton 
Euzebio de Lima (UNAIDS); Moe Masunaga (WHO Regional Office for South-East 
Asia); Virginia Macdonald (WHO Regional Office for the Western Pacific); Stacey 
Mearns (United Kingdom Public Health Rapid Support Team, seconded to WHO 
Infection Prevention and Control, WHO Health Emergencies Programme); Antons 
Mozalevskis (Global HIV, Hepatitis and STIs Programmes); Deus Mubangizi 
(Regulations and Prequalification, WHO Geneva, Switzerland); Takeshi Nishijima 
(WHO Regional Office for the Western Pacific); Pilar Ramon Pardo (Department of 
Communicable Diseases and Environmental Determinants of Health, PAHO); Mark 
Perkins (Epidemic and Pandemic Preparedness and Prevention, WHO Geneva, 
Switzerland); Jerome Pfaffmann (UNICEF); Moustafa Ramadan (Infection Prevention 
and Control, Regional Office for the Eastern Mediterranean); Kamara Rashidatu (WHO 
Regional Office for Africa); Ludovic Reveiz (Department of Evidence and Intelligence 
for Action in Health, PAHO); Jilian Sacks (Epidemic and Pandemic Preparedness and 
Prevention, WHO Geneva, Switzerland); Alice Simniceanu (Emerging Diseases and 
Zoonoses Unit, WHO Geneva, Switzerland); Valeska Stempliuk (Infection Prevention 
and Control PAHO); Omar Sued (Clinical Management, PAHO); Maha Talaat (Infection 
 
 
x 
Prevention and Control, WHO Regional Office for the Eastern Mediterranean); Joao 
Paulo Toledo (Infection Prevention and Control Unit and Hub, WHO Geneva, 
Switzerland); Teodora Wi (Global HIV, Hepatitis and STIs Programmes, WHO Geneva, 
Switzerland); Willibald Zeck (United Nations Population Fund). 
Guideline Development Group members (2022) 
Rodrigo Angerami (Hospital de Clínicas of the University of Campinas/UNICAMP, 
Brazil); Nawal Al-Kaabi (Sheikh KhalifaMedical City, United Arab Emirates); Javier 
Bellocq (Community Representative, Argentina); Enrique Castro-Sánchez (University 
of West London, Imperial College London; Universitat Oberta de Catalunya, Spain); 
Nizam Damani (Southern Health and Social Care Trust, United Kingdom; Sindh 
Institute of Urology and Transplant Centre, Pakistan); Candida Fernandes (Centro 
Hospitalario Universitário de Lisboa Central, Portugal); Esther Freeman (Global Health 
Dermatology at Massachusetts General Hospital, Harvard Medical School, United 
States of America); Sanjay Jain (Postgraduate Institute of Medical Education and 
Research, Chandigarh, India); Thierry Kalonji, (Ministry of Health, Kinshasa, Democratic 
Republic of the Congo); Aaron Kofman (CDC, United States of America); Brett Kurpiel 
(community representative, United States of America); Laurens Liesenborghs (Belgian 
Institute of Tropical Medicine, Belgium); Placide Mbala (National Institute of 
Biomedical Research, Democratic Republic of the Congo); Geeta Mehta (Lady 
Hardinge Medical College, New Delhi, India); Marc Mendelson (Groote Schuur 
Hospital, University of Cape Town, South Africa); Emmanuel Nakoune (Pasteur 
Institute of Bangui and University of Bangui, Central African Republic); Pius Okong 
(Health Service Commission, Uganda); Anne Rimoin (UCLA Jonathan and Karin 
Fielding School of Public Health and Infectious Disease Division of the David Geffen 
School of Medicine, United States of America); Mitchell J Schwaber (National Center 
for Infection Control, Israel Ministry of Health,Israel); Elena Sendagorta (University 
Hospital La Paz, Spain); Julian Tang (University Hospitals Leicester, United Kingdom); 
Margarida Tavares (São João University Hospital Centre, National Programme for 
Sexually Transmitted Infections and HIV Infection, Spain); Monica Thormann (Ministry 
of Public Health, Dominican Republic); Philippe Van de Perre (University of 
Montpellier, France); Tania Villa Reyes (General Directorate of Epidemiology, Mexico); 
Laura Waters (University College London, United Kingdom); Adesola Yinka (Nigeria 
Centre for Disease Control, Nigeria). 
External reviewers (2022) 
xi 
Aula Abbara (Operational Centre Amsterdam, Médecins Sans Frontières, Kingdom of 
the Netherlands); Carlos Alvarez (Universidad Nacional de Colombia, Clinica 
Colsanitas, Colombia); Francisco Bartolome (Médecins Sans Frontières, Spain);Anita 
Desai (National Institute of Mental Health and Neurosciences, India); Marcio da 
Fonseca (Access Campaign, Médecins Sans Frontières, Kingdom of the Netherlands); 
Masahiro Ishikane (National Center for Global Health and Medicine, Japan); Richard 
Kojan (Alliance for International Medical Action, Democratic Republic of the Congo); 
Buyiswa Lizzie Mazibuko (Independent Infection Prevention and Control Specialist, 
Zimbabwe). 
 
Special thanks to the Strategic Health Operations Centre for providing IT support for 
the meetings (Acute Emergency Management, WHO Health Emergencies 
Programme). 
  
 
 
xii 
Abbreviations 
ABCD airway, breathing, circulation, disability 
ACH air changes per hour 
AGP aerosol-generating procedure 
AIIR airborne infection isolation room 
ALT alanine transaminase 
ARDS acute respiratory distress syndrome 
ART antiretroviral therapy 
AST aspartate aminotransferase 
AVPU alert, voice, pain, unresponsive (scale) 
BMI body mass index 
BUN blood urea nitrogen 
CA-MRSA community-acquired methicillin-resistant Staphylococcus aureus 
CBT cognitive behavioural therapy 
CDC Centers for Disease Control and Prevention (United States of America) 
CFR case fatality ratio 
CSF cerebrospinal fluid 
DGI disseminated gonococcal infection 
DOI declaration of interest 
EMA European Medicines Agency 
FFR filtering facepiece respirator 
GDG Guideline Development Group 
GRADE Grading of Recommendations Assessment, Development and Evaluation 
HAI heath care-associated infection 
HR hazard ratio 
HSV herpes simplex virus 
IDP internally displaced person 
IFRC International Federation of Red Cross and Red Crescent Societies 
IITT Interagency Integrated Triage Tool (WHO/IFRC) 
IO intraosseous 
IPC infection prevention and control 
IRIS Immune reconstitution inflammatory system 
IRP infectious respiratory particles 
IV intravenous 
LGV lymphogranuloma venereum 
xiii 
MDR multidrug-resistant 
MEURI Monitored Emergency Use of Unregistered and Investigational 
Interventions 
mpox mpox is the preferred term as a synonym for monkeypox 
MPXV monkeypox virus 
MSSA methicillin-sensitive Staphylococcus aureus 
MUAC mid-upper arm circumference (in children) 
NIOSH National Institute for Occupational Safety and Health (United States of 
America) 
OR odds ratio 
PAHO Pan American Health Organization 
PCR polymerase chain reaction 
PEP post-exposure prophylaxis 
PPE personal protective equipment 
PTSD post-traumatic stress disorder 
RR relative risk 
RT-PCR real-time polymerase chain reaction 
STI sexually transmitted infections 
US FDA United States Food and Drug Administration 
VIG vaccinia immune globulin 
VZV varicella zoster virus 
WBC white blood count 
WHO World Health Organization 
  
 
 
xiv 
Definitions 
Aerosol-generating procedures: Medical procedures that are reported to be 
aerosol generating are consistently associated with an increased risk of pathogen 
transmission. The current list of procedures recognized by WHO as aerosol 
generating includes aspiration or open suctioning of respiratory tract specimens, 
bronchoscopy, intubation, cardiopulmonary resuscitation, manual ventilation before 
intubation, sputum induction by using nebulized hypertonic saline, dentistry and 
autopsy procedures [2,3]. 
Airborne infection isolation room (AIIR): A room with a high ventilation rate and 
controlled direction of airflow that can be used to contain airborne infections and 
acute respiratory infections caused by a novel agent with the potential to pose a 
public health risk. Such rooms can be naturally or mechanically ventilated [2]. 
• Naturally ventilated airborne precaution room: the airflow should be directed 
to areas free of transit, or should permit the rapid dilution of contaminated air 
into the surrounding areas and the open air; the average ventilation rate 
should be 160 L / s per patient. 
• Mechanically ventilated airborne precaution room: negative pressure is created 
to control the direction of airflow; the ventilation rate should be at least 12 air 
changes per hour (ACH). Such a room is equivalent to the “airborne infection 
isolation room” described by the United States Centers for Disease Control and 
Prevention (CDC). 
Airborne transmission/inhalation (formerly airborne transmission): Occurs when 
infectious respiratory particles (IRPs) are expelled into the air and enter, through 
inhalation, the respiratory tract of another person. This form of transmission can 
occur when the IRPs have travelled either short or long distances from the infectious 
person. The portal of entry of an IRP into respiratory tract tissue during airborne 
transmission can theoretically occur at any point along the human respiratory tract, 
but preferred sites of entry may be pathogen specific. It should be noted that the 
distance travelled will depend on multiple factors including particle size, mode of 
expulsion and environmental conditions (such as airflow, humidity, temperature, 
setting, ventilation, etc.) [4] 
Care workers: People who provide direct personal care services in the home, in a 
health care or residential setting, assisting with routine tasks of daily life and 
performing other tasks of a simple and routine nature. This term comprises [5,6]: 
xv 
• Health care assistants: institution-based, personal care workers who provide 
direct personal care and assistance with activities of daily living to patients and 
residents in a variety of health care settings, such as hospitals, clinics and 
residential nursing care facilities. They generally implement established care 
plans and practices under the direct supervision of medical, nursing or other 
health professionals or associate professionals. 
• Home-based personal care workers: provide routine personal care and 
assistance with activities of daily living to persons who are in need of such care 
due to effects of ageing, illness, injury or other physical or mental conditions, 
in private homes and other independent residential settings. 
Contact transmission: The spread of an infectious agent caused by physical contact 
of a susceptible host with people or objects [7]. 
• Direct contact transmission involves both a direct body-surface-to-body-
surface contact and physical transfer of micro-organisms between an infected 
or colonized person and a susceptible host [2,7]. In addition, direct contact 
transmission can occur when an infectious person directly transfers infectious 
pathogens from their own respiratory tract, not via IRPs, to another person by 
being in direct contact with that person (e.g., via a handshake), who then 
directly transfers the IRPs into their own mouth, nose or eyes [4]. 
• Indirect contact transmission involves contact of a susceptible host with a 
contaminated intermediate object (e.g., contaminated hands) that carries and 
transfers the micro-organisms [2,7]. Contaminated surfaces are also created 
when IRPs expelled into the air settle on a surface, or when an infected person 
transfers infectious respiratory secretions by first touching their own mouth, 
nose or eyes and then touching a surface or shaking hands. Infectious 
pathogens on the contaminated surfaces are then transferred to another 
person who touches that contaminated surface and then their own mouth, 
nose or eyes [4]. 
Direct deposition (formerly droplet transmission): Occurs when IRPs are expelled 
into the air following a short-range semi-ballistic trajectory, then are directly 
deposited on the exposed facial mucosal surfaces (mouth, nose or eyes) of another 
person, thus, entering the human respiratory tract via these portals and potentially 
causing infection [4]. 
Filtering facepiece respirator (FFR or respirator): Filtering facepiece respirators 
(FFRs or respirators) offer a balance of filtration, breathability and fit. Whereas 
 
 
xvi 
medical masks filter 3-micrometre droplets, N95-rated and FFP2-rated FFRs must 
filter more challenging 0.075-micrometre particles or particulates and must do so 
across the entire surface of the respirator as a result of the fitted design. European 
FFP2 FFRs, according to the EN 149 standard, filter at least 94% sodium chloride 
(NaCl) salt particles and paraffin oil droplets. The United States of America's N95 
FFRs, according to the National Institute for Occupational Safety and Health (NIOSH) 
NIOSH 42 CFR Part 84, filter at least 95% NaCl salt particles [8,9]. 
Health worker: Health and care workers are all people from the community to 
hospitals, primarily engaged in actions with the primary intent of enhancing health. 
This includes health service providers, such as doctors, nursing and midwifery 
professionals, public health professionals, technicians (laboratory, health, medical and 
non-medical), personal care workers, and healers and practitioners of traditional 
medicine. It also includes health management and support workers, such as cleaners, 
drivers, hospital administrators, district health managers, social workers and other 
occupational groups in health-related activities [6,10].This document uses the 
combined term of health and care worker to cover all roles and settings. 
Infectious respiratory particles: Pathogens, contained within a particle (known as 
“infectious particles”), that travel through the air and these infectious particles are 
carried by expired airflow which enter the human respiratory tract or are deposited 
on the mucosa of the mouth, nose or eye of another person [4]. 
Isolation: The separation of infected people with a contagious disease from people 
who are not infected [11]. 
Screening: A process through which an individual is evaluated to see whether that 
person meets a standardized case definition. Screening does not typically require 
close physical contact or clinical expertise [12,13]. 
Standard precautions: Aim to protect both health workers and patients by reducing 
the risk of transmission of micro-organisms from both recognized and unrecognized 
sources. They are the minimum standard of infection prevention and control (IPC) 
practices that should be used by all health and care workers, during the care of all 
patients, at all times, in all settings. When applied consistently, standard precautions 
can prevent the transmission of microorganisms between patients, health workers 
and the environment [14]. 
Transmission-based precautions: Transmission-based precautions are used in 
addition to standard precautions for patients with known or suspected infection or 
xvii 
colonization with transmissible and/or epidemiologically significant pathogens. The 
type of transmission-based precautions assigned to a patient depends on the 
transmission route of the micro-organism: contact, droplet or airborne [7]. 
Triage: The process of sorting patients into categories based on the need for time-
sensitive treatment using validated tools. Triage identifies those who require 
immediate medical intervention, and those who can safely wait. Triage may occur at a 
health post, primary health centre, clinic or emergency unit. It typically requires close 
physical contact (within 1 metre) with the patient during the assessment [12,13]. 
 
Clinical management and infection prevention and control for mpox 
xviii 
1. Executive summary 
1.1 Clinical question: What are the clinical and IPC 
interventions to use in caring for patients with mpox? 
Target audience: This document is for public health specialists, health emergency 
responders, clinicians, health facility managers, health and care workers and IPC 
practitioners including but not limited to those working in primary care clinics, sexual 
health clinics, emergency departments, dental practices, infectious diseases clinics, 
genitourinary clinics, maternity services, paediatrics, obstetrics and gynaecology and acute 
care facilities that provide care for patients with suspected or confirmed mpox. 
Context: Since the publication of the WHO interim mpox guideline in 2022 [1] the mpox 
virus, also known as the monkeypox virus (MPXV), and outbreaks associated with it have 
continued to evolve. Prior to 2022, cases were primarily reported in Central and West 
Africa. In 2022, a global outbreak of clade IIb was declared and continues to affect 
numerous countries. Subsequently, there have been outbreaks associated with clades Ia 
and Ib, primarily affecting the Democratic Republic of the Congo and neighbouring African 
countries. Since August 2024, increasing numbers of MPXV cases in Africa and detection of 
clade Ib beyond the African continent, have led to a second declaration by the WHO 
Director General of a public health emergency of international concern related to the 
epidemic risk and widespread transmission of MPXV. 
If the person with mpox is an acute infection patient or is at risk of complications, they 
should be managed in a health facility setting and have more supportive care. Only mild, 
non-complicated cases of mpox should be managed with home-based care. 
1.2 New infection prevention and control recommendations 
• Infection prevention and control measures including hand hygiene, dedicated 
personal items, appropriate handling of linens and laundry, cleaning and 
disinfection of the environment, and waste management should be followed for 
persons with mpox in the community until all lesions are healed.* (Good practice 
statement) 
• WHO suggests that persons with mild, uncomplicated mpox infection cared for at 
home are not required to isolate** provided their lesions are covered and they wear 
a well-fitting medical mask when in close proximity with others until all lesions are 
healed.* (Conditional recommendation, low certainty evidence) 
Executive summary 
xix 
• In patients with suspected or confirmed mpox infection, WHO suggests that health 
and care workers use contact and droplet precautions.*** (Conditional 
recommendation, low certainty evidence) 
* Healed lesions: lesions have crusted, scabs have fallen off and a fresh layer of skin has formed underneath.  
** Isolation means the separation of infected people with a contagious disease from people who are not 
infected. 
*** Contact precautions include the following personal protective equipment (PPE): gloves, gown. Droplet 
precautions include the following PPE: a medical mask and consider eye protection based upon a risk 
assessment. 
1.3 New clinical management recommendations 
• WHO recommends rapid initiation of antiretroviral therapy (ART) in people with 
mpox infection and HIV who are ART naïve or have had a prolonged interruption of 
ART. (Strong recommendation, moderate certainty evidence) 
• WHO suggests that mothers with mpox continue breastfeeding whilst limiting direct 
contact with their non-infected infant. (Conditional recommendation, low certainty 
evidence) 
• WHO suggests that mothers who recover from mpox infection and who had 
withheld breastfeeding and direct contact, to resume breastfeeding and direct 
contact with the infant as soon as lesions are healed.* (Conditional recommendation, 
very low certainty evidence) 
* Healed lesions: lesions have crusted, scabs have fallen off and a fresh layer of skin has formed underneath.  
 
What triggered this guideline: The spread of the current global outbreak (since 2022 to 
present) is sustained by human-to-human transmission occurring during close contact 
including sexual contact. As of 10 March 2025, a total of 129 172 confirmed cases, 
including 283 deaths, have been reported to WHO from 130 Member States/territories 
across all six WHO regions [23]. 
The need for evidence-based clinical guidance has become apparent as cases of mpox 
have arisen in the context of limited direct experience of patient management compared 
with prior outbreaks. The WHO mpox Steering Committee with the Guideline Development 
Group (GDG) previously made initial recommendations as interim guidance [1]. 
About this guideline: This living guideline from WHO incorporates new evidence to 
dynamically update recommendations for clinical management and IPC for mpox infection. 
The GDG typically evaluates an intervention when WHO judges sufficient evidence is 
available to make a recommendation. While the GDG takes an individual patient 
Clinical management and infection prevention and control for mpox 
xx 
perspective in making recommendations, it also considers resource implications, 
acceptability, feasibility, equity and human rights. Some IPC interventions are listed as 
good practice statements and have been formulated according to the principles outlined in 
the GRADE (Grading of Recommendations Assessment, Development and Evaluation) 
framework and further described in the Methods section of the document. This updated 
version of the guideline was developed according to standards and methods for 
trustworthy guidelines.  
Statements in the 2022 interim guidance about clinical care and IPC measures for patients 
with mpox infection were prioritized for review with the GDG chairs, the methodologist 
and subsequently reviewed with the Steering Committee and panel. The GRADE framework 
to generate evidence-based recommendations has been applied to the recommendations 
in the tables in this version and some prior recommendations have been imported. The 
remaining prior recommendations and any future recommendations will be reviewed 
according to the prioritization and as more evidence becomes available for future updates 
to this guideline. 
More information around the methodology followed to bring the recommendation in 
these updated guidelines can be found in Methods: how this guideline was created. 
 
Introduction 
1 
2. Introduction 
2.1 Mpox clades 
Mpox virus (MPXV) belongs to the Orthopoxvirus genus of the Poxviridae family. The 
human disease was first identified in 1970 in a 9-month-old boy in the Democratic 
Republic of the Congo. Until 2022, most cases have been reported from Central and 
West Africa [15,16]. 
There are two distinct clades of MPXV [17] 
• clade I (a, b), previously known as the Central African (Congo basin) clade; 
• clade II (a, b), previously known as the West African clade; 
o subclade IIb is the group of variants circulating as part of the 2022 
global outbreak. 
Historically, clade I was considered to be more virulent, with a case fatality ratio (CFR) 
ranging from 1% to 10% [16,18,19], while clade IIa is associated with an overall lower 
mortality rate of < 3% [19,20]. However, the emergence of clade IIb and global 
expansion in 2022, as well as the historic increase in Clade I mpox cases in 2023 and 
2024, have made these virulence differences less clear. 
The details of the virulence of different clades have been described [21,22]. As of 
December 2024, a total of 124 753 confirmed cases, including 272 deaths, have been 
reported to WHO from 128 Member States/territories across all six WHO regions 
[23]. 
2.1.1 Update of mpox outbreaks by virus clade using of evidence 
available by January 2025 
This section provides an overview of the major mpox outbreaks by MPXV subclade. 
2.1.2 Clade Ia MPXV 
Clade Ia MPXV is found primarily in the Democratic Republic of the Congo, where it 
affects endemic provinces and has increasingly been found in previously unaffected 
provinces in recent years, including the capital, Kinshasa. Sporadic cases continue to 
be reported in neighbouring Central African Republic and in the Republic of Congo. 
The Democratic Republic of the Congo and the Central African Republic report a 
Clinical management and infection prevention and control for mpox 
2 
higher proportion of children among cases, while in the Republic of Congo, most 
cases are among adults. 
Previously, genomic sequencing analysis had indicated that clade Ia MPXV typically 
emerged in human populations through zoonotic exposure, leading to limited 
human-to-human transmission. Current epidemiological data and phylogenetic 
analysis still suggest that many outbreaks of mpox due to clade Ia MPXV are the 
result of zoonotic spillover with secondary human-to-human transmission. 
2.1.3 Clade Ib MPXV 
Clade Ib MPXV is predominantly spreading in the Democratic Republic of the Congo, 
and neighbouring countries to the east, with community transmission reported in 
Burundi and Uganda, clusters of cases reported in Kenya and Rwanda, and mostly 
travel-related cases in other countries where it has been detected. No human case 
has been substantively linked to a suspected animal exposure for this clade yet, and 
current genomic sequencing data suggest that it is transmitted only through human-
to-human contact [24,25]. In the Democratic Republic of the Congo, it has been 
found in eight provinces: South Kivu, North Kivu, Kinshasa, Kasai, Tshopo, 
Tanganyika, Haut-Katanga and Mai-Ndombe, and it is the fastest expanding MPXV 
strain. The other most affected countries in Africa are Burundi and Uganda, where 
transmission has been ongoing since the end of 2024 and early 2025; while smaller 
clusters have been reported in Kenya and Rwanda, the extent of undetected 
transmission is unknown. Zambia and Zimbabwe have reported travel- related cases 
and very limited secondary transmission. Outside of Africa, imported travel-related 
cases have also been detected (in order of reporting) in Sweden, Thailand, India, 
Germany, the United Kingdom, the United States of America, Canada, Pakistan, 
Belgium, China and France. Secondary transmission from these cases has been 
reported in the United Kingdom, Germany, Belgium, China and France. 
Imported mpox cases have been among adults who travelled during their incubation 
periods or with early symptoms and were diagnosed once they arrived in the 
country. Often, they reported prior sexual contact with a person with known mpox 
infection or someone with signs and symptoms suggestive of mpox. Where initial 
clusters of mpox due to clade Ib MPXV expand and as the outbreak progresses, 
transmission patterns appear to evolve, with more spread within households, leading 
to a progressive shift in age and sex distribution, with a rising proportion of cases 
among children. The multi-country outbreak of mpox driven by clade IIb MPXV that 
Introduction 
3 
began in 2022 showed that sexual contact can sustain community transmission of 
MPXV. Likewise, subclades Ia and Ib are also spreading through sexual contact, much 
remains to be understood about the transmissibility and sustainability of 
transmission through nonsexual direct physical contact for all clades. In settings 
where transmission persists, it is likely driven by a combination of sexual, household 
and community contact. 
2.1.4 Clade IIa MPXV 
In 2024, Côte d'Ivoire, Guinea and Liberia reported mpox linked to clade IIa MPXV. 
Both countries have shown evidence of sustained community transmission of this 
strain, with cases dispersed over wide geographical areas. Outbreaks of clade IIa 
MPXV are a concerning new phenomenon as human-to-human transmission of this 
clade had not been reported before 2024 [21]. Furthermore, co-circulation of clade 
IIa and clade IIb MPXV has been reported for the first time, in both Côte d'Ivoire and 
Liberia. Mpox linked to clade IIa MPXV has been reported in adults and children, with 
many lacking a known epidemiological link, suggesting ongoing, largely undetected 
community transmission. Limited epidemiological investigations have constrained 
our understanding of the modes of transmission in these outbreaks and clade IIa 
MPXV remains the least described MPXV strain in the scientific literature. While there 
is no documented evidence of sexual contact transmission for this strain, all forms of 
close contact likely contribute to its spread, documented for the first time in 2024. 
2.1.5 Clade IIb MPXV 
Most mpox outbreaks in other parts of West, North and Southern Africa and other 
parts of the world are due to clade IIb MPXV, a continuation of the multi-country 
outbreak that began in 2022. Most regions report circulation of clade IIb lineage B.1, 
while lineage A.1 continues to circulate in Nigeria and some countries in the WHO 
Eastern Mediterranean Region. The most affected population outside of Africa 
continues to be men who have sex with men, primarily exposed through sexual 
contact [26,27]. In instances where others have been affected, such as women and 
children, it has not led to sustained transmission, unlike that being observed for 
clade I MPXV in the African context. Australia has seen an unprecedented rising trend 
in cases in recent months while most other reporting countries have reported 
ongoing low-level transmission mainly in the same population at risk. 
Clinical management and infection prevention and control for mpox 
4 
2.2 Natural history 
The incubation period of mpox is usually 3 to 17 days following exposure to MPXV 
[28]. Although most people recover within 1 to 2 weeks, severe complications and 
sequelae have been reported to be more common among those unvaccinated for 
smallpox compared with those vaccinated (74% vs 39.5%) [29], although overall the 
evidence is both inconsistent and uncertain (see Table 2). Clinical evaluation is 
underway to generate real-world evidence of effect. It is unclear if there is waning 
immunity to smallpox vaccination over time; however, studies indicate that smallpox 
vaccination is approximately 85% effective in preventing mpox [30,31]. Evidence of 
prior vaccination against smallpox can typically be found as a scar on the upper arm. 
Individuals born after smallpox eradication in 1980 are unlikely to have been 
vaccinated, although some laboratory personnel or health and care workers may 
have received the vaccine after this date [15]. 
To date, most reported deaths have occurred in babies, infants and 
immunocompromised individuals, such as those with poorly controlled HIV infection 
[20,29,32]. A study from the Democratic Republic of the Congo reported that in a 
cohort of 216 patients, there were three deaths in patients < 12 years of age. When 
compared with survivors, patients with fatal disease had higher amounts of mpox 
virus DNA in blood, a higher maximum skin lesion count, and raised liver enzymes 
(aspartate aminotranferase [AST] and alanine tranaminase [ALT]) at initial 
presentation [33]. Mortality rates decrease when there is access to good supportive 
of care, and in individuals who have a better background health and nutrition [34]. 
2.3 Signs and symptoms 
Descriptions of outbreaks prior to 2022 described two phases, with an initial 1 to 5 
day illness characterized by fever, headache, back pain, muscle aches, lack of energy 
and lymphadenopathy [33], followed by the appearance of a rash [31,35,36]. The rash 
typically presented in sequential stages – macules, papules, vesicles, pustules, 
umbilication before crusting over and desquamating over a period of 2 to 3 weeks. 
However, in the 2022 clade IIb outbreak, 52–64% of patients had skin lesions before, 
or at the time of, systemic symptoms [37,38,39]. Furthermore, lesions did not always 
present sequentially. For example, the initial lesion might be a pseudopustule or an 
ulcer without going through the typical progression, or multiple types of lesions may 
co-exist simultaneously [37]. 
Introduction 
5 
In prior outbreaks, mpox was noted to spread centrifugally, starting on the face and 
then extending out towards the palms and the soles [16,29,40]. In the 2022 clade IIb 
outbreak, as many as 70–78% of participants had lesions (and primarily their first 
lesion) in the groin, perineum or peri-anal region, and 43% in the oral or peri-oral 
area [37,38]. These rash distributions may have been influenced by the nature of the 
transmission events (sexual transmission) and sites of the body that had significant 
exposure to other lesions of an infected person (potential primary inoculation sites) 
[41]. Most (92%) of patients had fewer than 20 skin lesions, with a significant minority 
(39%) of patients having as few as 1 to 5 total lesions, though it is possible to have 
several hundred up to several thousand in number [15]. A distinct primary 
presentation was proctitis without perianal lesions [42]. 
Patients may develop lymphadenopathy – which was described in 98.6% of a cohort 
of over 200 patients with mpox in the Democratic Republic of the Congo recorded 
from 2007 to 2011 [16,33]. In more recent series, like the clade IIb outbreak in 2022, 
lymphadenopathies seem to be less common (around half) [43]. Oral ulcers are 
common and may affect a patient’s ability to eat and drink leading to dehydration 
and malnutrition [35,44]. Also described in the clade IIb outbreak case series, 
pharyngeal, conjunctival and genital mucosae also occur [35,45]. A large prospective 
observational study describing the natural history of 216 patients with mpox in the 
Democratic Republic of the Congo described the most common clinical symptoms to 
be rash (96.8%), malaise (85.2%) and sore throat (78.2%). The most common findings 
on physical examination were the classic mpox rash (99.5%); lymphadenopathy 
(98.6% – the cervical region was most frequently affected [85.6%], followed by the 
inguinal region [77.3%]); and mouth/throat lesions (28.7%) [33]. 
In the 2022 mpox clade IIb outbreak, it was noted that people living with HIV are 
disproportionately affected with mpox. Presently, 38–50% of individuals diagnosed 
with mpox are living with HIV [46]. Co-infection with HIV is associated with more 
frequent perianal lesions, and higher rash burden [47]. Atypical, large and severe skin 
lesions and wounds have been noted in immunocompromised individuals, especially 
those living with inadequately controlled HIV [48]. In one global case series, it was 
noted that individuals with both low CD4 count and high viral load had the greatest 
disease severity, hospitalization and mortality [46]. 
Clinical management and infection prevention and control for mpox 
6 
2.3.1 Severe disease and complications 
Though uncommon, patients with mpox may develop severe and life-threatening 
complications. For example, confluent skin lesions are at an increased risk of bacterial 
skin and soft tissue infections such as cellulitis, abscesses, necrotizing soft tissue 
infections requiring meticulous local wound care; subcutaneous accumulation of fluid 
in the crusting phase leading to intravascular depletion and shock; and exfoliation 
resulting in areas of skin that may require surgical debridement and grafting 
[35,36,44]. Other rarer complications include severe pneumonia and respiratory 
distress, infection of the cornea and other parts of the eye which may lead to vision 
loss, loss of appetite, vomiting and diarrhoea which may lead to severe dehydration, 
electrolyte abnormalities and shock, cervical lymphadenopathy and oropharynx 
involvement which may lead to retropharyngeal abscess or respiratory compromise, 
sepsis, septic shock, and encephalitis, proctitis, rectal perforation, myocarditis and 
death [20,29,32,33,35,36,45,49]. 
Most recently, two systematic reviews were conducted up to September 2024 (data 
mostly from the 2022 global outbreak) to understand prognosis, complications and 
risk factors. The search strategy returned 3606 results; after the screening, 130 
studies (19 for risk factors) were included, including 89 722 patients with a male 
percentage ranging from 42.9–100% and a median age range of 6.9 to 43 years [49]. 
Limited data were available on children and pregnant women to inform this 
systematic review. With current ongoing outbreak in the African Region, this 
systematic review will need to be updated and comparisons between clades and 
mode of transmission considered. 
2.4 Laboratory findings 
Small studies looking at laboratory abnormalities in patients with mpox indicate that 
leucocytosis, elevated liver transaminases, low or high blood urea nitrogen and 
hypoalbuminemia were common features during illness, and that lymphocytosis and 
thrombocytopenia were seen in more than one-third of patients evaluated [16,33,44]. 
2.5 Differential diagnosis 
The rash which develops in mpox may resemble the rashes caused by other 
infectious diseases or other conditions, including primary varicella zoster virus 
infectious (VZV, chickenpox), herpes simplex virus infection (HSV), primary or 
secondary syphilis, disseminated gonococcal infection (DGI), foot and mouth disease, 
Introduction 
7 
chancroid, lymphogranuloma venereum (LGV), granuloma inguinale, molluscum 
contagiosum, measles, scabies, rickettsia pox, chikungunya, Zika virus, dengue fever, 
vasculitis and other bacterial skin and soft tissue infections [50,51,52]. 
Disseminated cryptococcosis skin lesions may resemble mpox under some 
circumstances. Guidelines for diagnosing, preventing and managing cryptococcal 
disease among adults, adolescents and children living with HIV from WHO can be 
found here: https://www.who.int/publications/i/item/9789240052178
 [53] 
Often, the rash caused by VZV can be confused with mpox but may be distinguished 
as the VZV rash generally progresses more rapidly, is more centrally located than the 
centrifugal distribution of mpox, and patients usually do not classically have lesions 
on their palms and soles [16,29]. Additionally, patients with VZV typically do not have 
lymphadenopathy, which is a hallmark of mpox [29]. In the recent publication on 
cases from South Kivu, Democratic Republic of the Congo (Brosius et al., 2025), 
lymphadenopathy differed significantly between age groups, while common in adults 
(82%) and children between 5–14 years old (69%), it was less frequent in children less 
than 5 years old (16%). In adults, inguinal lymphadenopathies were primarily 
affected, whereas in children, the submandibular nodes were more commonly 
involved [54]. 
Despite the clinical differences between these two diseases, a study from the 
Democratic Republic of the Congo reported polymerase chain reaction (PCR)-
confirmed co-infection with mpox and VZV, with an incidence of 10–13% [55,56]. 
Patients with co-infection reported fatigue, chills, headache and myalgias. These 
individuals were less likely to report signs/symptoms of oral sores, axillary 
lymphadenopathy, cough or sore throat. Patients with co-infection had a higher 
lesion burden than seen with VZV alone but a lower rash burden than seen with 
mpox alone raising the suggestion that co-infection with these two viruses could 
modulate severity of the overall infection – an area for further investigation [55,56]. 
Other co-infections can occur, such as mpox and syphilis or gonorrhoea, mainly 
when sexual transmission. 
2.6 Pregnant people and postpartum period 
Mpox can affect pregnant persons and their fetuses [57]. In utero transmission of 
mpox has been documented, as well as transmission from mother to child via direct 
contact [58,59,61]. The former is from a longitudinal case series that reported 
outcomes of four pregnant persons: one delivered a healthy baby, two had early 
Clinical management and infection prevention and control for mpox 
8 
miscarriages and one a fetal death where the stillborn was covered with diffuse rash 
with virologic confirmation of mpox. This suggests that mpox infection may lead to 
adverse outcomes for the fetus, such as death or spontaneous abortion [33,59]. A 
2024 systematic review of seven studies identified 32 pregnant people with clade IIb 
MPXV infection between 6 and 31 weeks of gestation; 3 of the 12 pregnancies with 
reported gestational outcomes, half of them resulted in intrauterine fetal demise [60]. 
The association between severity of maternal illness and these outcomes is unclear 
[59,62]. 
2.7 Mid-and-long-term effects 
More information is needed about the clinical characterization of mid- and long-term 
effects of mpox. One study has reported > 90% of mpox survivors have no 
complications, regardless of smallpox vaccination status [35]. Of those who do 
develop long-term complications, most common sequelae are disfiguring scarring of 
the skin and blindness [29,35,63]. Pitted scars or pockmarks can develop [29,35]. Data 
also suggest that patients may be at risk for developing mental health complications 
[36]. 
2.8 Transmission and viral shedding 
MPXV DNA can be detected in a wide variety of clinical samples, including faeces, 
saliva, skin and mucosal lesions, as well as semen, urine and blood [64,65,66,67]. 
Replication-competent virus has been isolated from skin lesion swabs, oropharyngeal 
swabs, anal swabs, urethral swabs, conjunctival swabs and semen [64]. Studies have 
shown that skin lesions, anorectal lesions and saliva contain the highest 
concentration of viral DNA [64,65,66,67]. 
The data describing mpox transmission and viral shedding show that transmission 
can occur from animal to human, human to animal, human to human, and from 
contaminated environments to humans [90]. Previously, most of the available 
information was derived from the 2022 global mpox outbreak of clade IIb MPXV, 
which predominantly affected gay, bisexual and other men who have sex with men. 
In early 2024, a new MPXV strain, subclade Ib was identified in the Democratic 
Republic of the Congo and neighbouring countries. Since the publication of the 2022 
interim guideline two systematic reviews have been commissioned by WHO on 
transmission routes [68] with the latest review including literature published between 
September 2022 and September 2024 (review unpublished at the time of writing this 
guideline but information is available upon request). Both reviews found limited data 
Introduction 
9 
on transmission of mpox by clade, specifically clade Ia and clade Ib MPXV with no 
studies found reporting on clade IIa [68].  
MPXV can be transmitted from infected animals to humans via indirect or direct 
contact [31]. Transmission may occur from bites or scratches, or during activities such 
as hunting, skinning, trapping, cooking, playing with carcasses or eating animals, 
such as terrestrial rodents, non-human primates, antelopes and gazelles and tree 
squirrels [35]. Human-to-animal mpox transmission has been documented through 
close contact [69]. The extent of viral circulation in animal populations is not entirely 
known and further studies are underway [29,70]. Current evidence strongly suggests 
that the 2022 and 2024 multi-country outbreaks have not driven by animal-to-
human transmission, rather through sustained human-to-human 
transmission [71,72]. 
Human-to-human transmission can occur through direct physical contact with 
infectious lesions of the skin or mucous membranes, contact with fluids or exudate 
from those lesions or IRPs [11,16,73,72]. The 2024 review found only one report of a 
single case of self-reported “droplet exposure” out of the 32 317 cases that reported 
routes of transmission data (unpublished data). The single case was one of 12 
breakthrough infections after post-exposure vaccination against mpox (the study 
defined droplet transmission as occurring during the presence of the exposed person 
without masks at less than 2 metres for at least 3 hours with a PCR-confirmed mpox 
patient) [74]. There were no reported inhalation exposures. A study published in May 
2022 on the clinical characterization of 216 patients diagnosed between 2007 and 
2011 in the Democratic Republic of the Congo suggested that MPXV DNA in blood 
and the upper respiratory tract may be detected prior to onset of rash and that peak 
viral load may occur very early in the disease course [75]. While there have been 
studies that have shown the detection of MPXV DNA in air samples [76,77], and 
replicant-competent virus during bedding change in one United Kingdom hospital-
based study [77], there has been no epidemiological evidence to date of 
airborne/inhalation transmission. 
In the 2022 multi-country mpox outbreak, transmission was reported as primarily 
occurring through close physical, sexual contact (oral, vaginal, anal) [47]. Subsequent 
literature review conducted between September 2022 and September 2024 
supported this finding [11]. The 2024 systematic review of non-comparative studies 
(222 studies describing transmission routes for 32 317 cases of mpox) identified 
intimate physical contact (sexual contact and suspected sexual contact) as the 
Clinical management and infection prevention and control for mpox 
10 
primary mode of transmission (95.4%) followed by close (non-sexual) contact (2.9%). 
Therefore, contact transmission represented 98.3% of the 32317 cases of mpox 
reviewed.  
If infected during pregnancy, MPXV can cross the placenta leading to intrauterine 
exposure of the fetus and risk of congenital infection of the infant [78]. 
Environment-to-human transmission can occur through contact with MPXV 
contaminated objects, fabrics and surfaces (also described as fomite or indirect 
contact transmission) [79,80,81]. Pox viruses are generally more resistant to 
environmental conditions and show high environmental stability [48,49,82,83]. 
Studies conducted in health care facilities or in household settings, show that MPXV 
DNA can be found on several surfaces in the environment [43,45,84,85,86,87]. Some 
studies have shown the MPXV can also persist in the environment for several days 
after the patient with mpox has left the space [46,47]; however, transmission through 
percutaneous injury with a contaminated object, fomite, transplacental and animal 
products were uncommon, accounting for approximately 1.8%. In 24 studies 
reviewed between 2022–2024 describing 3331 household exposures,134 persons 
were infected (secondary infection rate of 4.02%) and the route of transmission was 
described as mainly close contact (non-sexual and sexual). Based on global 
surveillance data, less than 1% of reported cases have been attributed to fomite 
transmission [88,89]. While the risk of infection through contact with contaminated 
materials is low, it is not implausible [86,87]. Contaminated clothing or linens can 
disperse the MPXV if shaken [77,91]. The most recent systematic review conducted in 
2024 (see details in Methods section – data not yet published) did not find any 
health worker infections reported after exposure to contaminated bed linen of 
patients with mpox. 
Mpox transmission through percutaneous injury with contaminated sharp objects has 
been documented in health and care workers during specimen collection [92] as well 
as in community settings, in particular tattoo parlours [93]. The review conducted in 
2024 found 29 studies that examined exposures among health and care workers. Of 
the 1738 exposures reported, 14 became infected. Ten of these infections indicated 
percutaneous injuries as the route of transmission. 
2.8.1 Infectious period 
Mpox infectious period can vary, but it typically begins with the onset of symptoms 
and patients are considered infectious until new lesions have stopped appearing, 
Introduction 
11 
existing lesions have crusted, scabs have fallen off lesions that formed scabs, and 
fresh, healthy skin can be seen where lesions used to be. This may generally take 
from 2 to 4 weeks, but some patients have been found to have persistent lesions for 
much longer [46,54]. There are studies that have also suggested that some patients 
might be infectious before symptom onset [75,94,95,96]. The potential for pre-
symptomatic transmission remains unclear and more research is needed. 
2.8.2 Children 
Historically, mpox infection in countries in Central Africa has afflicted primarily 
children (under 18 years old) and younger age adults, mainly thought to be because 
older generations had smallpox vaccine-cross protection. The 2022 outbreak, which 
was dominated by clade IIb MPXV mostly affected gay, bisexual and other men who 
have sex with men, and children represented approximately only 1.3% of the total 
reported global cases [97]. Since 2023, the Democratic Republic of the Congo and 
the Central African Republic report a higher proportion of children among cases of 
mpox due to clade Ia MPXV [98]. Studies have shown that there is a difference in the 
exposure characteristics between younger children and older children mpox. Children 
between the ages of 0–12 years old most often acquired infection after direct skin-
to-skin contact with a caregiver or household member with mpox; whereas children 
between the ages 13–17 years old had similar exposure characteristics to those most 
commonly reported among adults (i.e., sexual contact) [97,99,100]. 
2.8.3 Wastewater surveillance 
MPXV can be detected in wastewater and guidance for wastewater and 
environmental surveillance for MPXV is available from WHO [101]. The virus present 
in mucosal and skin lesions can be released into grey water during activities 
including brushing teeth, hand washing, bathing, and from excretions into toilets 
[72]. There is no known case of mpox infection resulting from contact with 
contaminated wastewater to date [72] and detection of replication-competent MPXV 
in wastewater has not yet been reported [102,103]. 
 
 
3. Who do these recommendations 
apply to? 
This guideline applies to patients with mpox infection cared for in the community, at 
home or in a health facility. Recommendations may differ based on the severity of 
MPXV defined by the clinical assessment of patients: presence of risk factors for 
severe disease, danger signs or complications. 
WHO classification of severity of mpox disease and different pathways according to 
it: 
• Non-severe mpox: home-based care 
• Severe or complicated mpox: admission in health facility for closer monitoring 
and clinical care 
Table 1. Risk factors and clinical findings described as being associated with severe disease and poor 
outcomes (based on small, uncontrolled observational studies) (Published in 2022) 
Patient groups at higher 
risk of severe disease or 
complications 
Children, pregnant women, persons who are immunosuppressed such as 
persons living with HIV having poorly controlled disease have historically 
been at risk groups (low CD4 cell count) [106,18,45,29,32,46]. 
Though data are lacking, patients with chronic skin conditions (e.g. atopic 
dermatitis), acute skin conditions (i.e. burns) may also be at higher risk for 
complications, such as bacterial infection. 
Results of recent systematic review can be found in next chapter. 
Clinical signs and 
symptoms of 
complications 
Nausea and vomiting [29,40], painful cervical lymphadenopathy causing 
dysphagia, poor oral intake, eye involvement: eye pain, vision 
abnormalities, hepatomegaly, sepsis, dehydration, respiratory distress/ 
pneumonia, and/or confusion. 
Results of recent systematic review can be found in next chapter. 
Laboratory abnormalities Elevated hepatic transaminases (AST and/or ALT), low or high blood urea 
nitrogen (BUN), low albumin, elevated white blood count (WBC), or low 
platelet count [40]. 
Skin lesion severity score From smallpox experience [59,107]: 
Mild (< 25 skin lesions) 
Moderate (25–99 skin lesions) 
Severe (100–250 skin lesions) 
Very severe (> 250 skin lesions). 
3.1 Risk factors for severe disease 
Risk factors: Most recently, a systematic review was conducted up to September 
2024 [49] (data mostly from the 2022 global outbreak) to understand prognosis, 
Who do these recommendations apply to? 
13 
complications and risk factors. The search strategy returned 3606 results; after the 
screening, 130 studies (19 for risk factors) were included, including 89 722 patients 
with a male percentage ranging from 42.9% to 100% and a median age range of 6.9 
to 43 years. Limited data were available on children and pregnant women to inform 
this systematic review. With the current ongoing outbreak in the African Region, this 
systematic review will need to be updated and comparisons between clades and 
mode of transmission considered. 
Using previously agreed upon thresholds, in discussion with the methodology chair, 
and subsequently confirmed with the GDG, it was determined that the criteria for 
determining whether a risk factor was significant for predicting hospitalization in 
patients with non- severe disease was if in the review of observational data, the risk 
factor had an odds ratio (OR) of greater than 2.0 and there was at least a moderate 
certainty of evidence. Additional, but less impactful, risk factors were noted if they 
had at least a moderate certainty of evidence and an OR of between 1.7 and 2.0. 
Those with a low or very low certainty of evidence or an OR of less than 1.7 were not 
considered significant risk factors for severe disease. 
Thus, major factors noted to meet the specified criteria as significant risk factors for 
patients with non-severe mpox infection developing severe disease or hospitalization 
(see Table 2) are: 
• HIV positive 
• HIV (CD4 < 350 cells/mm
3) 
The next section will show the results of a recent systematic review that has data 
published up to September 2024 [49]. 
Table 2. Risk factors associated with severe disease or hospitalization 
Risk factors Study results and 
measurements 
Certainty of the 
evidence 
Summary 
Age (per 10 years 
increase) 
Odds ratio: 0.88 
(95% CI 0.63 to 1.23) 
Based on data from 16 939 
participants in 6 studies 
Low 
Due to serious 
inconsistency, Due to 
serious imprecision 
Age may be associated 
with little or no increase in 
severe disease. 
Sex (males vs 
females) 
Odds ratio: 0.78 
(95% CI 0.34 to 1.78) 
Based on data from 5501 
participants in 3 studies 
Low 
Due to serious 
inconsistency; Due to 
serious imprecision 
Males may be associated 
with little or no increase in 
severe disease compared 
with females. 
HIV (positive vs 
negative) 
Odds ratio: 1.79 
(95% CI 1.07 to 3.00) 
Moderate 
Due to serious 
inconsistency 
HIV is probably associated 
with increased odds of 
severe disease. 
Clinical management and infection prevention and control for mpox 
14 
Based on data from 9883 
participants in 7 studies 
HIV (CD4 < 350 
cells/mm3 vs HIV 
negative) 
Odds ratio: 2.45 
(95% CI 1.19 to 5.02) 
Based on data from 2321 
participants in 2 studies 
High Patients with CD4 < 350 
cells/ mm3 are associated 
with increased odds of 
severe disease compared 
with HIV negative patients. 
HIV (CD4 ≥ 350 
cells/mm3 vs HIV 
negative) 
Odds ratio: 0.82 
(95% CI 0.55 to 1.22) 
Based on data from 2321 
participants in 2 studies 
Low 
Due to serious 
inconsistency, Due to 
serious imprecision 
Patients with CD4 ≥ 350 
cells/mm3 may be 
associated with little or no 
increase in severe disease 
compared with HIV 
negative patients. 
Vaccination (mpox or 
smallpox) 
Odds ratio: 0.88 
(95% CI 0.57 to 1.36) 
Based on data from 7400 
participants in 7 studies 
Low 
Due to serious 
inconsistency; Due to 
serious imprecision 
Mpox or smallpox 
vaccination may be 
associated with little or no 
decrease in severe disease. 
Vaccination 
(childhood or prior 
smallpox) 
Odds ratio: 0.96 
(95% CI 0.61 to 1.51) 
Based on data from 7032 
participants in 6 studies 
Low 
Due to serious 
inconsistency; Due to 
serious imprecision 
Childhood or prior 
smallpox vaccination may 
be associated with little or 
no decrease in severe 
disease. 
 
Only one major factor noted to meet the specified criteria as significant risk factors 
for patients with non severe mpox infection for death (see Table 3) are: 
• HIV (positive) 
Table 3. Risk factors associated with mortality 
Risk factors Study results and 
measurements 
Certainty of the 
evidence 
Summary 
HIV (positive vs 
negative) 
Odds ratio: 10.81 
(95% CI 9.80 to 11.92) 
Based on data from 3377 
participants in 2 studies 
High HIV is associated with increased 
odds of all-cause mortality. 
Age (per year) Odds ratio: 0.90 
(95% CI 0.82 to 0.97) 
Based on data from 86 
participants in 1 study 
Very low 
Due to extremely 
serious imprecision 
We are uncertain whether age is 
associated with increased odds of 
all-cause mortality. 
Sex (males vs 
females) 
Odds ratio: 3.59 
(95% CI 0.54 to 23.60) 
Based on data from 86 
participants in 1 study 
Very low 
Due to extremely 
serious imprecision 
We are uncertain whether males 
are associated with increased odds 
of all-cause mortality compared 
with females. 
Who do these recommendations apply to? 
15 
3.2 Prognosis 
3.2.1 Risk for adverse outcomes 
Table 4 shows the baseline risk estimates from the systematic review. In the non-
severe cohort the rate of hospitalization is 4% (39 to 42) with very low mortality. 
Whereas, in patients from the severe cohort, already hospitalized, the rate of death is 
estimated to be 4.6% (36 to 58). 
Table 4. Baseline risk for adverse outcomes in patients with mpox 
Outcomes Event rate (95% CI per 1000) 
Non-severe cohort* Severe cohort* Overall 
Hospitalization 40 per 1000 (39 to 42) NA 42 per 1000 (40 to 43) 
ICU admission 0.3 per 1000 (0.1 to 0.7) 49 per 1000 (33 to 68) 0.4 per 1000 (0.1 to 0.9) 
Mechanical ventilation 8 per 1000 (1 to 19) 55 per 1000 (34 to 80) 26 per 1000 (16 to 39) 
All-cause mortality 0 per 1000 (0 to <0.001) 46 per 1000 (36 to 58) 0 per 1000 (0 to <0.001) 
* The review team used a 50% threshold to categorize studies as severe or non-severe. Studies 
with fewer than 50% of participants classified as having severe mpox or hospitalized for 
treatment were categorized as non-severe; studies with 50% or more were categorized as severe. 
3.3 Rate of complications 
3.3.1 Rate of complications 
Table 5 shows the rate of complications reported in mpox patients. Overall, 
complications were uncommon (< 10%) but significant variation was observed 
between the non-severe and severe cohort of patients. In the severe cohort, 
complications commonly reported (>10%) included: secondary bacterial infection 
(21%), gastroenteritis (13%), severe pain (27%), cellulitis (15%), proctitis (24%), 
urethritis (17%) and rectal bleeding (16%). These data are from the systematic review 
that included studies published up to September 2024. With current ongoing 
outbreak in the African Region, this systematic review will need to be updated and 
comparisons between clades and mode of transmission considered. 
Table 5. Baseline risk for complications of mpox 
Outcomes Event rate (95% CI per 1000) 
 Non-severe cohort* Severe cohort* Overall 
Clinical management and infection prevention and control for mpox 
16 
Acute kidney injury NA 14 per 1000 (2 to 34) 14 per 1000 (2 to 34) 
Secondary bacterial 
infection 
75 per 1000 (69 to 84) 210 per 1000 (188 to 232) 92 per 1000 (86 to 99) 
Respiratory failure NA 37 per 1000 (21 to 56) 37 per 1000 (21 to 56) 
Sepsis 0.3 per 1000 (0 to 1.5) 38 per 1000 (23 to 55) 2 per 1000 (0.3 to 3) 
Pneumonia 3 per 1000 (1 to 6) 32 per 1000 (8 to 67) 4 per 1000 (1 to 7) 
Gastroenteritis 12 per 1000 (0.2 to 35) 125 per 1000 (37 to 248) 23 per 1000 (6 to 48) 
Encephalitis 0 per 1000 (0 to 0.2) 3 per 1000 (0 to 9) 0 per 1000 (0 to 0.2) 
Severe pain 24 per 1000 (19 to 29) 273 per 1000 (243 to 303) 51 per 1000 (45 to 58) 
Cellulitis 42 per 1000 (35 to 51) 153 per 1000 (102 to 211) 46 per 1000 (38 to 55) 
Keratitis 63 per 1000 (30 to 
106) 
32 per 1000 (16 to 52) 39 per 1000 (24 to 58) 
Conjunctivitis 38 per 1000 (33 to 43) 20 per 1000 (13 to 30) 34 per 1000 (30 to 39) 
Abscess 27 per 1000 (18 to 38) 17 per 1000 (7 to 31) 24 per 1000 (16 to 32) 
Myocarditis 0 per 1000 (0 to 0.01) NA 0 per 1000 (0 to 0.01) 
Epiglottitis 1 per 1000 (0 to 7) NA 1 per 1000 (0 to 7) 
Tonsillitis 30 per 1000 (23 to 37) 70 per 1000 (40 to 107) 32 per 1000 (26 to 39) 
Pharyngitis 56 per 1000 (33 to 84) 71 per 1000 (21 to 146) 58 per 1000 (37 to 84) 
Urinary retention 7 per 1000 (0.2 to 19) 18 per 1000 (0 to 75) 7 per 1000 (0.5 to 19) 
Proctitis 67 per 1000 (62 to 72) 235 per 1000 (177 to 298) 69 per 1000 (64 to 74) 
Urethritis 11 per 1000 (8 to 14) 167 per 1000 (88 to 263) 12 per 1000 (8 to 15) 
Rectal bleeding 26 per 1000 (8 to 51) 160 per 1000 (111 to 215) 74 per 1000 (50 to 
101) 
Penile edema 45 per 1000 (35 to 56) NA 45 per 1000 (35 to 56) 
Paraphimosis 9 per 1000 (6 to 12) NA 9 per 1000 (6 to 12) 
* The review team used a 50% threshold to categorize studies as severe or non-severe. Studies 
with fewer than 50% of participants classified as having severe mpox or hospitalized for 
treatment were categorized as non-severe; studies with 50% or more were categorized as severe. 
 
Recommendations for the mpox care pathway 
17 
4. Recommendations for the mpox 
care pathway 
The following section of the guideline provides recommendations for screening, 
triage and testing for patients with suspected mpox. See figure 1 (Annex 4) for a 
visual description of the care pathway. 
4.1 Screening and triage 
4.1.1 Screening 
Interim guidance (Published 10 June 2022) 
WHO recommends, at the first point of contact with the health system, screening 
and triage should be performed for all persons who present with a rash and fever 
and/or lymphadenopathy, according to locally adapted WHO case definition, to 
identify individuals with suspected or confirmed mpox infection. 
• Persons with symptoms that meet the case definition for suspected mpox [108] 
(see Annex 1: WHO case definitions for mpox outbreak in non-endemic 
countries) should enter the mpox clinical care pathway and immediately be 
given a well-fitting medical mask and isolated in a well-ventilated single room. 
If a well-ventilated single room is not available, then group patients with 
similar clinical diagnosis and based on epidemiological risk factors, with a 
spatial separation (at least 1 metre between patients). 
• Suspected cases should not be cohorted together with confirmed cases. 
4.1.1.1 Practical info 
• A simplified questionnaire and screening protocol based on the WHO case 
definition adapted to local epidemiology can be implemented at the point of 
entry to health care (or during contact tracing) to screen patients based on the 
WHO case definition and local epidemiology. For example, during this outbreak, 
this can be done at primary care clinics, sexual health clinics, emergency 
departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, 
maternity and paediatrics clinics and others. 
Clinical management and infection prevention and control for mpox 
18 
• Depending on national (local) coordination pathways, telemedicine may be 
considered as a means of screening patients. 
• Medical masks and alcohol-based hand sanitizer should be available for patients 
presenting at screening areas. Signs should be posted for both respiratory 
hygiene and hand hygiene and instructions to put on a well-fitting medical mask. 
• Screening activities should be conducted maintaining a distance of at least 1 m 
from patients and using a “no touch” approach. Where these measures cannot be 
implemented or maintained then the facility should conduct a risk assessment to 
determine the level of PPE required according to the IPC recommendations for 
health facilities in the context of mpox. Health and care workers performing 
screening should follow the WHO Your 5 moments for hand hygiene [14,109,110]. 
• While waiting, crowding should be prevented between patients and a distance of 
at least 1 m should be maintained between patients [110]. 
• Consider implementing in-patient surveillance for mpox depending upon local 
epidemiology. 
4.1.2 Triage 
Interim guidance (Published 10 June 2022) 
WHO recommends after screening and isolation, patients with suspected mpox 
infection should be triaged using a standardized triage tool (e.g. 
WHO/International Federation of Red Cross and Red Crescent Societies (IFRC) 
Interagency Integrated Triage Tool), and evaluated to determine risk factors and 
presence of severe disease. 
• Triage refers to the sorting of patients by priority after screening, based on 
specific criteria (e.g. severity) and can be performed at any point of access to 
the health care system, including in both pre-health care and facility-based 
settings [111] and in hospital wards, during monitoring of patients. 
• Acuity based triage is the action of sorting and prioritizing patients based on 
the estimation of their severity. This is used to identify patients who require 
immediate medical intervention and those who can safely wait or who may 
need to be transported to a specific destination based on their condition [111]. 
Recommendations for the mpox care pathway 
19 
• The Interagency Integrated Triage Tool (IITT) is a novel triage tool developed to 
provide an integrated set of protocols for routine triage of adults and children. 
The tool focuses on a three-tier triage system and can be found in the WHO 
Clinical care for severe acute respiratory infection toolkit [111]. 
• Clinical assessment should focus on identifying signs and symptoms of severe 
or complicated disease and those at higher risk for severe disease (see Table 5). 
 
  
Clinical management and infection prevention and control for mpox 
20 
4.2 Testing for mpox 
Interim guidance (Published 10 June 2022) 
WHO recommends to test for monkeypox virus in patients with suspected mpox 
• Testing for mpox virus should be conducted as soon as possible to confirm 
diagnosis [106]. 
• Early HIV testing should be conducted when patients present with suspected or 
confirmed mpox infection [107]. 
• In areas with other endemic infections that cause rash and fever or 
lymphadenopathy, or if patient has risk factors for other diseases, as part of 
screening, febrile patients should be tested and treated per routine protocols 
(e.g. STIs such as syphilis, HSV and HIV, malaria testing in endemic areas for 
patients with fever, and other infectious diseases per clinical context and local 
epidemiology). 
 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
21 
5. Recommendations for patients with 
mild or uncomplicated mpox 
(home-based care) 
There is one updated IPC recommendation and one new best practice 
recommendation in this section. 
5.1 Infection prevention and control (IPC) considerations 
in home-based care 
Public health emergencies often begin and end in communities; therefore, an 
effective emergency response always includes communities and their interests. This 
requires a multifaceted approach that includes, but is not limited to, risk 
communication and community engagement strategies, public health and social 
measures, vaccination strategies, environmental services such as adequate water and 
sanitation infrastructure, and the application of IPC measures [114,115,116,117]. 
Health ministries and intersectoral partners at national and subnational levels should 
engage with communities and other actors to identify and provide the resources 
needed, implement risk communication strategies [118,119] to provide support, and 
look to other contexts for possible solutions to ensure that IPC measures can be met 
to provide safe care in settings where patients will be cared for [120]. 
In the context of emergency response, it is crucial that community IPC and WASH 
measures are implemented to mitigate and control transmission in high-risk settings, 
such as households with suspected cases, congregate settings, which includes 
internally displaced persons (IDP) and refugee camps and to ensure continuity of 
services such as schools. Infection prevention and control measures such as hand 
hygiene, dedicated personal items, handling of linen and laundry, environmental 
cleaning and disinfection and waste management, should be applied and adapted 
applied to community settings to mitigate and control transmission of mpox. 
Previous guidance (2022) advised persons with mpox recovering at home to isolate 
themselves. Given the evolving evidence and perceived values and preferences of 
persons with mpox to avoid home isolation, the updated recommendation by the 
GDG reflects a shift away from isolation during home-based care, provided IPC 
measures can be implemented and maintained. Further research needs for IPC during 
Clinical management and infection prevention and control for mpox 
22 
home-based care are listed in the section Uncertainties, emerging evidence and 
future research. 
5.1.1 Infection prevention and control measures 
Good practice statement (Published May 2025) 
Infection prevention and control measures including hand hygiene, dedicated 
personal items, appropriate handling of linens and laundry, cleaning and 
disinfection of the environment, and waste management should be followed for 
persons with mpox in the community until all lesions are healed.* 
* Healed lesions: lesions have crusted, scabs have fallen off and a fresh layer of skin has formed 
underneath. 
5.1.1.1 Practical info 
5.1.1.1.1 Implementation considerations 
• The person with mpox infection should wear a well-fitting medical mask and cover 
lesions when in close proximity to others until their existing lesions have crusted, 
scabs have fallen off lesions that formed scabs, and fresh, healthy skin can be seen 
where lesions used to be. 
• The person with mpox infection recovering at home should be able to manage 
their self-care or identify a designated caregiver, preferably someone who is in 
good health, that has no underlying health conditions and has had previous 
smallpox or mpox vaccination or MPXV infection (see the conditional 
recommendation for home care for details for caregivers). The activities 
undertaken by caregivers may include preparing meals, going to the grocery 
store, getting medications, etc. 
• The person with mpox infection recovering at home should refrain from contact 
with wild or domestic animals to avoid infecting the animal. This includes keeping 
possibly infectious and contaminated material, such as linens, towels and clothing 
away from pets and other animals. Another person should take care of domestic 
animals throughout the illness. 
• If a health and care worker is required to provide care to patients with mpox in 
the home, they should wear appropriate PPE (gloves, gown, eye protection and 
medical mask), perform hand hygiene (according to the WHO 5 moments and 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
23 
before putting on and after removing PPE) and clean and disinfect any patient 
care equipment used. 
5.1.1.1.2 Hand hygiene 
• Persons with mpox infection, and their caregivers or contacts should practice 
frequent hand hygiene [121]. This includes: 1) before preparing food; 2) before 
eating or feeding/breastfeeding; 3) after using the toilet or handling human 
and/or animal faeces; 4) after coughing, sneezing and/or disposing of a tissue; 5) 
each time they come in contact with their lesions; and 5) when hands are visibly 
dirty. 
• Alcohol-based hand rub or soap and water should be used for hand hygiene. 
• The person with mpox should have their own soap that they do not share with 
other household members. 
5.1.1.1.3 Personal belongings 
• The person with mpox and their family and household members should 
implement the following measures: 
• Avoid sharing personal items such as eating utensils, linens, towels, electronic 
devices. 
• Avoid sharing a bed or sleeping area with other people or animals. 
• Avoid direct contact with upholstered furniture, such as couches or chairs. 
Consider covering furniture with a clean sheet that can be laundered. 
5.1.1.1.4 Handling linen, laundry 
• Only the person with mpox or their dedicated caregiver should handle and 
launder their bedding, clothing etc. 
• Linens and bedding should be carefully lifted and rolled to prevent dispersion 
of infectious particles from lesions and body fluids. They should not be 
shaken. 
• Linens, towels, and clothing from the patient with MPXV should be laundered 
separately from other household laundry and can be reused after washing 
(manually or by machine) with detergent and preferably hot water (> 70°C) or 
in chlorine (a minimum of 0.05%) if hot water is not available [122]. 
5.1.1.1.5 Environmental cleaning 
• Only the person with mpox or their dedicated caregiver should clean and disinfect 
the environment and objects/surfaces. 
Clinical management and infection prevention and control for mpox 
24 
• Dishes and utensils and household surfaces, such as furniture, beds, toilets or 
floors, or any location where the patient has had contact should be cleaned with 
water and soap and disinfected regularly. 
• Common household disinfectants or sodium hypochlorite (household bleach) 
products may be used [123,[124,125,126]. Disinfectants should be prepared and 
applied to surfaces according to manufacturers’ instructions. 
• One study found that the use of a minimum of 0.05% sodium hypochlorite 
solutions or 70% ethanol is efficacious against MPXV when wiped on common 
non-porous surfaces in low-resource settings with a 1-minute contact time 
[123]. 
• Use damp mopping, avoid dry sweeping to prevent dispersion of particles. 
• Carpeting and household furnishing should be steam cleaned where possible. 
Avoid vacuuming. 
5.1.1.1.6 WASH and waste management 
• Authorities should ensure access to safe water, sanitation, hygienic supplies (soap 
and water) and waste collection and disposal for persons with mpox infection and 
their family members during home-based care. 
• Waste that is generated from caring for a patient with MPXV, such as bandages 
and PPE, should be placed in strong bags and securely tied before disposal and 
eventual collection by municipal waste services[127]. 
• If municipal waste services are not available, as an interim measure and 
according to local policies, safely burying or controlled burning of waste may 
be performed until more sustainable and environmentally friendly measures 
can made available in local contexts. 
5.1.1.2 Justification 
The GDG emphasized the critical role of applying IPC principles at the community 
level to reduce community MPXV transmission. Members of the GDG highlighted the 
importance of implementing these IPC measures as a cohesive package of 
interventions, ensuring a multi-pronged approach to minimizing the spread of the 
virus. The GDG acknowledged the primary route of transmission is contact (sexual or 
non-sexual) with the skin lesions, with fluids or exudate from those lesions of 
individuals infected with the MPXV. Given possible contamination of surfaces and 
objects as well as the potential for infectious respiratory particles, the risk of indirect 
contact transmission or direct deposition cannot be excluded. Standard and 
transmission-based precautions describe measures to reduce routes of transmission 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
25 
and are widely used in health care. The use of standard and transmission-based 
precautions are the cornerstone of IPC measures and the GDG noted these should be 
applied wherever there is human-to-human transmission [7,,103]. GDG members also 
noted the important role that ministry of health and implementing partners at 
national and subnational levels play in engaging with communities to identify and 
provide the resources needed, implement risk communication strategies and provide 
solutions to ensure that IPC measures can be met. 
5.1.2 Isolation of patients with mpox 
Conditional recommendation for, low certainty evidence (published May 2025) 
WHO suggests that persons with mild, uncomplicated mpox lesions cared for at 
home are not required to isolate* provided their lesions are covered and they wear 
a well-fitting medical mask when in close proximity with others until all lesions are 
healed.** 
• Persons with mpox who are unable to comply with covering their lesions or 
wearing a medical mask should be isolated at home. 
• IPC measures to reduce environmental contamination in the home should be 
implemented. 
* Isolation: the separation of infected people with a contagious disease from people who are not 
infected. 
** Healed lesions: lesions have crusted, scabs have fallen off and a fresh layer of skin has formed 
underneath. 
5.1.2.1 Practical info 
5.1.2.1.1 Implementation considerations 
For information on implementing IPC measures in a home/household setting refer to 
the good practice statement and its implementation considerations. 
For persons with mpox recovering at home without implementing isolation, the 
following measures, in addition to the IPC measures described in the good 
practice statement, should be followed: 
• Persons with mpox recovering at home should wear a medical mask (if a medical 
mask is not available, a fabric mask may be worn [118]) and cover their lesions 
when near others. 
Clinical management and infection prevention and control for mpox 
26 
• Covering lesions can be done with the use of bandaging and/or by wearing 
clothing that comfortably covers the lesions. 
• Clinical follow-up should be conducted using methods other than in-person visits 
(e.g. telemedicine, telephone). 
• Regular cleaning and disinfection of the environment the person with mpox 
occupies and frequently touched surfaces should be implemented. 
• Individuals with mpox should limit traveling outside their home. 
• If a person with mpox leaves their home they should wear a well-fitting 
medical mask and ensure all lesions are covered. 
• If they leave their home they should ideally use private transportation and 
ensure proper ventilation in the vehicle, such as open windows if feasible. 
• If a person with mpox leaves their home to seek medical attention, they 
should inform their health practitioner or the facility they will visit in advance 
of arrival (so the facility can implement transmission-based precautions). 
• The person recovering at home should be able to manage their self-care or 
identify a designated caregiver, preferably someone who is in good health, has no 
underlying health conditions and has had previous smallpox or mpox vaccination 
or MPXV infection (for example, this may include preparing meals, going to the 
grocery store, getting medications, etc.). 
• If there is a designated caregiver they should maintain a distance of at least 1 
m from the person with mpox. 
• When distance cannot be maintained, or when conducting activities such as 
assisting with laundry, cleaning the environment, the designated caregiver 
should wear a well-fitting medical mask and disposable gloves.* 
• Caregivers should clean their hands with either soap and water or an alcohol-
based hand sanitizer, before and after contact with the person with mpox or 
the environment and before putting on and after removing their gloves. 
In the event that a person with mpox cannot comply with wearing a mask and 
covering their lesions and therefore are required to isolate at home they should: 
• Designate one person to facilitate their self-care: preferably someone who is in 
good health, has no underlying health conditions and has had previous smallpox 
or mpox vaccination or mpox virus infection. For example, this may include 
preparing meals, going to the grocery store, getting medications, etc. 
• The person with mpox and the designated person that is facilitating self-care 
should be counselled regarding the risks of transmission. 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
27 
• The person with mpox should stay in a dedicated, well-ventilated room (e.g. 
with windows that can be opened frequently) separate from others in the 
household. In addition, household members should avoid entering the room. 
• If the designated person that is facilitating self-care needs to enter the 
isolation area, ideally with ensuite toilet and shower, and they should refrain 
from close contact with the person with mpox. 
• When distance cannot be maintained, the designated caregiver should wear a 
well-fitting medical mask and disposable gloves.* They should clean their 
hands with either soap and water or an alcohol-based hand sanitizer, before 
and after contact with the person with mpox or surrounding environment and 
before putting on and after removing their gloves. 
• The person with mpox should cover lesions (if tolerable) and wear a well-fitting 
medical mask when in proximity of others, and when moving outside of the 
designated isolation area (e.g. to use the toilet). 
• If adequate isolation and IPC measures cannot be ensured at home, then isolation 
may need to be arranged, with informed consent from the person with mpox and 
agreement from the caregiver and members of the household, in a health care 
facility or other designated facility. 
 
* For more information on implementation in resource-limited settings refer to the Infection 
prevention and control and water, sanitation and hygiene measures for home care and isolation for 
mpox in resource-limited settings: interim operational guide (2024) [ 119].  
Benefits and harms  
The use of isolation at home may reduce potential contacts and protect household 
members and vulnerable people in the community however there was insufficient 
evidence to determine this. On the other hand, isolation can lead to mental health 
challenges such as loneliness, anxiety and depression, amplify stigmatization and 
impose an economic burden due to absence from work or daily activities [122]. 
Based on the available data and the evidence on the modes of transmission of 
mpox, the GDG determined the harms outweigh the benefits. 
Certainty of the evidence Low 
The certainty of evidence was judged to be low and was rated down once for 
indirectness and once for risk of bias. The GDG noted that while there were no 
randomized or observational randomized studies for isolation versus no isolation in 

Clinical management and infection prevention and control for mpox 
28 
the home, inferences about the impact of isolation could be made on the basis of 
the epidemiological findings about the routes of transmission. Over 200 studies 
with over 32000 patients identified the primary mode of transmission as sexual 
(95.4%) or non-sexual close contact (2.9%). 
Values and preferences Substantial variability is expected or 
uncertain 
The GDG acknowledged that many individuals (the person with mpox) would prefer 
not to implement isolation because of the negative mental health, social and 
economic consequences. Values and preferences may vary in family members and 
communities depending on their level of fear of getting mpox if the person is not 
isolated.  
Resources and other considerations  
The use of isolation at home may require significant operational and financial costs 
and support for the affected person with mpox, their family/caregiver and the 
health system. There may be costs and resource implications to the person with 
mpox or the health system to ensure access to medical masks and materials to 
cover lesions where isolation is not implemented. 
Equity 
The GDG acknowledged that there may be inequities in managing isolation at 
home, in particular in low- and middle-income countries where support may not be 
available including social and financial and stigmatization may be increased. 
Acceptability 
The GDG noted that in some situations, the person with mpox or their family 
members may prefer to utilize home isolation to potentially reduce transmission 
within the household. However, others may find isolation unacceptable or difficult 
to implement. 
Feasibility 
The GDG acknowledged there may be issues with the feasibility of isolation at 
home as well as the wearing of masks and covering of lesions. 

Recommendations for patients with mild or uncomplicated mpox (home-based care) 
29 
5.1.2.2 Justification 
The GDG noted that while there were no randomized or observational randomized 
studies for isolation versus no isolation in the home and the low certainty of the 
evidence, inferences about the impact of isolation could be made on the basis of the 
transmission route. 
Over 200 studies with over 32 000 patients identified the primary mode of 
transmission as close contact (sexual or non-sexual) (data are not yet published but is 
available upon request). The review found that amongst 3331individuals documented 
to be exposed in the household, of whom 134 were infected (4.02% secondary 
infection rate) most reported non-sexual close contact or sexual contact. 
Similarly, amongst 3643 individuals documented to have been exposed in community 
or congregate settings, of whom 91 were infected (2.5% secondary infection rate), 
most reported non-sexual close contact or sexual contact. It was not clear in many 
studies what protective measures, if any, had been taken. Only possible routes of 
transmission were described. The GDG noted that there were limited studies available 
that describe the different MPXV clades and there was some concern on the possible 
impact on transmission which may differ depending upon the clade. 
The available evidence from the 2023 and 2024 systematic reviews presented on 
human-to-human transmission supports close contact (sexual or non-sexual) with the 
lesions of an infected person as, overwhelmingly, the primary mode of transmission 
[66]. The GDG acknowledged that while the main route of transmission is through 
direct contact (sexual or non-sexual) with the skin lesions (with fluids or exudate from 
those lesions of individuals infected with the MPXV), possible environmental 
contamination as well as the potential for IRP cannot be excluded. The GDG 
determined that IPC measures to prevent close contact would be paramount to 
transmission prevention while including the additional measure of isolation at home 
could cause undue hardship. IPC measures include avoiding direct contact with the 
lesions, use of source control measures for any IRP, and mitigating environmental 
contamination through use of cleaning and disinfection. 
Based on the discussion of the evidence, the benefits and harms associated with 
isolation at home, as well as concerns regarding resource, equity, feasibility and 
acceptability, the GDG formulated a conditional recommendation that includes 
covering the lesions and wearing a medical mask, in addition to IPC measures, to 
prevent environmental contamination rather than isolation of the individual. 
Clinical management and infection prevention and control for mpox 
30 
5.1.2.3 Clinical question/ PICO 
• Population: Person with non-severe mpox is being cared for at home 
• Intervention: Mpox patient isolated until all lesions are fully healed 
• Comparator: Mpox patient does not isolate when all non-healed lesions are 
covered and wears a medical mask 
5.1.2.4 Summary 
The systematic review was conducted in two phases (see Annex 5 for details) and the 
data is not yet published but is available. The Summary of Findings table is based on 
non-comparative studies identified to indirectly inform the IPC PICO question. These 
studies described routes of transmission for suspected and confirmed mpox cases. 
Based on these studies, ten mpox transmission routes were identified amongst the 
32 317 cases of MPXV infection reported in these studies: confirmed sexual 
contact(65.1% of mpox cases),, suspected sexual contact (30.3%)close contact (non-
sexual)( 2.9%), fomite/environment (0.36%), transplacental (0.01%), percutaneous 
injury (0.09%), direct deposition (formerly droplet) (0.003%),inhalation (0%), 
animal/animal products (0.48%) and multiple routes 
(0.83%)[26,27,47,57,86,87,97,102,103,128,130,131,132]. Close contact was the 
predominate route of transmission (95.3 %). Transmission through other routes 
including percutaneous injury with contaminated object, fomite and transplacental 
and animal products were uncommon, accounting for approximately 1.8%. 
An additional sub-analysis was conducted to assess the route of transmission for 
each mpox clade: Clade I, Clade Ib, and Clade IIb. Only 29 out of 222studies reported 
clade information, covering 24% of patients. No cases of Clade IIa were reported in 
the literature. Among the 10788 patients in which the clades were identified, cases 
with clade Ib and IIb MPXV infection describe close contact (confirmed sexual, 
suspected sexual and non-sexual) as the primary routes of transmission. For clade 1a 
there was a total of 218cases identified. Amongst these cases, the routes of 
transmission were primarily described as 40.6% (205) as multiple routes, 30.9% (156 
cases) as exposure to animals /animal products, 17% (86 cases) as close contact (non-
sexual) and 11.5% (58 cases) as other routes of transmission. There was no 
description of droplet or inhalation transmission in any of the 29 clade specific 
studies. 
These findings align with the previous systematic review [68]. 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
31 
Lastly the review also looked at secondary infections reported amongst 8712 patients 
by exposure setting, specifically in health care settings amongst health care workers, 
household exposures and congregate/community settings (including amongst 
community contacts, flight attendants, workplace, gay-oriented festivals, piercing and 
tattooing services, persons and students). A total of 3331 individuals were 
documented to be exposed in the household, of which 134 were infected (4.02% 
secondary infection rate), most of whom reported non-sexual close contact. There 
were 3643 individuals documented to be exposed in the community or in congregate 
settings, of which 91 were infected (2.5% secondary infection rate), most reported 
non-sexual close contact or sexual contact. 
Amongst the 1738 health care workers documented to be exposed to mpox of which 
13 were infected (0.8% secondary infection rate), three probable exposures were 
primarily described as due to unspecified occupational exposures and 10 (71.4%) of 
the cases involved percutaneous (needlestick) injuries. 
Outcome 
Timeframe 
Study results and 
measurements 
Comparator 
Covered 
lesions, medical 
mask, no 
isolation 
Intervention 
Isolation until 
lesions fully 
healed 
Certainty of the 
evidence 
(Quality of 
evidence) 
Summary 
Mpox infection 
inferred from 
transmission 
route frequency 
data 
(Observational (non- 
randomized)) 
31 742 reported cases of 
transmission as a result of close 
contact in 32 318 patients 
(210/222 studies). This can be 
disaggregated further as: 21 025 
cases due to confirmed sexual 
contact; 9788 cases due to 
suspected sexual contact; and 930 
due to non-sexual close contact. 
Inferred odds: 1 
Low 
Due to serious risk 
of bias, Due to 
serious 
indirectness 
1 
Isolating patients 
probably does not 
prevent transmission 
of mpox compared 
with not isolating 
patient provided all 
lesions are covered, a 
medical mask is worn 
and physical contact 
with others is avoided. 
Risk of Bias: serious. Inconsistency: no serious. Indirectness: serious. Imprecision: no serious. Publication 
bias: no serious. 
5.1.3 Symptomatic management 
5.1.3.1 Pain and fever management 
Interim guidance (Published 10 June 2022) 
WHO recommends patients with mpox be given symptomatic treatment such as 
antipyretics for fever and analgesia for pain. 
Clinical management and infection prevention and control for mpox 
32 
5.1.3.1.1 Practical info 
• See Annex 2 for recommendations for symptomatic care. 
• Headache and pain from skin rash, oral, ocular and genital lesions, swollen lymph 
nodes and generalized muscle aches are common. 
• Pruritic lesions and itching can also be bothersome. 
• For oral lesions, rinse the mouth with clean, salt water at least four times a day 
[135]. Consider use of oral antiseptic to keep lesions clean (e.g. chlorhexidine 
mouthwash) or local anaesthetic (e.g. viscous lidocaine) [136] [137]. 
• For genital or anorectal lesions warm sitz baths (warm bath made up of water and 
baking soda or epsom salt to heal and cleanse the perineal, perianal, penile and 
vulvar area) and/or topical lidocaine may offer symptomatic relief [135]. 
5.1.3.2 Nutrition 
Interim guidance (Published 10 June 2022) 
WHO recommends patients with mpox be assessed for their nutritional status and 
given adequate nutrition and appropriate rehydration. 
• Symptomatic and supportive care is essential to maintain good nutrition and 
hydration. 
5.1.3.2.1 Practical info 
Key actions: 
• Assess the nutritional and hydration status of all patients with mpox whether on 
admission to a health facility or when seen in the community. Nutritional intake 
can be compromised due to oropharyngeal lesions and/ or painful cervical 
lymphadenopathy. Nutritional support is described as an important intervention 
[33]. 
• Adults: history of reduced appetite or weight loss, body weight, height, 
calculation of body mass index (BMI), look for signs of malnutrition (e.g. 
muscle wasting, nutritional oedema etc.); a standardized tool can be used (e.g. 
Malnutrition Universal Screening Tool [138]). 
• Children: same as above plus mid-upper arm circumference (MUAC) (6–59 
months). A nutrition specialist or trained clinician should evaluate children and 
those with severe malnutrition [139]. 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
33 
• Oral nutrition should be encouraged daily, as patients need sufficient energy (kcal) 
and essential nutrients, in addition to fluids and electrolytes [140]. If the patient is 
well enough for oral food intake, offer nutrient dense therapeutic foods; especially 
for children and those at risk of malnutrition per the WHO Pocket book of hospital 
care for children [141]. 
• If food intake is not tolerated, evaluate for reason and treat appropriately. For 
example, if poor feeding is a result of nausea or vomiting, antiemetic medication 
can improve intake ability; if it is due to weakness, the patient should be assisted 
with feeding by a health care provider; or, if tolerated, due to pain from oral 
lesions or cervical adenopathy, treat pain. 
• Provide vitamin A supplements according to standard recommendations, 
especially for children who have not recently received a dose. It plays an 
important role in all stages of wound healing and eye health [142]. 
5.1.3.3 Monitoring of signs and symptoms of complications 
Interim guidance (Published 10 June 2022) 
WHO recommends to counsel patients with mild mpox about signs and symptoms 
of complications that should prompt urgent care. 
5.1.3.3.1 Practical info 
• Communication between the patient and trained health workers, should be 
established for the duration of the home-based care period. 
• Monitoring patients and caregivers in the home can be done by trained 
community workers or outreach teams by telephone, telemedicine or email 
initially on a daily basis (when possible) or as considered clinically necessary after 
initial assessments. The patient’s willingness to engage in medical assessments 
should also be considered. 
• Patients with mpox infection and their families should be counselled about the 
signs and symptoms of complications and how to recognize a deterioration in 
their health status that requires medical attention. For example, patients should 
be informed to contact their health worker immediately if their lesions get worse 
or increase in quantity, if they develop worsening pain, persistent fever, nausea or 
vomiting and decreased oral intake, visual symptoms, difficulty breathing or 
dizziness or confusion. 
Clinical management and infection prevention and control for mpox 
34 
• If a pregnant person has chosen to be cared for at home, counsel the person 
about maternal, fetal and newborn signs and to seek care if they develop 
worsening illness or danger signs. Self-care interventions should be encouraged. 
• Counsel about healthy behaviours including diet, physical activity, intake of 
micronutrients, tobacco alcohol and other substance use, per WHO 
recommendations on antenatal [143] and postnatal [144] care. 
• For people requiring abortion services, consider alternative modes of service 
delivery, including self-management of medical abortion up to 12 weeks’ 
gestation, where there is access to accurate information and to a health care 
provider at any stage of the process, per the WHO Abortion care guideline [145]. 
5.1.3.4 General skin care 
Interim guidance (Published 10 June 2022) 
WHO recommends conservative treatment of rash lesions, dependent on their 
stage, with aims to relieve discomfort, speed healing and prevent complications, 
such as secondary infections or exfoliation. 
• Patients should be instructed to avoid scratching the skin and keeping skin 
lesions clean and dry to prevent bacterial infection. They should be instructed 
to wash hands with soap and water or use alcohol-based hand sanitizer before 
and after touching the skin rash or lesions to prevent infection. Lesions may be 
cleaned gently with sterile water or antiseptic solution (see poster Care of skin 
lesion in mpox Infection, WHO [242]). 
• Healing of lesions would by promoted by being uncovered and exposed to air 
when possible. However, while in the proximity of other people, lesions should 
be covered to reduce the risk of transmission. 
• For complications of skin lesions, such as exfoliation or suspicion of deeper soft 
tissue infection (pyomyositis, abscess, necrotizing infection), consider 
consultation with an appropriate specialist (i.e. wound care specialist, ID 
specialist, and/or surgeon). Debridement of the skin should not be done unless 
performed by an expert wearing appropriate PPE [156]. 
5.1.3.4.1 Justification 
Optimal management of skin lesions is uncertain and needs further research. 
Recommendations for patients with mild or uncomplicated mpox (home-based care) 
35 
5.1.3.5 Antimicrobial therapy or prophylaxis 
Interim guidance (Published 10 June 2022) 
WHO recommends that antibiotic therapy or prophylaxis NOT be used in patients 
with uncomplicated mpox. However, lesions should be monitored for secondary 
bacterial infection (i.e. cellulitis, abscess) and if present be treated with antibiotics 
with activity against normal skin flora, including Streptococcus pyogenes and 
methicillin-sensitive Staphylococcus aureus (MSSA). 
• The decision to initiate antimicrobial therapy should be based on individual 
clinical assessment and local antimicrobial resistance patterns. If the patient 
does not improve clinically or the infection continues to spread, reassess the 
patient and the antibiotic regimen to consider if adjustments are necessary. See 
WHO Essential Medicines List: antibiotic book for more information regarding 
selection of antimicrobials and appropriate use [147] (see Annex 3. 
Antimicrobial recommendations and dosages for secondary bacterial skin 
infection). 
 
5.1.3.5.1 Practical info 
• The skin lesions in patients with mpox may be inflamed causing mild erythema 
and/or skin hyperpigmentation – this does not need to be treated with 
antimicrobial therapy [45]. Empiric or prophylactic use of antibiotics should be 
discouraged, as it increases the risk of emergence and transmission of multidrug-
resistant (MDR) bacteria and places individuals at risk of possible side- effects of 
antibiotics such as Clostridium difficile associated diarrhoea. Infections with MDR 
bacteria are more difficult to treat, and associated with increased morbidity and 
mortality [147,148,149]. 
• Secondary bacterial infection of skin lesions has been reported as a common 
complication of mpox and patients should be monitored closely [45,32,40,146]. A 
swab of a superficial skin infection is unlikely to be helpful unless the patient has 
had a prolonged hospitalization and there is concern for an MDR organism. Signs 
of bacterial infection include erythema, induration, warmth, worsening pain, a 
purulent drainage, malodorous discharge or recurrence of fever. See Annex 3 for 
oral options of antibiotics. In selected cases based on individual risk factors, 
known colonization and local prevalence, consideration may be given to initiate 
Clinical management and infection prevention and control for mpox 
36 
treatment for community-acquired methicillin-resistant Staphylococcus aureus 
(MRSA). 
• Patients with bacterial superinfection of mpox rashes may develop an abscess 
which is the collection of pus within the dermis or subcutaneous tissue and most 
commonly due to bacteria from the skin (Streptococcus spp. and Staphylococcus 
spp.) [150]. An abscess may appear as a painful, red, shiny nodule with or without 
fluctuance. This may be associated with surrounding cellulitis, fever and worsening 
pain at the site of infection. 
• Treatment of an abscess is incision and drainage done by sterile aseptic technique 
by a qualified health worker using appropriate IPC measures, to prevent 
complications related to untreated abscess such as osteomyelitis, septic arthritis, 
pyomyositis, sepsis and shock. Depending on the location in the body (e.g. 
adjacent to major blood vessels), size and complexity of the abscess, the incision 
and drainage may need to be performed in the operating theatre. Fluid should be 
aspirated and sent for microbiology and culture to help target antimicrobial 
therapy [150]. 
 
Recommendations for patients at high risk and those with complications or severe mpox  
37 
6. Recommendations for patients at 
high risk and those with 
complications or severe mpox 
There is one updated IPC (Infection prevention and control in health facilities) and 
two new clinical management recommendations (Timing of ART initiation in people 
living with HIV and Breastfeeding and mpox) in this section that are focused on 
patients at high risk for developing severe mpox. 
6.1 Infection prevention and control in health facilities 
(New recommendations) 
Implementation of appropriate IPC measures is essential to mitigate and control risks 
of transmission of mpox in health care facility and community settings [109,151]. 
Implementing a hierarchy of controls [152] is central to reducing the risk of exposure 
to mpox within health care settings. As such, considerations for the application of 
engineering and administrative controls and the use of PPE have been integrated 
throughout the recommendations outlined. 
It is critical to ensure that basic IPC standards are put in place at the national and 
health facility level to provide adequate protection to patients, health workers, 
caregivers and visitors and thereby protect the community. WHO provides guidance 
on the minimum requirements [153] for IPC at the national level and in health care 
facilities. Achieving the IPC minimum requirements and more robust and 
comprehensive IPC programmes based on WHO Guidelines on core components of 
infection prevention and control programmes at the national and acute health care 
facility level across health systems is essential to sustaining efforts to control 
emerging infectious diseases, health care-associated infections (HAIs) and 
antimicrobial resistance [151]. 
Health and care workers should always follow standard precautions and perform a 
risk assessment to evaluate the need to use transmission-based precautions. 
Standard precautions are summarized in the WHO aide-memoire
 [14]. 
Infection prevention and control is crucial in mitigating and containing the spread of 
MPXV. If appropriate IPC measures are not taken, transmission can be amplified via 
health care-associated (nosocomia) [153]) infections and/or health and care worker 
infections within health-care settings [154]. This can result in further spread into 
Clinical management and infection prevention and control for mpox 
38 
communities and across borders, resulting in increased morbidity and mortality. 
Public health officials should ensure that robust IPC measures, environment infection 
control and practices accompanied by WASH services are in place at all health care 
settings, as well as in all communities, to mitigate these impacts. During an outbreak, 
support for IPC should include all relevant points of health-seeking practices within 
the local context, including government health facilities, private facilities, traditional 
healers and facilities such as mpox treatment centres established to manage the care 
of patients suspected of having or confirmed to have the pathogen of interest during 
an outbreak. 
Strengthening IPC preparedness and operational readiness will lead to more robust 
responses, contain outbreaks and prevent health systems from becoming 
overwhelmed. Existing IPC capacity should be mapped and assessed (e.g. using the 
Health Emergency Readiness to Response Operations Capabilities checklist [HERO] 
tool), identifying the critical areas that are missing or that need development. 
Additional information can be found in the 
Framework and toolkit for infection 
prevention and control for outbreak preparedness readiness and response at the 
National Level [154] and the Framework and toolkit for infection prevention and 
control in outbreak preparedness, readiness and response at the health-care facility 
level [ 155].  
Outbreak management is optimal where established national or subnational IPC 
programmes exist, with dedicated support and trained IPC teams at the national, local 
and health care facility level. Although MPXV has specific IPC considerations, standard 
and transmission-based precautions should be followed when caring for suspected or 
confirmed mpox patients. 
All patients with mpox should receive respectful, patient-centred care that respects 
and promotes gender equity, maintains dignity, privacy and confidentiality [1]. 
Further research needs for IPC focusing on understanding transmission routes and 
IPC measures in health care settings are listed in the section Uncertainties, emerging 
evidence and future research. 
  
Recommendations for patients at high risk and those with complications or severe mpox  
39 
6.1.1 Infection prevention and control considerations 
Conditional recommendation for, low certainty evidence (published May 2025) 
In patients with suspected or confirmed mpox, WHO suggests that health and care 
workers use contact and droplet precautions.* 
• Consider using a respirator when the ventilation is poor or unknown or based 
upon a risk assessment (e.g. immunocompromised status or presence of 
mucosal lesions). 
• Airborne precautions should be implemented if varicella zoster virus (i.e. 
chickenpox) or measles are suspected and until they are excluded. 
• Airborne precautions should be implemented when performing aerosol-
generating procedures (AGPs). 
• If single rooms are not available or in limited supply, cohort confirmed patients 
and prioritize single rooms for suspect and probable patients. 
* Contact precautions include the following PPE: gloves, gown. 
Droplet precautions include the following PPE: a medical mask, consider eye protection based 
upon a risk assessment. 
** Confirmed mpox means via laboratory confirmation; probable meets clinical signs and 
symptoms with epidemiological link. 
6.1.1.1 Practical info 
6.1.1.1.1 Implementation considerations 
• Contact and droplet precautions should be used by all health and care workers 
providing direct or indirect care (e.g. cleaning the environment, handling linen or 
waste) to patients with mpox. 
• In addition to droplet and contact precautions, standard precautions should be 
followed for all patients at all times. The measures described below provide 
additional considerations for implementing droplet and contact precautions [7] in 
the context of mpox. 
• Health and care workers should be trained in the use of standard and 
transmission-based precautions such as contact and droplet precautions and the 
proper use of PPE. 
Clinical management and infection prevention and control for mpox 
40 
6.1.1.2 Risk assessment 
• Health and care workers should conduct a risk assessment to determine if 
additional PPE is required, such as a respirator rather than a medical mask and eye 
protection. The risk assessment should take into consideration: 1) the ventilation 
rate of the room and if an AGP is being performed; or 2) other activities are taking 
place that may increase the presence and risk of infectious respiratory particles, 
such as changing the bed linens of a patient with suspect or confirmed mpox; and 
3) the patient’s condition (e.g. number of lesions, location, i.e. mucosal, and 
patient's immune status). 
6.1.1.2.1 Hand hygiene 
• Hand hygiene should be performed according to the WHO 5 moments for hand 
hygiene[240]. 
6.1.1.2.2 Patient placement 
• Place patients on contact and droplet precautions for mpox in a single room. 
• If a single room is not available or single rooms are limited: 
• Patients suspected to have mpox and patients deemed as probable mpox 
cases should be prioritized for a single rooms; 
• Consider cohorting patients who are confirmed to have mpox. 
• Physically separate patients by at least 1 metre (3 feet) and draw privacy curtains. 
• Whenever others are in the room and if transport is necessary: 
• Cover any wounds or lesions on the patient’s body though the use of 
bandages, clothing and/or sheet that comfortably covers the lesions. 
• The patient should wear a wear a medical mask (if able and tolerates) and 
follow respiratory hygiene and cough etiquette. 
6.1.1.2.3 Personal protective equipment 
• Contact and droplet precautions include the following PPE: gown, gloves, medical 
mask and eye protection based upon a risk assessment. 
• Consider a respirator instead of a medical mask based on a risk assessment 
(details above). 
• Use dedicated footwear that can be decontaminated. Disposable shoe covers are 
not recommended [171,172,173]. 
6.1.1.2.4 Safe injections and sharps injury prevention 
• Follow standard precautions for safe injections and sharps injury prevention. 
Recommendations for patients at high risk and those with complications or severe mpox  
41 
• Avoid use of sharp instruments for specimen collection. Lesions should be 
swabbed. Follow WHO guidance for diagnostic testing for MPXV. 
6.1.1.2.5 Environmental cleaning and disinfection 
• Increase cleaning and disinfection of mpox patient care areas to at least twice 
daily as well as immediate cleaning and disinfection of any surface that is visibly 
soiled with blood or body fluids. 
• More frequent cleaning and disinfection should be performed on frequently 
touched surfaces including toilets, latrines and showers. 
• Clean first with detergent and water then disinfect surfaces with a chemical 
disinfectant and allow disinfectant to remain untouched on surface for the contact 
time recommended by the manufacturer. Alternatively, a combined detergent-
disinfectant product (when available) can be used to perform both cleaning and 
disinfection in a single step, provided it is effective against the targeted 
pathogens. 
• Use products for disinfecting the environments that are approved for 
environmental cleaning in health care with virucidal activities (follow national or 
facility guideline) and will not damage surfaces or equipment. 
• Disinfectants should be prepared and applied to surfaces according to 
manufacturers’ instruction: 
• One study found that the use of 0.05% and 0.5% sodium hypochlorite solutions 
and 70% ethanol is efficacious against MPXV when wiped on common non-
porous surfaces in low-resource settings with a 1 minute contact time [117] 
• Quaternary ammonium compounds were found to achieve sufficient log reduction 
of the MPXV on non-porous surfaces only with a contact time of between 1–10 
minutes (not on porous surfaces such as wood) [117]. 
6.1.1.2.6 Handling and transport of linen 
• Handle soiled linen from patients with mpox carefully (with minimal manipulation 
or agitation) to prevent personal contamination and transfer to other patients. 
• Carefully lift and roll linens. Do not shake linen or laundry. 
• Linens should be carefully placed into designated containers or bag for transport 
to laundry services. 
• Remove heavily soiled material (e.g. faeces) from linen, while wearing 
appropriate PPE, before placing it in the laundry bag. 
Clinical management and infection prevention and control for mpox 
42 
• Laundry and linen may be decontaminated by manual or machine washing for at 
least 20 minutes with hot water (70°C, hot water mixed with detergent or hot 
water mixed with a low-concentration sodium hypochlorite solution (0.05%) [116]. 
6.1.1.2.7 Decontamination and reprocessing of reusable patient care items and equipment 
• Use disposable or dedicated patient care equipment. 
• Clean and disinfect equipment before use on other patients. 
• Clean and disinfect or sterilize reusable equipment/devices according to the 
manufacturer’s instructions, and national or international standards, using efficient 
methods and based on intended use. 
6.1.1.2.8 Waste management 
• Handle and treat bodily fluids and solid waste of patients with mpox as infectious 
waste. 
• Segregate waste according to standard precautions (general waste, infectious 
waste and sharps) and place in appropriate bins at point of use. 
• Management and disposal of waste (including PPE) should be performed in 
accordance with local regulations for infectious waste. 
Evidence to decision 
Benefits and harms Small net benefits, or little 
difference between alternatives 
The GDG assessed the benefits and harms of respirator use; from a public health 
perspective, the GDG felt it was important to reserve respirators for situations 
where respirators are known to make a difference. The GDG also highlighted 
potential challenges in availability, particularly in low- and middle-income 
countries. 
Limited access in these settings may reduce supply in areas where respirators are 
essential. GDG members noted that other potential harms include the possible 
mental health consequences such as anxiety and stress related to wearing 
respirators. 
Certainty of the evidence Low 

Recommendations for patients at high risk and those with complications or severe mpox  
43 
The certainty of evidence was judged to be low and was rated down once for 
indirectness and once for risk of bias. The use of a respirator possibly makes little or 
no difference in prevention MPXV transmission compared with a medical mask. 
Values and preferences Substantial variability is expected or 
uncertain 
The GDG anticipated that although health and care workers caring for patients with 
mpox will place priority on safety, when evidence does not support the 
effectiveness of an intervention, such as the use of respirators, most would decline 
use of the intervention. The GDG acknowledged the uncertainty and the likelihood 
of variability in the values and preferences of health and care workers. Furthermore, 
the GDG placed a high value on avoiding wasteful expenditure on interventions 
unlikely to be effective and thus on preserving resources for interventions with a 
higher certainty of benefit. 
Resources and other considerations  
Resources 
The GDG anticipated that the use of respirators for the care of patients with mpox 
in health care facilities requires additional investment of financial and logistical 
resources (including fit testing), particularly impacting low- and middle-income 
countries. 
Equity 
The GDG acknowledged that health and care workers believe safety is a priority and 
respirators should be available, however, in low-resource settings supply may be 
limited and respirators need to be prioritized for other pathogens where it is known 
that they are required. 
Acceptability 
Some health and care workers may not like to wear a respirator and may prefer the 
use of a medical mask. Use of respirators has been associated with reports of 
communication barriers (verbal and non-verbal). 
Feasibility 
The GDG expressed concern over supply chain implications and availability of 
respirators where needed if they are used for pathogens where the evidence 

Clinical management and infection prevention and control for mpox 
44 
suggests they possibly make little or no difference in prevention compared with a 
medical mask. 
6.1.1.3 Justification 
The GDG noted that that among more than 32 000 cases of infections there were no 
reports of transmission by inhalation, and only one case of self-reported droplet 
exposure, and thus concluded the use of a respirator possibly makes little or no 
difference in prevention MPXV transmission compared with a medical mask. Amongst 
1738 health and care worker documented exposures to mpox, of which there were 14 
infections, 10 cases (71.4%) were identified as related to percutaneous injuries 
(needlesticks), one ocular exposure and three due to unspecified factors. 
There may be situations where the use of a respirator is required such as during an 
AGP or if varicella zoster virus (chickenpox) or measles are suspected and until they 
are excluded. The GDG stressed that health and care workers should conduct a risk 
assessment to determine the need for a respirator or any additional PPE (e.g. eye 
protection). In areas where ventilation is poor or unknown or it is not possible to 
ensure adequate ventilation a respirator may be preferred. 
The GDG also highlighted the importance of assessing the risk of transmission related 
to the status of the patient, noting the patient’s condition (number and location of 
lesions, immune status) may increase the risk of transmission and should be taken 
into consideration during the risk assessment to determine the use of a respirator. 
Given the primary mode of transmission described was close contact (sexual or non-
sexual) this conditional recommendation for mpox should be considered in the 
context of accepted practices (transmission-based precautions) for IPC. The GDG 
acknowledged that while the main route of transmission is through direct contact 
(sexual or non-sexual) with skin lesions (with fluids or exudate from those lesions of 
individuals infected with the MPXV), possible environmental contamination as well as 
the potential for IRPs cannot be excluded. A conditional recommendation was made 
to implement droplet and contact precautions when interacting with patients with 
mpox or their environment, in addition to the use of standard precautions. PPE, 
including gown, gloves and eye protection (based on a risk assessment), must be 
worn as per contact and droplet precautions. 
Recommendations for patients at high risk and those with complications or severe mpox  
45 
6.1.1.4 Summary 
The systematic review was conducted in two phases (see Annex 5 for details) and the 
data is not yet published but is available. The Summary of Findings table is based on 
non-comparative studies identified to indirectly informs the IPC PICO question. These 
studies described routes of transmission for suspected and confirmed mpox cases. 
Based on these studies, ten mpox transmission routes were identified amongst the 
32317 cases of MPXV infection reported in these studies: confirmed sexual 
contact(65.1% of mpox cases), suspected sexual contact(30.3%), close contact (non-
sexual)(2.9%), fomite/environment (0.36%), transplacental (0.01%), percutaneous 
injury (0.09%),direct deposition(formerly droplet) (0.003%), inhalation (0%) 
animal/animal products (0.48%) and multiple routes (0.83%) 
[26,27,47,57,86,87,97,102,103,128,130,131,132].Close contact (sexual /nonsexual) was 
the predominate mode of transmission (95.3 %). Transmission through percutaneous 
injury with contaminated object, fomite and transplacental and animal products were 
uncommon, accounting for approximately 0.1%. There was only one case of self-
reported droplet exposure out of the 32, 317 cases that reported route of 
transmission data [74]. The single case was one of 12 breakthrough infections after 
postexposure vaccination against mpox. The study defined droplet transmission as 
occurring during the presence of the exposed person without masks at less than two 
meters for at least three hours with a PCR-confirmed mpox patient [74]. There were 
no reported inhalation exposures. 
An additional sub-analysis was conducted to assess the route of transmission for 
each mpox clade: Clade I, Clade Ib, and Clade IIb. Only 29 out of 222 studies reported 
clade information, covering 23.6% of patients. No cases of Clade IIa were reported in 
the literature. Among the 10788 patients for whom the clades were identified, cases 
with clade Ib and IIb MPXV infection describe close contact (confirmed sexual, 
suspected sexual and non-sexual) as the primary modes of transmission. For clade 1a 
there was a total of 218 cases identified. Amongst these cases, the modes of 
transmission were primarily described as 40.6% (205 cases) as multiple routes, 30.9% 
(156 cases) as exposure to animals /animal products, 17% (86 cases) as close contact 
(non-sexual) and 11.5% (58 cases) as other routes of transmission. There was no 
description of droplet or inhalation transmission in any of the 29 clade specific 
studies. These findings align with the previous systematic review [68] 
Clinical management and infection prevention and control for mpox 
46 
Outcome 
Timeframe 
Study results and 
measurements 
Comparator 
Respirators in 
addition to 
contact and 
droplet 
precautions 
Intervention 
Medical masks 
as a part of 
contact and 
droplet 
precautions 
Certainty of the 
evidence 
(Quality of 
evidence) 
Summary 
Mpox infection 
inferred from 
transmission 
route frequency 
data 
(Observational (non- 
randomized)) 
1 reported case of transmission by 
droplet in 32318 patients (1/270 
studies) 
Inferred odds ratio: 1 
Low 
Due to serious 
indirectness, Due 
to serious risk of 
bias
1 
The use of a respirator 
probably makes little 
to no difference in 
preventing mpox 
transmission 
compared to a 
medical mask 
1 Risk of Bias: serious. Inconsistency: no serious. Indirectness: serious. 
Imprecision: no serious. Publication bias: no serious. 
6.1.2 Visitors to isolated mpox patients 
Interim guidance (Published 10 June 2022) 
WHO recommends that for patients isolated with mpox measures should be put in 
place to support patient interaction with family and visitors to promote well-being 
• Visitors or caregivers should perform appropriate hand hygiene before and 
after entering/exiting the patient room, receive instruction and be closely 
supervised on the use (putting on and removal) of PPE for contact and droplet 
precautions. 
• Vulnerable and high-risk individuals should be counselled regarding the risks in 
order to make an informed decision on whether to visit the patient. 
• Alternate modes of communication such as videoconference to be offered. 
 
6.1.3 Optimized supportive care 
6.1.3.1 Admission to hospital 
Interim guidance (Published 10 June 2022) 
Recommendations for patients at high risk and those with complications or severe mpox  
47 
WHO recommends that patients at high risk for complications (i.e. young children, 
pregnant persons and those who are immunosuppressed) or those with severe or 
complicated mpox should be admitted to the hospital for closer monitoring and 
clinical care under appropriate isolation precautions to prevent transmission of 
mpox virus 
For further details of systematic evaluation, see [1].  
6.1.3.1.1 Practical info 
A job aid describing systematic monitoring of patients is attached in Annex 7. 
6.1.3.2 Optimised supportive care 
Interim guidance (Published 10 June 2022) 
WHO recommends that patients with mpox who develop complications or severe 
disease should be managed with optimized supportive care interventions. 
6.1.3.2.1 Practical info 
A table describing optimized supportive care measures for patients with 
complications or severe disease can be found in Annex 6. 
  
Clinical management and infection prevention and control for mpox 
48 
6.2 Timing of ART initiation in people living with HIV (New 
recommendation) 
6.2.1 Rapid ART initiation as the standard of care 
WHO strongly recommends rapid ART initiation (≤ 7 days of HIV diagnosis) for 
adults, adolescents and children, including the offer of same-day start. This guidance 
is based on high-certainty evidence for adults and adolescents, low-certainty 
evidence for children (WHO consolidated guidelines on HIV prevention, testing, 
treatment, service delivery and monitoring (2021) [160]). Three randomized clinical 
trials showed strong mortality benefits of rapid ART compared with delayed ART (RR 
0.47, 95% CI 0.24–0.93) as well as positive impact on the frequency of ART initiation, 
retention in care and suppression of viral loads at 12 months. 
The recommendation of rapid ART initiation acknowledges concerns of paradoxical 
immune reconstitution inflammatory system (IRIS) in the context of 
immunosuppression. Restoration of the immune function through ART is considered 
an important intervention in the management of opportunistic infections, especially if 
effective treatment is unavailable. However, for infections with central nervous system 
involvement such as TB and cryptococcal meningitis, and in case of TB, targeted 
antimicrobial treatment and delay of ART with a few weeks is recommended to 
reduce the likelihood of paradoxical IRIS with adverse outcomes. 
6.2.2 Mpox and ART initiation 
There are currently no randomized clinical trials comparing early vs delayed ART 
initiation in people with HIV and mpox. 
One observational study of 19 patients with HIV and mpox showed uncertain effect of 
delaying the ART initiation; but it showed a higher rate of hospitalization compared 
with the early ART initiation group. There is low-certainty evidence that initiation of 
ART at the late stages of HIV infection may increase hospitalizations in mpox patients 
that were not on ART (5 non-randomized studies, 2037 participants, OR = 4.19, 95% 
CI 2.11–8.34). 
Mpox IRIS following ART initiation may occur, but the frequency is uncertain. 
Differentiating between mpox IRIS and progressive mpox is complicated given the 
lack of clear case definition and overlapping manifestations. 
In a technical meeting organized by WHO, expert consensus was that the general 
mortality reduction benefits of rapid ART initiation extend to patients with mpox, 
Recommendations for patients at high risk and those with complications or severe mpox  
49 
accepting the risk of paradoxical IRIS, and noting that delaying ART initiation may 
possibly be harmful. These conclusions were based on the lack of available evidence-
based effective therapy for mpox, the continued mpox viral replication and disease 
progression in patients with immunosuppression, the estimation that mpox central 
nervous system manifestations are uncommon, and the concurrence of other 
opportunistic infections with mpox that would benefit from rapid ART initiation. 
People with symptoms of mpox should access health services and HIV testing early to 
reduce the risk of severe mpox disease. 
Strong recommendation for, moderate certainty evidence (published May 2025) 
WHO recommends rapid initiation of ART in people with mpox and HIV who are 
ART naïve or have had a prolonged interruption of ART (Strong recommendation, 
moderate certainty of evidence) 
• Early HIV testing should be conducted when patients present with suspected or 
confirmed mpox infection. 
• The patient should be referred to appropriate services for ART initiation as soon 
as possible, aiming to provide therapy within 7 days of HIV diagnosis including 
the offer of same-day start. 
• In people who are already on ART and with undetectable viral load, ART 
regimen should be continued without interruption or change. The viral load 
test result should be less than 1 year old; if not, a new viral load test should be 
conducted. 
 
6.2.2.1 Practical info 
The latest guidance from WHO on HIV prevention, testing, treatment, service delivery 
and monitoring can be found here: 
https://www.who.int/publications/i/item/9789240031593
.[160] 
Disseminated cryptococcosis skin lesions may resemble mpox under some 
circumstances. Guidelines for diagnosing, preventing and managing cryptococcal 
disease among adults, adolescents and children living with HIV from WHO can be 
found here: https://www.who.int/publications/i/item/9789240052178
.[53] 
Clinical management and infection prevention and control for mpox 
50 
6.2.2.2 Evidence to decision 
Benefits and harms Substantial net benefits of the 
recommended alternative 
There is high-quality indirect evidence of the mortality benefits of initiating 
antiretrovirals (ART) as soon as possible. In the absence of any effective mpox-
specific treatment to lower the viral load, the panel judged there to be little benefit 
in delaying ART initiation. 
The panel judged there to be harms from delay of ART initiation. Immune recovery 
is central to viral control and recovery from disease, and treatment delay will likely 
delay immune recovery. The panel judged harms from delay very likely, including 
reduced linkage and retention in care, and progression of mpox viral replication. 
Despite the absence of direct evidence from patients with mpox, the harms of 
uncontrolled, progressive mpox infection in the context of advanced 
immunosuppression is very well documented and can be fatal. The panel judged 
that these harms likely outweigh any potential harm arising from IRIS. 
Certainty of the evidence Moderate 
Current WHO recommendation for rapid ART initiation is based on high-quality 
evidence from three randomized controlled trials , with 7418 patients which 
inferred mortality benefits. The study populations within these trials did not include 
mpox patients, therefore, due to indirectness, the certainty in mortality benefit was 
assessed to be moderate. 
IRIS can be severe when it occurs due to other opportunistic infections, but 
occurrence rates are uncertain in mpox. 
Values and preferences No substantial variability expected 
The GDG inferred that most HIV patients with mpox would place a higher value on 
the mortality benefit of initiating antiretrovirals (ART) as soon as possible than on 
the possible increased risk of developing IRIS. 
Resources and other considerations No important issues with the 
recommended alternative 
Resources 

Recommendations for patients at high risk and those with complications or severe mpox  
51 
No issues in a system which already provides antiretrovirals. 
Equity 
No issues in a system which already provides antiretrovirals. 
Acceptability 
No issues in a system which already provides antiretrovirals. 
Feasibility 
No issues in a system which already provides antiretrovirals. 
6.2.2.3 Justification 
Currently, in contrast to other opportunistic infections in which delayed ART is 
recommended, direct evidence regarding the timing of ART for mpox is only very low 
certainty. There is low-certainty evidence from comparison of uncontrolled versus 
controlled HIV in mpox that delayed ART may increase hospitalizations in mpox 
patients (5 non-randomized studies, 2037 participants, OR = 4.19, 95% CI 2.11–8.34). 
There is very low-certainty evidence regarding the impact of early treatment versus 
delay on occurrence and effects of IRIS in mpox/ HIV co-infected patients. 
The GDG considered that the evidence from people who did not have mpox would 
pertain to those who did (with this high-quality evidence being rated down for 
indirectness, and therefore an overall moderate certainty evidence for benefits in 
mpox). 
On values and preferences, the panel judged that all or almost all HIV patients with 
mpox would place a higher value on the likely mortality benefit of initiating ART as 
soon as possible than on the possible increased risk of developing IRIS. 
The panel acknowledged that a strong recommendation would reduce the likelihood 
of accrual of direct evidence pertaining to the PICO. However, observational data 
from clinical case series would allow estimation of the incidence of IRIS. 
6.2.2.4 Clinical question/ PICO 
Population: HIV with Mpox 
Intervention: Delayed ART 
Comparator: Early ART 
Clinical management and infection prevention and control for mpox 
52 
 
Outcome 
Timeframe 
 
Study results and 
measurements 
 
Comparator 
Early ART 
 
Intervention 
Delayed ART 
Certainty of 
the evidence 
(Quality of 
evidence) 
 
Summary 
Mortality (high 
risk) 
Odds ratio 2.08 
(CI 95% 1.08 — 3.99) 
Based on data from 
7418 participants in 3 
studies. (Randomized 
controlled) 
46 
per 1000 
91 
per 1000 
Moderate 
Due to serious 
indirectness1 
Delayed ART 
probably increases 
mortality in mpox 
patients as inferred 
from comparison of 
delayed versus early 
ART in HIV 
45 more per 1000 
(CI 95% 3 more – 115 more) 
Mortality (low 
risk) 
Odds ratio 2.08 
(CI 95% 1.08 — 3.99) 
Based on data from 
7418 participants in 3 
studies. (Randomized 
controlled) 
3 
per 1000 
6 
per 1000 
Moderate 
Due to serious 
indirectness2 
Delayed ART 
probably increases 
mortality in mpox 
patients as inferred 
from comparison of 
delayed versus early 
ART in HIV 
3 more per 1000 
(CI 95% 0 fewer – 9 more) 
Hospitalization Odds ratio 7 
(CI 95% 0.29 — 
167.93) 
Based on data from 
19 participants in 1 
studies. 
(Observational (non- 
randomized)) 
82 
per 1000 
385 
per 1000 
Very low 
Due to serious 
risk of bias, Due 
to serious 
imprecision
3 
We are uncertain 
about the effect of 
delayed versus early 
ART initiation in mpox 
on hospitalisation 
303 more per 1000 
(CI 95% 57 fewer – 856 more) 
IRIS Odds ratio 1.13 
(CI 95% 0.06 — 21.09) 
Based on data from 
19 participants in 1 
studies. 
(Observational (non- 
randomized)) 
100 
per 1000 
112 
per 1000 
Very low 
Due to serious 
risk of bias, Due 
to serious 
imprecision4
 
We are uncertain 
about the effect of 
delayed versus early 
ART initiation in mpox 
on occurrence of IRIS 
12 more per 1000 
(CI 95% 93 fewer – 601 more) 
1, 2. Inconsistency: no serious. Indirectness: serious. Downgraded once for indirectness as population did 
not include mpox cases. Imprecision: no serious. Publication bias: no serious. 
3. Risk of Bias: serious. Unadjusted estimate. Inconsistency: no serious. Indirectness: no serious. 
Imprecision: serious. One study with few events. Publication bias: no serious. 
4. Risk of Bias: serious. Unadjusted estimate. Inconsistency: no serious. Indirectness: no serious. 
Imprecision: serious. Downgraded once for risk of bias as the estimate is unadjusted, downgraded 
once for imprecision as there is one study with few events. Publication bias: no serious. 
  
Recommendations for patients at high risk and those with complications or severe mpox  
53 
6.3 Breastfeeding and mpox (New recommendation) 
The current recommendations on breastfeeding outside of the mpox context were 
summarized, by the technical working group (see Methods section) to provide 
foundational evidence for mpox guideline development. They noted that WHO has 
existing guidelines which pertained, specifically Recommendations on postnatal care 
of the mother and newborn (2013) [161]. 
• WHO recommends that “All babies should be exclusively breastfed from birth 
until 6 months of age. Mothers should be counselled and provided support for 
exclusive breastfeeding at each postnatal contact (Strong recommendation, based 
on moderate quality evidence). 
• Remarks: 
• This recommendation is applicable in all settings. 
• Exclusive breastfeeding should be promoted during all antenatal and postnatal 
care contact. 
• Particular support for exclusive breastfeeding should be provided when the 
mother has had a caesarean section or the baby is born preterm. 
• WHO low-birth-weight feeding guidelines for LMIC recommend exclusive 
breastfeeding for all preterm and low-birth-weight infants 
(https://www.who.int/publications/i/item/9789241548366
).[162] 
• The GDG reviewed evidence for neonatal outcomes; the 6-month duration of 
exclusive breastfeeding is based on existing WHO recommendation and an 
updated Cochrane review. 
The technical group structured the PICOs below to address separately the risk of 
mother to child transmission of mpox through two potential routes, via breastmilk or 
via direct contact. The final PICO addresses whether mothers who recover from mpox 
and who had withheld breastfeeding and direct contact, should resume breastfeeding 
and direct contact with the infant. 
6.3.1 Breastfeeding 
Conditional recommendation for, low certainty evidence (published May 2025) 
Clinical management and infection prevention and control for mpox 
54 
WHO suggests that mothers with mpox continue breastfeeding, whilst limiting 
direct contact with their non-infected infant, until lesions are fully resolved (lesions 
are crusted, the scab of lesions have fallen off and a fresh layer of intact skin has 
formed underneath). (Conditional recommendation, low certainty evidence) 
• If breastfeeding is continued between a suspected or confirmed mother with 
mpox and a non-infected infant, IPC measures must be established including 
limited contact between mother and infant except during breastfeeding and 
coverage of active lesions on other parts of the body whilst breastfeeding. 
• The presence of areolar lesions should prompt careful consideration and 
mothers should not use that breast to breastfeed the infant. In the case of 
unilateral lesions, until lesions are healed per WHO criteria (lesions are crusted, 
the scab of lesions have fallen off and a fresh layer of intact skin has formed 
underneath), breastfeeding may take place from the unaffected breast whilst 
covering all active lesions. 
• Health and care workers should inform the mother about the risk of infection to 
infants whilst breastfeeding and availability of appropriate alternatives. 
• Context will drive the feasibility, availability and safety of alternatives to breast 
feeding. Whenever it is safe and feasible, expressed breastmilk or milk 
substitutes and no direct contact, may be pursued to reduce transmission. 
6.3.1.1 Practical info 
Additional guidance on breastfeeding can be found in WHO Recommendations on 
postnatal care of the mother and newborn and can be accessed here: 
https://www.who.int/publications/i/item/9789241506649.[161] 
General protective IPC measures should be taken by mothers with mpox when 
handling and feeding their infants, e.g. washing hands before and after each feeding, 
wearing a medical mask and covering any lesions on the areola or on areas which 
have direct contact with the infant. Alternatively, if only one breast has lesions, 
mothers can express/pump from the breast with lesions on the areola and discard the 
milk and feed from the non-affected breast. In all cases, monitor the mother-infant 
pair closely for development of signs and symptoms of mpox and treat accordingly. 
Infants of mothers with mpox should be closely monitored for signs and symptoms 
with the main goal of early supportive care to prevent the development of severe 
disease and poor outcomes. 
Recommendations for patients at high risk and those with complications or severe mpox  
55 
In the event of replacement feeding with breastmilk substitute, it is essential to track 
the infant’s growth, development and other illnesses as well as for signs and 
symptoms of mpox. 
6.3.1.2 Evidence to decision 
Benefits and harms  
The benefits of continuing breastfeeding are based on the moderate quality 
evidence that exclusively breastfed neonates are at lower risk of all-cause mortality 
and infection-related mortality in the first month of life compared with partially 
breastfed neonates. Also, there is low-quality evidence that exclusively breastfed 
neonates are at lower risk of sepsis, acute respiratory infection and diarrhoea in the 
first month of life compared with partially breastfed neonates. 
Harms of continuing breastfeeding include the risk of transmission of infection to 
the infant through contact with lesions or expressed milk. The evidence available 
about transmission through expressed milk (with no contact) due to presence of 
viable virus in the milk is limited. 
Certainty of the evidence Low 
The certainty of the evidence ranged between moderate and very low. Aside from 
the indirect evidence regarding the impact of breast feeding, seven publications 
providing potentially direct evidence were identified; five were case reports and two 
were case series. However, in none of these studies was there clarity about the 
existence of lesions specifically on the breasts. 
Six of these studies report on breastfeeding and direct contact. In five of the 
studies, the infant was infected compared with no infant being infected in the one 
study that reported on no breastfeeding and no contact. There was moderate 
certainty evidence that breastfeeding and direct contact between mothers with 
mpox with no lesions on the breasts probably resulted in infection of some infants. 
However, there is less clarity about the frequency of this event. There was, however, 
very low certainty evidence of the magnitude of any increase of mpox infection in 
infants as a result of breastfeeding and direct contact with mother with mpox and 
no lesions on the breasts. 
Regarding hospitalization of infants due to mpox infection, four out of six infants 
who were breastfed and had close contact were hospitalized compared with the no 

Clinical management and infection prevention and control for mpox 
56 
breastfeeding and no direct contact (the case hospitalized in the group of no 
breastfeeding and no direct contact was to monitor the infant and not because of 
infection). 
Concerning mortality, there was one death in the breastfeeding and direct contact 
group compared with the no breastfeeding and no direct contact. There was low 
certainty of evidence for breastfeeding and direct contact and increase of infant 
mortality and very low certainty regarding the magnitude of any increase in infant 
deaths that may occur as a result of breastfeeding and direct contact between 
mothers with mpox, with no lesions on the breasts and the infant. 
There was only one case report that described breastfeeding and no direct contact. 
The certainty of evidence was rated very low due to lack of clarity of how 
breastfeeding and no direct contact (e.g. expressed milk) affects the risk of 
infection, hospitalization and mortality of the infant. 
No adverse events were reported in any of the studies. 
No studies reported on infants of mothers with confirmed mpox infection and 
lesions on the breasts. Therefore we do not have published evidence on the effect 
of breastfeeding and close contact with the infant when the mother has lesions on 
the breasts. 
Values and preferences Substantial variability is expected or 
uncertain 
There is likely to be substantial variability in values and preferences between 
mothers, and these are related to the availability and safety of the resources to use 
as milk substitutes, as well as beliefs, religion, culture and family traditions. 
No formal studies are available to inform patient values and preferences in mpox. 
Nevertheless, the panel inferred that parents generally and strongly wish to avoid 
harms to their babies. At the same time, experience from Ebola virus disease and 
from mpox outbreaks in the Democratic Republic of the Congo reported by panel 
members suggests that when faced with competing priorities of harm reduction 
and the desirability of breastfeeding, mothers valued breastfeeding highly. 
In settings in which alternatives to breastfeeding (appropriate milk substitutes) are 
not feasible, available and safe, the panel inferred that most parents would place a 
higher value on the possible beneficial effects of breastfeeding with direct contact 

Recommendations for patients at high risk and those with complications or severe mpox  
57 
or expressed milk (no direct contact) over eliminating the uncertain magnitude of 
risk of infants getting infected with mpox. 
Resources and other considerations Important issues, or potential issues 
not investigated 
Resources 
The affordability of alternatives to breastfeeding in many contexts may be limited, 
and costs will more likely fall on the family or the health care system. The GDG 
noted the complexities of providing safe breastmilk substitutes including the 
requirement for available safe water and equipment to provide it. 
There were significant other resources required in terms of IPC measures 
irrespective of the choice of breastfeeding or not. 
During the PALM007 study in the Democratic Republic of the Congo, breastmilk 
substitute was provided as part of the research, but that apart from this support, 
mothers would not usually have access to it. Outside of research settings, 
downstream events occurring as a result of not-breastfeeding may have a 
significant cost and resource implication especially following diarrhoeal disease or 
malnutrition. 
Equity 
Increasing costs associated with use of alternatives to breastfeeding could drive 
inequity or increase pre- existing inequities. 
Acceptability 
Breastfeeding is accepted and promoted in all settings and environments as the 
best option for infant feeding. 
Feasibility 
There is large heterogeneity in accessibility to alternatives to breastfeeding (see 
Resources, above). Specifically, the potential to pasteurize breastmilk was also 
noted, but felt to be not feasible in many contexts. 
6.3.1.3 Justification 
Overall, the certainty of evidence about breastfeeding of mothers with mpox to their 
infants was rated as moderate to very low. The GDG felt that no strong 
recommendation could be made given the certainty of the evidence available. 
Clinical management and infection prevention and control for mpox 
58 
The GDG considered the benefits of continuing breastfeeding by a mother with mpox 
infection are based on moderate certainty evidence that exclusively breastfed 
neonates are at lower risk of all-cause mortality and infection-related mortality in the 
first month of life compared with partially breastfed neonates. 
The GDG also considered in their deliberations that alternatives to breastfeeding may 
be not feasible or not safe and expose the infant to harm. In settings where 
alternatives to breastfeeding (appropriate milk substitutes) are not feasible, available 
and safe, the panel inferred that most parents would place higher value on the 
possible beneficial effects of breastfeeding with direct contact or expressed milk (no 
direct contact) over eliminating the uncertain magnitude of risk of infants getting 
infected with mpox via breastfeeding. The GDG also noted there is little research 
available on parent preferences and this should be highlighted as a further area of 
research. 
In considering harms and risks, the GDG also reflected that in the pre-symptomatic 
stage, before the lesions emerge and before the mother has presented for treatment, 
the infant may have already been already exposed. If that is the case, there may be 
little benefit in subsequent avoidance of breastfeeding. Additionally, lesions in other 
parts of the body, in the context of intimate care of an infant may make an isolated 
recommendation on breastfeeding have little impact on the likelihood of the infant 
being infected. 
All these considerations support the conditional recommendation for continuing 
breastfeeding. 
6.3.1.4 Clinical question/ PICO 
Population: People with suspected or confirmed mpox without lesions on the breast 
who are breastfeeding their infant 
Intervention: Continue breastfeeding and direct contact 
Comparator: Stop breastfeeding and no direct contact 
Outcome 
Timefram
e 
Study results 
and 
measurements 
Comparator 
No 
breastfeedin
g + no 
contact 
Intervention 
Breastfeed + 
contact 
Certainty of 
the evidence 
Summary 
Mpox 
disease in 
infant 
Based on data 
from 7 
participants in 5 
0 83 
per 100 
Moderate for 
transmission 
(due to 
Breastfeeding and direct 
contact between mpox 
infected mother with no 
Recommendations for patients at high risk and those with complications or severe mpox  
59 
studies. 
(Observational 
(non- 
randomized)) 
extensive 
evidence of 
transmission). 
Very low for 
magnitude of 
increase (due 
to very serious 
risk of bias 
and 
imprecision)
1 
lesions on the breasts 
probably results in 
infection of some infants. 
We are very uncertain of 
the magnitude of any 
increase in mpox infection 
in infants as a result of 
breastfeeding and direct 
contact between mpox 
infected mother with no 
lesions on the breasts and 
the infant. 
Hospitaliza
tion of 
infant due 
to mpox 
Based on data 
from 6 
participants in 5 
studies. 
(Observational 
(non- 
randomized)) 
0 67 Moderate for 
transmission 
(due to 
extensive 
evidence of 
transmission). 
Very low for 
magnitude of 
increase (due 
to very serious 
risk of bias 
and 
imprecision) 
Breastfeeding and direct 
contact between mpox 
infected mother with no 
lesions on the breasts and 
the infant, probably 
results in some 
hospitalizations We are 
very uncertain of the 
magnitude of 
hospitalization of infants 
that occurs as a result of 
breastfeeding and direct 
contact of mothers with 
no lesions on the breasts 
and the infant. 
Infant 
mortality 
Based on data 
from 6 
participants in 5 
studies. 
(Observational 
(non- 
randomized)) 
0 17 Low for infant 
mortality (due 
to very serious 
risk of bias 
and 
imprecision). 
Very low for 
magnitude of 
increase (due 
to very serious 
risk of bias 
and very 
serious 
imprecision) 
Breastfeeding and direct 
contact between mpox 
infected mother with no 
lesions on the breasts and 
the infant, may increase 
infant mortality We are 
very uncertain of the 
magnitude of any 
increase in infant deaths 
that may occur as a result 
of breastfeeding and 
direct contact between 
mpox infected mother 
with no lesions on the 
breasts and the infant 
Adverse 
events of 
not 
breastfeedi
ng for 
infant and 
mother 
    Not reported in included 
studies 
Clinical management and infection prevention and control for mpox 
60 
Adverse 
events of 
not 
breastfeedi
ng for 
infant and 
mother 
    Not reported in included 
studies 
1. Risk of Bias: very serious. due to risk of bias in reporting for case-reports and case-series. 
6.3.1.5 Clinical question/ PICO 
Population: People with suspected or confirmed mpox with lesions on the breast 
who are breastfeeding their infant 
Intervention: Continue breastfeeding and no direct contact (expressed milk) 
Comparator: Stop breastfeeding and no direct contact 
Outcome 
Timeframe 
Study results and 
measurements 
Comparator 
No 
breastfeeding 
+ no contact 
Intervention 
Breastfeed + 
no contact 
Certainty of 
the evidence 
Summary 
Mpox disease 
in infant 
(Observational (non- 
randomized)) 
   No studies. We do 
not know the effect. 
Hospitalization 
of infant due to 
mpox 
(Observational (non- 
randomized)) 
   No studies. We do 
not know the effect. 
Infant mortality (Observational (non- 
randomized)) 
   No studies. We do 
not know the effect. 
Adverse events 
of not 
breastfeeding 
for infant and 
mother 
    Not reported in 
included studies 
Adverse events 
of not 
breastfeeding 
for infant and 
mother 
    Not reported in 
included studies 
6.3.2 Resuming breastfeeding 
Conditional recommendation for, very low certainty evidence (published May 
2025) 
Recommendations for patients at high risk and those with complications or severe mpox  
61 
WHO suggests that mothers who recover from mpox and who had withheld 
breastfeeding and direct contact, to resume breastfeeding and direct contact with 
the infant as soon as lesions are fully resolved (lesions are crusted, the scab of 
lesions have fallen off and a fresh layer of intact skin has formed underneath). 
(Conditional recommendation, very low certainty evidence) 
• This recommendation applies to mothers with confirmed mpox who withheld 
breastfeeding and close contact with their infant. 
• The mother needs to be supported to continue to express milk while not 
breastfeeding to maximize the likelihood of reinitiating breastfeeding once 
recovers and avoid complications (e.g. mastitis). 
6.3.2.1 Practical info 
Additional guidance on breastfeeding can be found in WHO recommendations on 
postnatal care of the mother and newborn (2013) and can be accessed here: 
https://www.who.int/publications/i/item/9789241506649
 [233]. 
6.3.2.2 Evidence to decision 
Benefits and harms Substantial net benefits of the 
recommended alternative 
The benefits of resuming breastfeeding are based in the moderate quality evidence 
that exclusively breastfed neonates are at lower risk of all-cause mortality and 
infection-related mortality in the first month of life compared with partially 
breastfed neonates. Also, there is low quality evidence that exclusively breastfed 
neonates are at lower risk of sepsis, acute respiratory infection and diarrhoea 
morbidity in the first month of life compared with partially breastfed neonates. 
Harms of resuming breastfeeding after recovery include the risk of transmission of 
infection to the infant through persistence of virus in the breastmilk of recovered 
mothers. Evidence around presence of viable virus in the milk after is limited. 
Certainty of the evidence Very low 
All evidence is of very low certainty, including infection, hospitalization and infant 
mortality endpoints, as it was derived from two case reports. One of these reports 

Clinical management and infection prevention and control for mpox 
62 
was in the context of less than 2 weeks' post resolution of lesions and the other in 
more than 2 weeks' post lesion resolution. 
There were no events in either group for infection, hospitalization or mortality of 
the infant. Adverse events were not reported. 
Values and preferences Substantial variability expected or 
uncertain 
There was likely to be a substantial variability in values and preferences, and these 
are closely related to the available resources. 
No data are available from the literature to inform on patients' values and 
preferences in mpox specifically. The panel noted that parents generally and 
strongly wish to avoid harms to their babies. Experience from Ebola virus disease 
and mpox outbreaks in the Democratic Republic of the Congo reported by panel 
members suggests that in these circumstances, mothers valued breastfeeding 
despite the known potential for transmission of disease. 
Most parents would place higher value on the possible beneficial effects of 
breastfeeding with direct contact over reducing the uncertain magnitude of risk of 
infants getting infected with mpox and the possible serious consequences with 
feeding infants expressed milk (no direct contact). 
Resources and other considerations Important issues or potential issues 
not investigated 
Resources 
The affordability of alternatives to breastfeeding was questioned in many contexts, 
and these costs will more likely fall on the family or the health care system. The 
complexities of providing safe breastmilk substitutes include the requirement for 
available safe water and equipment to provide it. 
There were significant other resources required in terms of IPC irrespective of the 
choice of breastfeeding or not. 
It was noted that during the PALM007 study in the Democratic Re[ublic of the 
Congo, breastmilk substitutes were provided as part of the research, but that apart 
from this support, mothers would not usually have access to it. Outside of research 
settings, downstream events occurring as a result of not breastfeeding may have a 

Recommendations for patients at high risk and those with complications or severe mpox  
63 
significant cost and resource implication especially following diarrhoeal disease or 
malnutrition if it occurs. 
Equity 
Increasing costs associated with alternatives to breastfeeding could drive inequity 
Acceptability 
Breastfeeding is accepted and promoted in all settings and environments as the 
best option for infant feeding. 
Feasibility 
There is large variability in access to alternatives to breastfeeding (see Resources, 
above). 
6.3.2.3 Justification 
Overall there was very low certainty evidence which precluded a strong 
recommendation. 
The GDG discussed alternative ascertainment of the time point at which 
breastfeeding might be reinitiated. Two weeks was used as a initial practical threshold 
considering the ability to maintain lactation through expression of breastmilk and 
lesion resolution. However, the GDG agreed to adopt the dermatological definition of 
recovery: “when lesions have crusted over, the scabs have fallen off and a new layer 
of skin has formed underneath, and all the lesions on the eyes and in the body (in the 
mouth, throat, eyes, vagina and anus) have healed” as clinical progression may vary at 
the individual patient level. 
Recommencing breastfeeding will benefit both mother and infant and infection of 
the infant once lesions are healed lesions is likely to be low. 
Clinical management and infection prevention and control for mpox 
64 
6.4 Caring for people with mpox during and after 
pregnancy 
6.4.1 Place of care during pregnancy 
Interim guidance (Published 10 June 2022) 
WHO recommends pregnant or recently pregnant persons with mild or 
uncomplicated mpox may not require acute care in hospital but monitoring in a 
health facility may be preferred; those with severe or complicated disease should 
be admitted to a health facility for care as they require optimized supportive care 
and/or interventions to improve maternal and fetal survival. 
6.4.1.1 Practical info 
Counsel patients about healthy diet, mobility and exercise, intake of micronutrients 
for herself and her infant, tobacco use and second- hand smoke exposure, use of 
alcohol and other substances, as per WHO recommendations on antenatal care for a 
positive pregnancy experience and WHO recommendations on maternal and 
newborn care for a positive postnatal experience [143,144]. 
6.4.1.2 Justification 
Limited data suggest that mpox virus infection in pregnant women may lead to 
vertical transmission as well as adverse outcome for the fetus, such as spontaneous 
abortion and stillbirths [33,78,59,62,60]. 
6.4.2 Care during pregnancy 
Interim guidance (Published 10 June 2022) 
WHO recommends that pregnant and recently pregnant persons with mpox should 
have access to patient-centred, respectful, skilled care, including midwifery, 
obstetric, gynaecological, fetal medicine and neonatal care, as well as mental 
health and psychosocial support, with readiness to care for maternal and neonatal 
complications. 
Recommendations for patients at high risk and those with complications or severe mpox  
65 
6.4.2.1 Practical info 
• Patient-centred, respectful, skilled care refers to care organized for and provided 
to all patients in a manner that maintains their dignity, privacy and confidentiality, 
ensures freedom from harm and mistreatment, and enables informed choice. 
• During labour and childbirth this includes a companion of choice, pain relief, 
mobility during labour and birth position of choice. Screen birth companions 
using the WHO case definition for mpox. 
• If the companion has suspected or confirmed mpox, arrange for an alternative, 
healthy birth companion in consultation with the woman. 
• Emphasize to any and all companions the importance of IPC measures during 
labour, childbirth and during the woman’s and newborn’s postnatal stay in the 
health facility. Include appropriate training on and use of PPE and limit movement 
in the health care facility. 
• If a pregnant person has chosen to be cared for at home, then counsel the woman 
about maternal, fetal and newborn signs and to seek care if they develop 
worsening illness or danger signs. Self-care interventions should be encouraged. 
• Counsel patient about healthy behaviours including diet, physical activity, intake 
of micronutrients, tobacco alcohol and other substance use, per WHO 
recommendations on antenatal and postnatal care [143,144]. For patient requiring 
abortion services, consider alternative modes of service delivery, including self-
management of medical abortion up to 12 weeks’ gestation, where women have 
access to accurate information and to a health care provider at any stage of the 
process, per the WHO Abortion care guideline [145]. 
6.4.3 Mode of birth 
Interim guidance (Published 10 June 2022) 
WHO recommends that mode of birth should be individualized, based on obstetric 
indications and the mother’s preferences. WHO recommends that induction of 
labour and caesarean section should only be undertaken when medically justified 
and based on maternal and fetal condition. 
• Interventions to accelerate labour and childbirth (e.g. augmentation, 
episiotomy, operative vaginal birth) should only be undertaken if medically 
justified and based on maternal and fetal clinical condition per the WHO 
recommendations for intrapartum care [163]. 
Clinical management and infection prevention and control for mpox 
66 
• Delayed umbilical cord clamping (not earlier than 1 minute after birth) is 
recommended for improved maternal and infant health and nutrition 
outcomes. There is no evidence that delaying cord clamping increases the 
possibility of viral transmission from the mother to the newborn. The proven 
benefits of a 1–3 minute delay, at least, in clamping the cord outweigh the 
theoretical, and unproven, harms. 
• Individualized decisions should be taken about postponing planned (elective) 
induction or caesarean section in pregnant person with suspected or confirmed 
mild mpox [171]. 
• Placenta and any pregnancy related tissue or fluids, such as amniotic or fetal 
tissue fluid, must be disposed of following specific IPC protocols for potentially 
infectious materials. 
6.4.3.1 Justification 
Emergency decisions about childbirth and pregnancy termination are complex and 
depend on various factors, including gestational age, the severity of the maternal 
condition, fetal viability and well-being, as well as regulatory and legal barriers in the 
country or state. 
6.4.4 Pregnancy and postpartum period 
Interim guidance (Published 10 June 2022) 
WHO recommends that pregnant and recently pregnant persons who have 
recovered from mpox should be enabled and encouraged to receive routine 
antenatal, postpartum or abortion care, as appropriate. Additional care should be 
provided if there are any complications. 
• Pregnant persons with or recovering from mpox should be provided with 
information related to the potential risk of adverse pregnancy outcomes and 
offered counselling when they request or desire it. Closer follow up is 
recommended, because of higher risk of stillbirth/pregnancy loss. 
• Pregnant persons with mpox should be informed that it is unknown whether 
transmission can occur if others are exposed to pregnancy-related fluids or 
tissues, such as amniotic fluid, placenta or fetal tissue. Instructions should be 
provided on how to handle potentially infectious specimens. 
Recommendations for patients at high risk and those with complications or severe mpox  
67 
• All pregnant persons with confirmed mpox and their infants should be followed 
up through national registries for signs of complications. 
• Patient’s choices and rights to sexual and reproductive health care should be 
respected, including access to contraception and safe abortion per the WHO 
Abortion care guideline [145]. 
• Counsel pregnant persons on safe sexual practices. 
6.4.4.1 Justification 
Limited data suggest that mpox virus infection in pregnant persons may lead to 
vertical transmission as well as adverse outcome for the fetus, such as spontaneous 
abortion and stillbirths [33,78,59,62,60]. 
6.5 Caring for infants and young children with mpox 
6.5.1 Monitoring of newborn infants 
Interim guidance (Published 10 June 2022) 
WHO recommends that newborn infants of mothers with mpox should be 
monitored closely for evidence of potential congenital or perinatal infection. 
Mothers and infants or young children can also be exposed through close contact. 
• Children should not sleep in the same room or bed or drink/eat from the same 
utensils as an individual with mpox. 
• Young children should not be isolated alone. There should be one person 
(parent or caregiver), who is healthy and not at high risk, providing care to the 
child with mpox with appropriate IPC measures. 
• Young children may be considered for care in health facility to monitor for 
disease progression, and if they occur to recognize and treat these 
complications with optimized supportive care. 
Clinical management and infection prevention and control for mpox 
68 
6.6 Recommendations for patients with mpox that are 
sexually active 
6.6.1 Sex and close physical contact 
Interim guidance (Published 10 June 2022) 
WHO recommends all patients should be advised to abstain from sex and close 
physical contact until ALL skin lesions from mpox have crusted, the scabs have 
fallen off and a fresh layer of skin has formed underneath. 
• For patients who are sexually active: among persons presenting with rash or 
skin lesions that are suspected to have mpox, co- infection with other STIs 
should also be considered. The patient should have the following assessment: 
• Thorough sexual history. 
• Full physical examination using appropriate IPC measures with special 
attention on examination for: lymphadenopathy; rash or skin lesions in oral 
mucosae, genitals, anogenital region, and other parts of skin. 
• Testing should be performed for HIV, syphilis, genital HSV, and screening 
for STIs and managed per WHO Guidelines for the management of 
symptomatic sexually transmitted infections [184]; patients should be 
encouraged to use condoms consistently during sexual activity for 
prevention of HIV and other STIs but should be made aware that the use of 
condoms alone cannot offer protection against acquisition and 
transmission of diseases. 
• For persons living with HIV, particularly those with poorly controlled disease, 
who have mpox may be at greater risk for severe disease [46]. Data suggest 
they may be at risk for genital ulcers, secondary bacterial infection and 
prolonged duration of illness [32]. 
• If a person living with HIV is diagnosed with mpox, they should continue 
ART as before (see recommendation above of rapid initiation of ART in 
people with mpox and HIV who are ART naïve or have had a prolonged 
interruption of ART) [185]. People with lower CD4 counts are at greater risk 
of complications related to mpox so should be prioritized for starting ART 
[32]. 
Recommendations for patients at high risk and those with complications or severe mpox  
69 
• Should a person be diagnosed with both mpox and HIV at the same time, 
address the most urgent issues and treatment for mpox and consider drug-
drug interactions. 
6.6.1.1 Justification 
The GDG acknowledged that the risk of transmission from direct contact with infected 
skin or mucocutaneous lesions can amplify transmission, and thus abstaining from 
sexual activity during the infectious period would curtail transmission. As well, the 
potential for sexual transmission is unknown and subject to further research. 
Note: This recommendation is based on existing WHO recommendations from 
Clinical management and infection prevention and control for monkeypox: interim 
rapid response guidance (June 2022) [1]. 
6.6.2 Use of barrier contraception 
Interim guidance (Published 10 June 2022) 
Based on the precautionary principle, WHO suggests the use of condoms 
consistently during sexual activity (receptive and insertive oral/anal/vaginal) for 12 
weeks after recovery to prevent the potential transmission of mpox. 
• As there are no available data about after recovery sexual mpox transmission, 
the precautionary principle is being applied for this public health intervention. 
As more information becomes available and our understanding related to 
transmission improves the guidance will be updated accordingly. 
6.6.2.1 Justification 
Small case series have reported mpox virus DNA detection in bodily fluids after 
healing of skin lesions; this raises uncertainty about the persistence of mpox virus in 
bodily fluids such as semen, vaginal fluids, saliva and blood, and the risk of onward 
transmission. As this is an emergency guidance produced in a quickly evolving 
situation the precautionary principle is being applied for this public health 
intervention. As more information becomes available and our understanding related 
to transmission improves the guidance will be updated accordingly. 
Clinical management and infection prevention and control for mpox 
70 
6.7 Recommendations for caring for mpox patients after 
acute infection 
6.7.1 Follow-up care  
Interim guidance (Published 10 June 2022) 
WHO recommends that patients with suspected or confirmed mpox should have 
access to follow-up care. All patients with mpox (and their caregivers) should be 
counselled to monitor for any persistent, new or changing symptoms. If this occurs, 
they should seek medical care according to national (local) care pathways. 
• National (local) coordinated care pathways should be established that can 
include primary care providers (e.g. general practitioners), relevant specialists 
(e.g. sexual health, infectious diseases, dermatologist, surgeons, wound care 
specialists), mental health and psychosocial providers, nutritionists and social 
care services for patients and families. 
• Management should be tailored according to patient needs and be 
coordinated. Management interventions may entail education, advice on self-
management strategies, caregiver support and education, peer-to-peer groups, 
stress management, stigma mitigation and home medication, and/or specialty 
management. 
6.8 Recommendations on antiviral and other therapies 
(under revision) 
Under revision[164,165,166,167,168,169,170]. 
The antiviral and therapeutics section of this guideline will be updated following the 
systematic review and meta-analysis of multiple ongoing therapeutic trials. 
6.9 Recommendation on mental and psychosocial 
support of patients with mpox 
6.9.1 Anxiety and depressive symptoms 
Interim guidance (Published 10 June 2022) 
Recommendations for patients at high risk and those with complications or severe mpox  
71 
WHO recommends prompt identification and assessment for anxiety and 
depressive symptoms in the context of mpox and to initiate basic psychosocial 
support strategies and first-line interventions for the management of new anxiety 
and depressive symptoms. 
• Patients with mpox should receive compassionate, respectful, people-centred 
care consistently, while ensuring appropriate and adequate protection of 
household members, visitors and health workers. 
• When a patient with mpox arrives at a health facility, the patient and family 
members should be informed about mpox and encouraged to remain calm. 
They should be informed about how the disease is transmitted and educated 
about the precautions that should be taken to prevent the disease from 
spreading. Families should be updated on the patient’s condition and provided 
with any additional information. 
• Ideally, a psychologist, social worker or nurse psychosocial provider fluent in 
the local language will be involved from the onset of the disease to counsel the 
patient on what will happen during any isolation. If this is not possible, then 
general nurses in the health centre should be trained and supervised to provide 
basic psychological support, using standardized resources. 
• For people who are experiencing symptoms of depression, brief psychological 
interventions based on the principles of cognitive behavioural therapy (CBT), 
problem management and relaxation training can be considered [173]. 
Consider using remote mental health support (i.e. telephone therapy) when 
access to regular services is disrupted. 
• If a person’s anxiety or depressive symptoms persist beyond recovery from 
mpox, then an underlying anxiety or depressive disorder may be suspected, 
and a mental health professional should be consulted, and these conditions 
should be managed appropriately. Refer to the mhGAP humanitarian 
intervention guide for mental, neurological and substance use disorders in non-
specialized health settings [174,175]. 
Clinical management and infection prevention and control for mpox 
72 
• It is important to ask about thoughts or acts of self-harm, particularly during 
mpox, due to risk factors for self-harm and suicide such as sense of isolation, 
loss of a loved one, job, or financial loss and hopelessness. Remove possible 
means of self-harm, activate psychosocial support, follow up with the person 
and consult a mental health professional as necessary. Refer to the mhGAP 
humanitarian intervention guide for mental, neurological and substance use 
disorders in non-specialized health settings [174,175]. 
• To ensure comprehensive care and based on the initial assessment, following 
discharge, link the person to employment, education, social services (including 
housing) and other relevant sectors [176]. 
• CBT with a trauma focus, eye movement desensitization and reprocessing or 
stress management should be considered for adults with post-traumatic stress 
disorder (PTSD) [174,177]. 
6.9.1.1 Practical info 
• The WHO Psychological first aid: guide for field workers and Inter-Agency 
Standing Committee guidance on basic psychosocial skills [177,178] promote care 
according to the following principles: 
• Provide non-intrusive, practical care and support. 
• Assess needs and concerns. 
• Help to address basic needs (food, water, information). 
• Listen to patients and families, but do not pressure them to talk. 
• Provide accurate information on the patient’s condition and treatment plan in 
easily understood and non-technical language, as lack of information can be a 
major source of stress. 
• Help people address urgent needs and concerns and help with decision-
making as necessary. 
• Comfort patients and families while helping them feel calm. Inform them that 
the vast majority of mpox patients survive, so be sure to communicate to 
patients and their families that recovery is expected. 
• Help people connect to information, services and social supports. Information 
about mpox is important as it helps to dispel myths, share clear messages 
about healthy behaviour and improve understanding of the disease. 
• Encourage patients and caregivers to use evidence-based stress management 
and self-help tools such as the WHO stress management guide Problem 
management plus (PM+) [179]. 
Recommendations for patients at high risk and those with complications or severe mpox  
73 
• Following recovery, patients may suffer from lingering scars or disfigurement 
and psychological distress as a result. Psychological and social care should be 
included in the follow-up care plan and as part of a multidisciplinary team of 
care. 
6.9.1.2 Justification 
The mpox outbreak can lead to significant mental and psychosocial effects, similarly 
as observed in COVID-19 and EVD, [178,179] [180], including: 
• Fear of the disease or death, loss of sense of meaning of life, or loss of faith. 
• Physical and social isolation from family or community. 
• Stigma associated with diagnosis and returning to the community. 
• Scarring and disability (e.g. blindness) associated with the disease. 
Basic psychosocial support skills are essential for management of all patients and 
represent an integral part of care that should be provided for all. 
6.9.2 Sleep problems 
Interim guidance (Published 10 June 2022) 
WHO recommends psychosocial support strategies as the first-line interventions 
for management of sleep problems in the context of acute stress. 
• Sleep hygiene advice (including avoiding the use of psychostimulants such as 
caffeine, nicotine or alcohol) and stress management (including relaxation 
techniques and mindfulness practices) are effective in reducing sleep problems 
and may be offered. Psychological interventions based on the principles of CBT 
may also be considered. 
• For people who are hospitalized for mpox, additional causes of insomnia may 
include environmental factors (e.g. excessive light and noise at night), anxiety, 
persistent cough, delirium, agitation or pain. Identifying and promptly 
addressing underlying causes should be prioritized before using any 
pharmacological sleep aids. 
 
Clinical management and infection prevention and control for mpox 
74 
6.10 Recommendation of deceased patient management 
6.10.1 Handling of human remains 
Interim guidance (Published 10 June 2022) 
WHO recommends that the handling of human remains of deceased individuals 
with mpox should be done with appropriate IPC measures. 
• Handling of the deceased should be kept to a minimum. 
• Perform hand hygiene and wear PPE according to contact and droplet 
precautions (gloves, gown, medical mask and eye protection based on risk 
assessment) as patients with rashes that have not healed may still have 
infectious virus. 
• Airborne precautions should be implemented when performing AGPs. 
(This section has been modified from the interim guidance to reflect current 
recommendations) 
6.10.1.1 Practical info 
• Ensure that any leakage of body fluids is contained. 
• The body should be wrapped in a cloth or shroud and transferred to the mortuary 
as soon as possible. 
• The dignity of the dead, their cultural and religious traditions, and their families 
should be respected and protected. Family and friends may view the body after it 
has been prepared for burial, in accordance with local customs. They should not 
touch or kiss the body and should clean their hands with soap and water or 
alcohol-based hand sanitizer after the viewing [136,147] 
6.10.1.2 Justification 
This recommendation derives from the Clinical management and infection prevention 
and control for monkeypox: interim rapid response guidance (2022) [1], which 
recommended the use of airborne precautions in addition to droplet and contact 
precautions. In line with changes to WHO guidance, this recommendation has been 
revised from the interim guidance to remove the stipulation for airborne precautions. 
Recommendations for patients at high risk and those with complications or severe mpox  
75 
6.11 Recommendations for health and care workers with 
occupational exposure to mpox 
6.11.1 Occupational exposure to mpox 
Interim guidance (Published 10 June 2022) 
WHO recommends staff with an occupational exposure to mpox should have an 
assessment and management plan 
• Health and care workers should notify infection control, occupational health 
and public health authorities of possible exposures to receive a medical 
evaluation and instructions on follow up. 
• Health and care workers who have had an exposure to a person with confirmed 
mpox should undergo medical evaluation and consideration for possible 
interventions (vaccination or post-exposure prophylaxis [PEP]) under 
prospective data collection protocol or clinical trial. 
• Health and care workers who have had an occupational exposure (i.e. not 
wearing appropriate PPE) do not need to be excluded from work if they are 
asymptomatic, but should undergo active surveillance for symptoms for 21 
days post-exposure and be instructed not to work with vulnerable patients. 
6.11.1.1 Practical info 
These plans should be in accordance with national or subnational policies. The term 
national describes a government entity at national level and subnational describes 
any government entity below the national level (regardless of the political, financial 
and administrative design of the country) involved in the management of health 
workers in the context of mpox. 
 
Clinical management and infection prevention and control for mpox 
76 
7. Methods: how was this guideline 
created 
This guideline was developed according to the standards and methods described in 
the WHO Handbook for guideline development [181]. The initial content was derived 
from the Clinical management and infection prevention and control for monkeypox: 
interim rapid response guidance [1]; which did not undergo a formal Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) process, given 
it was written as a rapid guidance in the context the first mpox Public Health 
Emergency of International Concern (2022). 
The topical areas updated from the Clinical management and infection prevention 
and control for monkeypox: interim response guidance (10 June 2022) were revised 
based on priorities identified by the WHO mpox Steering Committee and the Safe 
Scalable Care Cluster in the Mpox Incident Management Support Team, which was 
established during the Public Health Emergency of International Concern declared by 
WHO on 1 4August 2024 [105]. For prioritized questions, the GRADE approach was 
used to rate the strength and direction of evidence, and to produce 
recommendations (see Stepwise approach - application of GRADE methodology). 
Several interim statements from the 2022 guidance were not subject to systematic 
reviews, as the WHO technical team determined they were appropriate for inclusion 
in the updated document as good practice statements (following GRADE 
methodology), as implementation considerations, or to be updated at a later date. 
These interim statements were reviewed and categorized in collaboration with the 
methodologist, the WHO technical unit and the GDG co-chairs. They were then 
presented to the GDG members for review and inclusion. 
WHO convened a technical meeting with experts on the 15 November 2024 to 
discuss and interpret the available evidence on ART initiation in people living with 
HIV and mpox [188].. Additionally, WHO convened a technical meeting with experts 
on the 26 November 2024 to discuss and interpret the available evidence on 
breastfeeding and mpox. On 12 December 2024, the GDG was convened to make 
recommendations on breastfeeding and ART initiation after the presentation of the 
considerations summarized in the technical groups. On 27 November 2024, 10 
December 2024 and 21 January 2025, the GDG convened to make recommendations 
on transmission-based precautions and home isolation. 
Methods: how was this guideline created 
77 
The Steering Committee and GDG members agreed to retain many of the interim 
recommendations to ensure a consolidated and single- sourced guideline, supporting 
a more comprehensive emergency response. 
The new recommendations are categorized as either strong or conditional 
recommendations (for or against), or as good practice statements. The interim 
statements will remain tagged as such. 
7.1 Types of statements 
7.1.1 Recommendations 
Formal recommendations are actionable statements about the choice between two or 
more interventions in a specific population and if relevant, a specific setting. They are 
based on the best available evidence and follow a transparent methodology that 
considers the certainty of the evidence and determines the strength of the 
recommendation following the evidence to decision framework, see Table 6. 
7.1.2 Good practice statements and implementation considerations 
Good practice statements are necessary, actionable and clear guideline statements 
that are important but do not warrant formal ratings of evidence quality. Formulating 
a good practice statement includes adhering to five principles: 
1) Is collecting and summarizing the evidence poor use of the panel's limited 
time, energy and resources? 
2) Is the message necessary about health care practice? 
3) Does implementing the good practice statement unequivocally result in a net 
positive consequence? 
4) Is there a well-documented and clear rationale connecting the indirect 
evidence? 
5) Is the statement clear and actionable? 
Statements in the document for IPC that are identified as good practice statements 
were reviewed with the methodologist and GDG chairs to determine if they met the 
criteria for a good practice statement according the identified principles. The 
statements that were categorized as meeting the criteria were then presented to the 
panel for discussion and consensus. 
Implementation considerations support the implementation of the recommendations 
and statements and describe the “who, what, when and how” of implementing the 
Clinical management and infection prevention and control for mpox 
78 
recommendation. They may include tools and strategies relevant to supporting the 
implementation of the intervention but may not have a clear link to evidence. They 
translate standard and transmission-based precautions into practical guidance for 
managing mpox [7]. Many of these considerations are derived from WHO documents 
such as the Transmission-based precautions for the prevention and control of 
infections: aide-memoire [7] and the Standard precautions for the prevention and 
control of infections: aide-memoire [14] along with generic recommendations adapted 
to mpox transmission modes. These were validated by the GDG. 
Table 6. Readership cues used for statements in the guideline 
Interim The purple “interim” indicated as a statement that was retained from the 
Clinical management and infection prevention and control for monkeypox: 
interim rapid response guidance (10 June 2022). 
Strong 
recommendation 
The green “strong recommendation” indicates an updated/new statement 
Conditional 
recommendation 
The yellow “conditional recommendation” indicates an updated/new 
statement 
Good  practice 
statement 
The blue “good practice statement” indicates an updated/new statement 
7.2 Step-wise approach - application of GRADE 
methodology 
The GRADE process was followed for iterations after the interim guidance. 
7.2.1 Step 1: Evidence monitoring and mapping and triggering of 
evidence synthesis 
Guidelines are periodically updated to assess data that have undergone peer review 
in the intervening period and new data. Once practice-changing evidence, or 
increasing international interest, is identified, the WHO mpox Steering Committee 
triggers the guideline development process. The trigger for producing or updating 
specific recommendations is based on the following (any of the three may initiate a 
recommendation): 
• likelihood to change practice; 
• sufficient data to inform the high-quality evidence synthesis; 
• relevance to a global audience. 
Methods: how was this guideline created 
79 
This guideline is formulated as a “living” guideline", meaning revisions and updates 
will occur on an ongoing basis or are based on the availability of new evidence and 
evolving issues from the field leading to new PICOs. Other factors that may inform 
the need to update the guideline include changes in transmission intensity, changes 
in epidemiology and/or health systems' capacity to respond to new epidemiological 
scenarios. 
7.2.2 Step 2: Convening the GDG 
WHO selected GDG members to ensure global geographical representation, gender 
balance, appropriate technical and clinical expertise, and community representatives. 
For each intervention, the technical unit collected and managed declarations of 
interests (DOIs) and found no GDG member or co-chairs to have a conflict of interest 
that prevented or limited their participation. In addition to the distribution of a DOI 
form, during the meeting, the WHO Secretariat described the DOI process, and an 
opportunity was given to GDG members to declare any interests not provided in 
written form. No verbal conflicts were declared. Web searches did not identify any 
additional interests that could be perceived to affect an individual’s objectivity and 
independence during the development of the recommendations. One member was 
found to have an affiliation with a company that makes and sells simple, field usable 
tests to detect and quantify fecal bacteria in drinking water; however, since mpox is 
not a pathogen transmitted by contaminated drinking water, no conflict of interest 
was identified. 
The GDG (see Acknowledgments) was convened to review analyses, including pre-
specified subgroup analyses presented in summary of findings tables. In making 
recommendations, the GDG primarily took an individual patient perspective and 
secondarily a population, public health, or systems perspective. Issues of feasibility 
specific to proposed interventions were particularly relevant to this latter perspective. 
The GDG considered all issues in the GRADE evidence to decision framework in 
formulating recommendations. 
Given the scope of the guideline, the GDG was divided into four sections: clinical 
management, IPC, breastfeeding and initiation of ART in HIV patients. Only GDG 
members with relevant expertise contributed to the recommendations (e.g. the IPC 
GDG formulated IPC recommendations, while the clinical management GDG made 
decisions on clinical management). For more details on the specific subgroups, see 
the section GDG topic-specific working groups. 
Clinical management and infection prevention and control for mpox 
80 
7.2.3 Step 3: Evidence synthesis and assessment 
An independent systematic review team conducted rapid systematic reviews of 
published literature and examined the benefits and harms of the interventions. This 
team includes systematic review, clinical experts and biostatisticians. The technical 
unit collected and managed DOIs and found no systematic review team members to 
have a conflict of interest. The certainty of evidence for each question was assessed 
using GRADE as outlined in the WHO handbook for guideline development, 2nd 
edition (Table 7 provides the definitions for the four levels of certainty of evidence). 
The GRADE assessment considers the risk of bias/study limitations, inconsistency, 
imprecision, indirectness and publication/reporting biases [182]. 
Table 7. Levels of certainty of evidence 
High We are very confident that the true effect lies close to that of the estimate of 
effect. 
Moderate We are moderately confident in the effect estimate: the true effect is likely to be 
close to the estimate of the effect, but there is a possibility that it is 
substantially different. 
Low Our confidence in the effect estimate is limited: the true effect may be 
substantially different from the estimate of the effect. 
Very low We have very little confidence in the effect estimate: the true effect is likely to 
be substantially different from the estimate of effect. 
7.2.4 Step 4: Recommendations 
The GRADE approach provided the framework for establishing evidence certainty and 
generating both the direction and strength of recommendations. Methods and 
clinical co-chairs facilitated deliberations to reach final recommendations. All GDG 
members were invited to participate and contribute to discussions in any GDG 
meetings. Decisions were made via consensus amongst the GDG members identified 
for the relevant recommendation. If consensus was not achieved, then the GDG 
members specific to the pertinent topic would be asked to vote. 
The following key factors informed transparent and trustworthy recommendations: 
• absolute benefits and harms for all patient-important outcomes through 
structured evidence summaries (e.g. GRADE summary of findings tables) 
that include effect estimates and confidence intervals for each outcome, 
with an associated rating of certainty in the evidence findings. If such data 
are not available, the GDG reviews narrative summaries [183]; 
Methods: how was this guideline created 
81 
• quality/certainty of the evidence [184,185]; 
• values and preferences of patients [186]; 
• resources and other considerations (including considerations of cost, 
feasibility, applicability, equity) [186]; 
• recommendations are rated as either conditional or strong, as defined by 
GRADE. If the GDG members disagree regarding the evidence assessment 
or strength of recommendations, WHO will apply voting according to 
established rules [186]. A pre- specified decision rule for making a strong 
recommendation of 70% of eligible GDG members was in place. 
7.2.5 Step 5: External and internal review 
An external review group reviewed the final guideline document to identify factual 
errors, and to comment on clarity of language, contextual issues and implications for 
implementation. The technical unit collected and managed DOIs of the external 
reviewers and found no external reviewers to have a conflict of interest. However, for 
certain therapeutics, pharmaceutical company technical representatives may be asked 
to comment on a new drug from industry perspectives, in line with the WHO 
handbook for guideline development, as comments from such individuals or 
organizations on a draft guideline may be helpful in anticipating and dealing with 
controversy, identifying factual errors and promoting engagement with all 
stakeholders. Comments on contextual issues were considered considering their 
interests. The affiliation of all individuals appears in the Acknowledgement section. 
The guideline was finally reviewed and approved by the WHO Guideline Review 
Committee. 
7.3 GDG topic-specific working groups 
The process to develop this updated guideline was based in a structure that consisted 
on two working groups that functioned as GDG: Clinical Management and Infection 
Prevention and Control, engaged to specifically consider recommendations within 
their domain of expertise, i.e. the IPC working group primarily formulated IPC 
recommendations, while the clinical management working group focused on clinical 
management. 
Besides, there were two technical groups: one on HIV and one on Breastfeeding. Both 
included some of the GDG members and several additional topical experts that were 
not GDG members (see Acknowledgements); they worked on bringing up the 
Clinical management and infection prevention and control for mpox 
82 
considerations of these topics to be presented to the GDG members who were 
responsible for making the final recommendations for the guidelines. 
While all perspectives and viewpoints were welcome in the discussions, the 
formulation of the recommendations for IPC were made specifically by the respective 
IPC GDG members; and in the Clinical Management GDG meetings only Clinical 
Management GDG members were responsible for making recommendations. 
7.3.1 Infection prevention and control technical working group 
The IPC working group members convened for three separate meetings (27 
November 2024, 10 December 2024 and 21 January 2025) to review available 
evidence and formulate the recommendations, good practice statements and 
implementation considerations contained in this document. 
7.3.1.1 Evidence synthesis 
A commissioned systematic review underpins the current guideline and is an update 
of a previously published systematic literature review. The systematic review 
performed in 2023 assessed publications up to and including September 2022. A 
subsequent review was commissioned in 2024 given the evolution of new MPXV 
clades. Both reviews synthesize and update evidence for the three research questions 
outlined below and were developed in consultation with the GDG following the 
publication of the interim guidance in 2022. 
1) Does the use of respirator versus a medical mask when interacting with a 
patient with suspected or confirmed mpox during the infectious period (as 
defined in the footnote) reduce occurrence of mpox in health and care workers 
in a household, congregate living or health care setting? 
2) Does the use of an airborne precaution room versus an adequately ventilated 
room in a health care facility for a patient with mpox during the infectious 
period (as defined in the footnote) reduce the occurrence of mpox in health 
and care workers? 
3) In the event that a person with non-severe mpox is being cared for at home, 
does isolating the person with non-severe mpox until all lesions are fully 
healed reduce occurrence of mpox in persons who are contacts, compared 
with not isolating when the patient wears a medical mask, covers all unhealed 
lesions, refrains from close contact and does not share any materials that could 
be contaminated? 
Methods: how was this guideline created 
83 
The reviews occurred in two stages. The first stage appraised available evidence from 
comparative interventional trials, which yielded no evidence. In the absence of such 
data, the second stage was preformed to synthesize evidence on the reported routes 
of MPXV infection using non-comparative study designs to indirectly inform the three 
IPC intervention review questions. Details on the search strategy and key terminology 
can be found in Annex 5: Search strategy and terminology for reported routes of 
MPXV infection. 
Throughout these discussions, research gaps were identified, prompting the 
development of the IPC research agenda and ongoing research prioritization efforts 
(see: Uncertainties, emerging evidence and future research). 
7.3.2 Breastfeeding technical working group pre-GDG discussion 
WHO convened a technical meeting with experts on 26 November 2024 to guide the 
review of relevant evidence and to support the update of recommendations 
concerning breastfeeding and mpox. The technical working group included external 
experts with experience in infant feeding and nutrition, paediatric care, with wide 
geographical representation and gender balance. The full meeting report can be 
found here [187]. 
A summary of synthesized evidence on the following PICO questions that relate to 
breastfeeding during and after recovery from mpox infection was presented and 
discussed: 
• Should a mother with suspected/confirmed mpox and no lesions on the breast 
continue breastfeeding and direct contact with their non-infected infant? 
• Should a mother with confirmed mpox and active lesions on the breast continue 
breastfeeding and direct contact with their non-infected infant? 
• When after recovery from confirmed mpox (after stopping breastfeeding and 
close contact) should the mother resume breastfeeding and direct contact with 
their non-infected infant? 
• Does pasteurization inactivate mpox in breastmilk to allow feeding the infant with 
expressed milk without direct contact with mother with mpox? 
Overall there were very few studies to answer the four PICO questions. Identified 
studies were mostly observational, non- comparative study designs and with 
significant methodological limitations. 
Clinical management and infection prevention and control for mpox 
84 
The meeting points are summarized below, and were presented to the GDG for 
further discussion and interpretation. 
7.3.2.1 Routes of transmission 
The TWG reiterated that guidance on breastfeeding and infant contact in mpox 
infection needs to differentiate between the following potential MPXV routes of 
transmission from mother to child: 
• through breastmilk (presence and viability of virus in breastmilk is unknown) 
• direct contact during the process of breastfeeding (from the breast) 
• other direct contact with the infant (not from the breast) during care 
• air droplets 
• saliva through kissing. 
7.3.2.2 What are the evidence gaps? 
• It is still unknown if MPXV is secreted in milk although laboratory experiments 
have shown that it can be viable in milk. This was thought to be the first critical 
question because if studies show that breastmilk does NOT contain MPXV, then 
this would help to answer the question if breastfeeding should be recommended 
and if so how? 
• If mpox can be transmitted via breastmilk, then there would be need for an 
additional PICO, whether heat treatment of expressed breastmilk can make it safe 
[?] and what is the feasibility of this intervention at an individual and population 
level. 
7.3.2.3 What are the implementation considerations? 
• There is a need to involve, where possible, another caregiver to take care of the 
infant particularly for mothers that are in isolation to limit the duration of contact 
with between the infant and a mother with mpox. 
• The duration of infant-to-mother contact will vary depending on the age. Early 
initiation of breastfeeding requires longer contact, and later the infant may need 
shorter contact during breastfeeding. A newborn (up to 2, 6 or even 8 weeks) 
usually needs constant access to the breast to successfully breastfeed. 
• A lesion on the areola would make breastfeeding very painful, and therefore for 
breast health, the mother should express from that breast in order to prevent 
engorgement or mastitis and preserve lactation for later resumption of 
breastfeeding. 
Methods: how was this guideline created 
85 
• Alternative milk substitutes may not readily be available, or not affordable, or not 
safe in many locations. 
7.3.3 HIV antiretroviral technical working group pre-GDG discussion 
WHO convened a technical meeting with experts on 15 November 2024 to discuss 
and interpret the available evidence on ART initiation in people living with HIV and 
mpox. Participants included HIV medicine experts, infectious diseases specialists, and 
programme managers with significant mpox experience; a full list of participants and 
meeting report can be accessed here [188]. The technical meeting was led by an 
independent chair. 
The objective of the meeting was to identify the evidence sources that would best 
inform the GDG and place these in the context of the current WHO guidelines that 
include a strong recommendation for rapid ART initiation, with the option of same-
day initiation, in people living with HIV. To facilitate discussions, a literature review 
compiled by WHO technical staff summarized the available direct and indirect 
evidence. 
The meeting reported the following findings, which were presented to the GDG for 
further discussion and interpretation. 
7.3.3.1 ART initiation in people living with HIV with mpox 
• ART is a life-saving intervention for people living with HIV, with or without mpox 
virus infection. 
• Rapid ART initiation (within 7 days of HIV diagnosis) or re-initiation is the standard 
of care for people living with HIV that are ART-naive or have interrupted ART 
(WHO, strong recommendation). This includes people with opportunistic 
infections other than tuberculosis and central nervous system infections. 
• Immune restoration through effective ART is important to control MPXV and delay 
in ART initiation may potentially be harmful. 
• There is uncertainty about the incidence of mpox IRIS; mpox IRIS may occur but it 
is difficult to distinguish from progressive mpox given the lack of clear case 
definition, delayed clinical presentation and concurrence of other (opportunistic) 
infections. 
• Central nervous system manifestations of mpox are estimated to be uncommon 
and based on clinical expertise not a reason to delay ART initiation provided that 
assessment of other etiologies is conducted. 
Clinical management and infection prevention and control for mpox 
86 
• The expert group proposed the values and preferences statement that “Most HIV 
patients with mpox would place a higher value on the mortality reduction benefit 
of initiating ART as soon as possible than on the possible increased risk of 
developing IRIS”. 
7.3.3.2 What are the evidence gaps? 
• Lack of direct evidence comparing rapid vs delayed ART initiation in people living 
with HIV and mpox. Only one small cohort study that directly addressed the 
question of timing of ART initiation was identified; this study did not show a 
difference in outcomes. 
• Understanding progressive mpox, mpox IRIS and associated morbidity and 
mortality. There is limited evidence on viral pathogenesis, immune response and 
disease progression in people with and without ART initiation for HIV. 
7.3.3.3 What are implementation considerations? 
• Ensure all patients with presumed or confirmed mpox receive HIV testing at their 
first presentation to health care providers. 
• Ensure individuals engage with health care services at an early stage of mpox 
symptoms to avoid disease progression and late ART initiation. 
• Ensure clinical assessment is conducted in all patients prior to ART initiation to 
ensure comprehensive care of people living with HIV, in particular those with 
advanced HIV disease. 
7.4 Risk factors for severe disease and prognosis 
methodology 
To provide the GDG with a comprehensive understanding of mpox prognosis, a 
systematic review of observational studies published up to 20 September 2024, was 
conducted. The review aimed to: 1) establish baseline risk estimations for clinical 
adverse outcomes, including but not limited to hospitalization and mortality, in 
patients with mpox, differentiating between severe and non-severe cases as defined 
in the literature; and 2) identify adjusted risk factors associated with mpox prognosis 
[49]. 
With assistance from an expert librarian, the review team searched MEDLINE, Embase, 
CENTRAL, CINAHL, Global Health, medRxiv, bioRxiv, and SSRN from inception to 
September 2024, using search terms including "mpox", ”cohort”, "case-control ", 
"observational study", “cross-sectional”, “epidemiologic”, “population surveillance”, 
Methods: how was this guideline created 
87 
"retrospective", “prospective” and ”randomized controlled tria”". To identify 
additional eligible studies, the review team screened the reference lists of included 
studies and relevant systematic reviews. 
The review included studies of patients with laboratory-confirmed mpox virus 
infections that reported the rate of clinical adverse outcomes and adjusted risk 
factors for adverse outcomes. 
To estimate pooled baseline risks and their associated 95% confidence intervals for 
each adverse outcome, the review team conducted meta-analyses of proportions 
using fixed effects models. The review team performed analyses for all patients, 
severe patients and non-severe patients separately. For every candidate risk factor, as 
most eligible studies reported odds ratios (OR) as the measure of association, if 
studies reported relative risks (RRs) or hazard ratios (HRs), the review team converted 
them to ORs and pooled ORs using the random effects model. 
The review team examined different thresholds to classify studies as reporting on 
severe disease or non-severe disease and decided on a 50% threshold to categorize 
studies as severe disease or non-severe disease. Studies with fewer than 50% of 
participants classified as having severe mpox or hospitalized for treatment were 
categorized as non-severe; studies with 50% or more were categorized as severe. 
Clinical management and infection prevention and control for mpox 
88 
8. How to access and use this 
guideline 
This is a living guideline from WHO. The recommendations included here will be 
updated, and new recommendations will be added over time: 
8.1 How to access the guideline 
• WHO website: This is a full read out of the MAGICapp content for those without 
reliable web access. It can also be downloaded directly from MAGICapp (see 
cogwheel on top right). 
• MAGICapp in online, multilayered formats: This is the fullest version of the 
guideline, as detailed below. 
8.2 How to navigate this guideline 
The guideline is written, disseminated and updated in MAGICapp, with a format and 
structure that ensures user-friendliness and ease of navigation [168]. It 
accommodates dynamic updating of evidence and recommendations that can focus 
on what is new while keeping existing recommendations, as appropriate, within the 
guideline. 
The purpose of the online formats and additional tools, such as the infographics, is to 
make it easier to navigate and make use of the guideline in busy clinical practice. The 
online multilayered formats are designed to allow end-users to find 
recommendations first and then drill down to find supporting evidence and other 
information pertinent to applying the recommendations in practice, including tools 
for shared decision-making (clinical encounter decision aids
) [168] 
The online multilayered formats are designed to allow end-users to find 
recommendations first and then drill down to find supporting information pertinent 
to applying the recommendations in practice. End-users will also need to understand 
what is meant by strong and conditional recommendations (displayed immediately 
below) and certainty of evidence (the extent to which the estimates of effect from 
research represent true effects from treatment). 
For each recommendation additional information is available through the following 
tabs: 
How to access and use this guideline 
89 
• Research evidence: Readers can find details about the research evidence 
underpinning the recommendations as GRADE Summary of Findings tables and 
narrative evidence summaries. 
• Evidence to decision: The absolute benefits and harms are summarized, along with 
other factors such as the values and preferences of patients, practical issues 
around delivering the treatment as well as considerations concerning resources, 
applicability, feasibility, equity and human rights. These latter factors are 
particularly important for those in need of adapting the guidelines for the national 
or local context. 
• Justification: Explanation of how the GDG considered and integrated evidence to 
decision factors when creating the recommendations, focusing on controversial 
and challenging issues. 
• Practical information: For example, dosing, duration and administration of drugs, 
or how to apply tests to identify patients in practice. 
• Decision aids: Tools for shared decision-making in clinical encounters. 
8.3 Additional educational modules and implementation 
tools for health workers 
• WHO Essential items estimator tool 
(https://partnersplatform.who.int/tools/essentialitemsestimator)
 assists 
governments, partners and other stakeholders to forecast the necessary volume of 
PPE, diagnostic test equipment, consumable medical supplies, biomedical 
equipment for case management, and essential drugs for supportive care and 
treatment of COVID-19. 
• WHO website mpox clinical management (https://www.who.int/teams/health-
care-readiness/clinical-management-of-monkeypox) includes multiple tools and 
infographics about clinical diagnosis and management of patients with mpox. 
Such as the Atlas of mpox lesions: a tool for clinical researchers, posters about 
screening, triage and differential diagnosis, skin care, etc. in patients with mpox 
infection. Also, it includes the link for the Global Clinical Data Platform for Mpox. 
• Interim practical manual for designing, setting up and assessing health facilities in 
the context of mpox outbreaks (2024) (https://iris.who.int/handle/10665/380532
). 
• Health emergencies - infection prevention and control and water sanitation and 
hygiene (https://www.who.int/teams/health- care-readiness/infection-prevention-
and- 
Clinical management and infection prevention and control for mpox 
90 
control#:~:text=Infection%20prevention%20and%20control%20%28IPC%29%20a
nd%20water,%20sanitation,%20and%20hygiene). 
8.4 Collection of standardized data and the WHO Clinical 
Platform 
As the cluster of mpox cases continues to expand in countries across WHO regions it 
is important that we understand the clinical features, prognostic factors and 
outcomes in patients so we can better inform our clinical management guidelines 
and inform public health. The WHO Global Clinical Platform collects patient-level 
anonymized clinical data and has been used to understand various emerging 
pathogens. As we work to understand more about the current cases, we have 
developed a case report form for mpox, and invite Member States to contribute data 
to this platform. 
The objectives of the platform are: 
• describe the clinical characteristics of mpox. 
• assess the variations in clinical characteristics of mpox. 
• identify the association of clinical characteristics of mpox with symptoms. 
• describe temporal trends in clinical characteristics of mpox. 
For more details, please see the WHO Global Clinical Platform for mpox website [link]
 
[189]. A statistical analysis plan is available [link] [190]. 
 
Uncertainties, emerging evidence and future research 
91 
9. Uncertainties, emerging evidence 
and future research 
While formulating recommendations and prioritizing questions for this guideline, the 
GDG identified key areas of uncertainty, and in which they felt research would enable 
future recommendations to be made with higher certainty. 
9.1 Transmission 
• Limited epidemiological evidence on pre-symptomatic or asymptomatic phases of 
disease. 
• Routes for human-human transmission, including how viral dynamics and 
trajectories correlate with viral culture in the various bodily fluids and the impact 
of this on transmission, infectious periods, subgroup by disease manifestation and 
disease severity. 
• Potential for reverse zoonosis and spillback events. 
• Natural history of disease: disease severity and risk factors for severe, disease in 
different subpopulations (neonates, children and young people, 
immunosuppressed, pregnant women and older persons). 
• Difference and similarities in transmissibility between clade I (a and b), clade II (a 
and b). 
• Risks related to particle and aerosol-generating activities (e.g. shaking linen). 
• Infectious dose of MPXV in humans. 
• Characterization of viral evolution. 
• Wastewater sampling and predicting trends for outbreak response. 
9.2 Clinical management 
• Establish disease severity classification and risk factors for severity. 
• Co-infection: other viruses (varicella zoster [VZV], HIV), STIs (such as herpes 
simplex virus [HSV], syphilis, chancroid, lymphogranuloma venereum [LGV]), and 
others, parasitic infections (malaria, dengue, filariasis) etc. Understand if co-
infection impacts disease severity. 
• Clinical management of patients with advanced HIV and mpox. 
• The incidence of IRIS and its contribution to morbidity and mortality. 
• Racial and ethnic disparities in incidence and access to countermeasure and care. 
• Best symptomatic care for skin care, rash management, nutrition. 
Clinical management and infection prevention and control for mpox 
92 
• Best optimized care package for complications such as ocular and central nervous 
system complications. 
• Long-term outcomes for recovered patients, including mothers and babies, 
immunosuppressed patients. Evidence of post viral syndrome and clinical 
presentation. 
• Efficacy and safety of therapeutics, including in pregnant and breastfeeding 
mothers and children. 
• Presence and transmission of mpox through breastmilk. Measures to inactivate 
mpox virus to make the breastmilk safe (e.g. pasteurization).[129] 
9.3 Infection prevention and control 
• Description of close proximity and impact on transmission. 
• Effectiveness of covering lesions and impact on fomite/environmental 
contamination. 
• Health worker exposure risk categories and post-exposure prophylaxis (PEP). 
• Susceptibility of the mpox virus to disinfectants and their virucidal properties (i.e. 
active ingredients and concentrations, contact time). 
• Stability of virus in the environment and on surfaces. 
• Optimal ventilation to reduce disease transmission. 
• Duration of transmission-based precautions to maintain patients in isolation 
(when can transmission-based precautions be lifted). 
• Effects of home-based care (what can be learned, models of care, etc.). 
• Effectiveness of isolation at home to prevent transmission. 
9.4 Methods questions 
• Value and preference surveys of affected populations. 
 
References 
93 
10. References 
1. World Health Organization. Clinical management and infection prevention and control for 
monkeypox: interim response guidance. 2022. https://www.who.int/publications/i/item/WHO-
MPX-Clinical-and-IPC-2022.1  
2. World Health Organization. Infection prevention and control of epidemic-and pandemic-prone 
acute respiratory infections in health care. 2014. 
https://www.who.int/publications/i/item/infection-prevention-and-control-of-epidemic-and-
pandemic-prone-acute-respiratory-infections-in-health-care  
3. World Health Organization. Infection prevention and control in the context of coronavirus 
disease (COVID-19): a living guideline, 25 April 2022: updated chapter: mask use, part 1: health 
care settings. 2022.
 https://iris.who.int/bitstream/handle/10665/353565/WHO-2019-nCoV-ipc-
guideline-2022.2-eng.pdf  
4. World Health Organization. Global technical consultation report on proposed terminology for 
pathogens that transmit through the air. https://www.who.int/publications/m/item/global-
technical-consultation-report-on-proposed-terminology-for-pathogens-that-transmit-through-
the-air  
5. International Labour Organization. International Standard Classification of Occupations (ISCO 
2008). https://isco.ilo.org/en/
  
6. World Health Organization. World Health Organization Health Workforce-related terminology; 
Terminology work carried out by the WHO Language department at the request of the Health 
Workforce department. https://www.who.int/publications/m/item/health-workforce-terminology
  
7. World Health Organization. Transmission-based precautions for the prevention and control of 
infections. 2022. https://www.who.int/publications/i/item/WHO-UHL-IHS-IPC-2022.2  
8. Atkinson J, Chartier Y, Pessoa-Silva CL, Jensen P, Li Y, Seto WH. Natural ventilation for infection 
control in health-care settings. Geneva: World Health Organization; 2009. Annex C, Respiratory 
droplets. 2020. https://www.ncbi.nlm.nih.gov/books/NBK143284/  
9. World Health Organization. Technical specifications of personal protective equipment for 
COVID-19. 2020. https://iris.who.int/bitstream/handle/10665/336622/WHO-2019-nCoV-
PPE_specifications-2020.1-eng.pdf  
10. World Health Organization. The world health report : 2006 : working together for health. 
https://iris.who.int/bitstream/handle/10665/43432/9241563176_eng.pdf  
11. U.S Department of Health & Human Services. What is the difference between isolation and 
quarantine?. 2022. 
https://www.hhs.gov/answers/public-health-and-safety/what-is-the-
difference-between-isolation-and-quarantine/index.html  
12. World Health Organization. Operational considerations for case management of COVID -19 in 
health facility and community; Interim guidance. 
https://iris.who.int/bitstream/handle/10665/331492/WHO-2019-nCoV-HCF_operations-2020.1-
eng.pdf  
13. OpenWHO. Clinical management of patients with COVID-19: Initial approach h to the acutely ill 
patient. https://openwho.org/playlist/dedicated/500316/0_xfe055ah/0_sgcgs6yg  
14. World Health Organization. Standard precautions for the prevention and control of infections: 
aide-memoire. https://www.who.int/publications/i/item/WHO-UHL-IHS-IPC-2022.1
  
Clinical management and infection prevention and control for mpox 
94 
15. Jezek Z., Grab B., Szczeniowski MV, Paluku KM, Mutombo M. Human monkeypox: secondary 
attack rates. Bull World Health Organ 1988;66(4):465-70 
https://www.ncbi.nlm.nih.gov/pubmed/2844429  
16. Brown K., Leggat PA. Human Monkeypox: Current State of Knowledge and Implications for the 
Future. Trop Med Infect Dis 2016;1(1) http://dx.doi.org/10.3390/tropicalmed1010008   
17. Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New nomenclature for mpox 
(monkeypox) and monkeypox virus clades. The Lancet Infectious Disease 2023. 
https://www.thelancet.com/journals/lancet/article/PIIS1473-3099(23)00055-5/fulltext
  
18. Li Y., Zhao H., Wilkins K., Hughes C., Damon IK. Real-time PCR assays for the specific detection of 
monkeypox virus West African and Congo Basin strain DNA. J Virol Methods 2010;169(1):223 -7 
http://dx.doi.org/10.1016/j.jviromet.2010.07.012  
19. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and 
implications for outbreak strategy. PLoS Negl Trop Dis 2019;13(10):e0007791 
http://dx.doi.org/10.1371/journal.pntd.0007791
  
20. Yinka-Ogunleye A., Aruna O., Dalhat M., Ogoina D., McCollum A., Disu Y., et al. Outbreak of 
human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis 
2019;19(8):872-879 http://dx.doi.org/10.1016/S1473-3099(19)30294-4  
21. Americo JL, Earl PL, Moss B. Virulence differences of mpox (monkeypox) virus clades I, IIa, and 
IIb.1 in a small animal model. Proceedings of the National Academy of Sciences of the United 
States of America 2023;120(8):e2220415120 http://dx.doi.org/10.1073/pnas.2220415120
  
22. Bangwen E. Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of 
national epidemiological and laboratory surveillance data, 2010-23. Lancet 2025. 
http://dx.doi.org/10.1016/S0140-6736(24)02669-2
  
23. World Health Organization. Multi-country outbreak of mpox, External situation report #48 - 10 
March 2025. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--
external-situation-report--48---10-march-2024  
24. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, Kalonji-Mukendi T, Pukuta E, Hoff NA, et al. 
Clade I-Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the 
Congo. Emerging infectious diseases 2024;30(1):172-176 
http://dx.doi.org/10.3201/eid3001.231164  
25. Marsirika LM, Udahemuka JC, Martinez GS, Kelvin P, Nadine MB, Steeven BK, et al. FK. 2024. 
https://www.medrxiv.org/content/10.1101/2024.03.05.24303395v1
  
26. Laurenson-Schafer H, Sklenovská N, Hoxha A, Kerr SM, Ndumbi P, Fitzner J, et al. Description of 
the first global outbreak of mpox: an analysis of global surveillance data. The Lancet. Global 
health 2023;11(7):e1012-e1023 http://dx.doi.org/10.1016/S2214-109X(23)00198-5
  
27. Vaughan AM, Afzal M, Nannapaneni P, Leroy M, Andrianou X, Pires J, et al. Continued circulation 
of mpox: an epidemiological and phylogenetic assessment, European Region, 2023 to 2024. 
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable 
disease bulletin 2024;29(27) http://dx.doi.org/10.2807/1560-7917.ES.2024.29.27.2400330
  
28. Centers for Disease Control and Prevention. MPOX: Clinical Recognition. 2023. 
https://www.cdc.gov/poxvirus/mpox/clinicians/clinical-recognition.html
  
29. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58(2):260-7 
http://dx.doi.org/10.1093/cid/cit703  
References 
95 
30. World Health Organization. Multi-country outbreak of mpox, External situation report # 18-16 
March. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-
situation-report--18---16-march-2023  
31. Damon IK. Smallpox, Monkeypox, and Other Poxvirus Infections. Goldman's Cecil Medicine, 
Twenty-fourth Ed.: Elsevier 2012;2117-2121 
https://www.sciencedirect.com/science/article/pii/B9781437716047003808?via%3Dihub   
32. Ogoina D., Iroezindu M., James HI, Oladokun R., Yinka-Ogunleye A., Wakama P., et al. Clinical 
Course and Outcome of Human Monkeypox in Nigeria. Clin Infect Dis 2020;71(8):e210 -e214 
http://dx.doi.org/10.1093/cid/ciaa143  
33. Pittman PR, Martin JW, Kingebeni PM, Tamfum J-JM, Wan Q, Reynolds MG, et al. Clinical 
characterization of human monkeypox infections in the Democratic Republic of the Congo. 
medRxiv 2022;2022.05.26.22273379 http://dx.doi.org/10.1101/2022.05.26.22273379
  
34. PALM007. Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox 
clade 1. IDweek2024 2025. https://i-base.info/htb/50006
  
35. Damon IK. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine 
2011;29 Suppl 4:D54-9 http://dx.doi.org/10.1016/j.vaccine.2011.04.014
  
36. Adler H., Gould S., Hine P., Snell LB, Wong W., Houlihan CF, et al. Clinical features and 
management of human monkeypox: a retrospective observational study in the UK. Lancet Infect 
Dis 2022;22(8):1153-1162 http://dx.doi.org/10.1016/S1473-3099(22)00228-6
  
37. Prasad S, Galvan Casas C, Strahan AG, Fuller LC, Peebles K, Carugno A, et al. A dermatologic 
assessment of 101 mpox (monkeypox) cases from 13 countries during the 2022 outbreak: Skin 
lesion morphology, clinical course, and scarring. Journal of the American Academy of 
Dermatology http://dx.doi.org/10.1016/j.jaad.2022.12.035  
38. Català A., Muñoz-S antos C., Galván -C asas C., Roncero Riesco M., Revilla Nebreda D., Solá-
T
ruyols A., et al. Cutaneous reactions after SARS-C
oV-2
 vaccination: a cross-s
ectional Spanish 
nationwide study of 405 cases*. British Journal of Dermatology 2022;186(1):142- 152 
h
ttp://dx.doi.org/10.1111/bjd.20639  
39. Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical 
presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a 
prospective observational cohort study. Lancet (London, England) 2022;400(10353):661-669 
http://dx.doi.org/10.1016/S0140-6736(22)01436-2
  
40. Weinstein RA, Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: 
prevalence, diagnostics, and countermeasures. Clinical infectious diseases 2005;41(12):1765 -
1771 https://www.
 https://doi.org/10.1086/498155  
41. Low N. Mpox virus and transmission through sexual contact: Defining the research agenda. PLoS 
Med 2023. http://dx.doi.org/10.1371/journal.pmed.1004163
  
42. Bruzzesi E, Raccagni AR, Mileto D, Candela C, Canetti D, Castagna A, et al. Isolated monkeypox 
proctitis among men who have sex with men. Infection 2023;51(5):1597-1598  
http://dx.doi.org/10.1007/s15010-023-02051-6  
43. Thornhill JP. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. The 
New England Journal of medicine 2022. http://dx.doi.org/10.1056/NEJMoa2207323  
44. Huhn GD, Bauer AM, Yorita K., Graham MB, Sejvar J., Likos A., et al. Clinical characteristics of 
human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005;41(12):1742- 51 
http://dx.doi.org/10.1086/498115
  
Clinical management and infection prevention and control for mpox 
96 
45. Petersen E., Kantele A., Koopmans M., Asogun D., Yinka-Ogunleye A., Ihekweazu C., et al. Human 
Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis Clin 
North Am 2019;33(4):1027-1043 http://dx.doi.org/10.1016/j.idc.2019.03.001  
46. Mitja O, Alemany A, Marks M, Jezer M. Mpox in people with advanced HIV infection: a global 
case series. The Lancet 2023. 
https://www.thelancet.com/journals/lancet/article/PIIS0140-
6736(23)00273-8/fulltext  
47. Angelo KM, Smith T, Camprubí-Ferrer D, Balerdi-Sarasola L, Díaz Menéndez M, Servera-Negre G, 
et al. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel 
Network: a cross-sectional study. The Lancet Infectious Diseases 
http://dx.doi.org/10.1016/S1473-3099(22)00651-X  
48. Miller M. Severe monkeypox in hospitalized patients—United States, August 10–october 10, 
2022. Morbidity and Mortality Weekly Report 2022. 
https://www.cdc.gov/mmwr/volumes/71/wr/mm7144e1.htm  
49. Gao YA, Hao Q. Incidence and risk factors for adverse outcomes and complications among 
patients with mpox: a systematic review and meta-analysis. Unpublished work 2025 (see Annex) 
50. Gupta A.K. Differential diagnosis, prevention and treatment of mpox (monkeypox): A review for 
dermatologists. Am J Clin Dermatol 2023. http://dx.doi.org/10.1007/s40257-023-00778-4
  
51. WHO. Atlas of mpox lesions: a tool for clinical researchers, 28 April 2023, version 1.0. 2024. 
https://www.who.int/publications/i/item/WHO-MPX-Clinical-Lesions-2023.1
  
52. WHO. Infographic: Poster Differential diagnosis mpox lesions. 2024. 
https://www.who.int/teams/health-care-readiness/clinical-management-of-monkeypox
  
53. WHO. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, 
adolescents and children living with HIV. 
https://www.who.int/publications/i/item/9789240052178
  
54. Brosius I. Epidemiological and clinical features during the clade Ib in South Kivu, Democratic 
Republic of the Congo: A prospective cohort study. Lancet 2025. 
http://dx.doi.org/10.1016/S0140-6736(25)00047-9
  
55. Hughes CM, Liu L., Davidson WB, Radford KW, Wilkins K., Monroe B., et al. A Tale of Two Viruses: 
Coinfections of Monkeypox and Varicella Zoster Virus in the Democratic Republic of Congo. Am 
J Trop Med Hyg 2020;104(2):604-611 http://dx.doi.org/10.4269/ajtmh.20-0589
  
56. Hoff NA, Morier DS, Kisalu NK, Johnston SC, Doshi RH, Hensley LE, et al. Varicella Coinfection in 
Patients with Active Monkeypox in the Democratic Republic of the Congo. Ecohealth 
2017;14(3):564-574 http://dx.doi.org/10.1007/s10393-017-1266-5
  
57. D'Antonio F, Pagani G, Buca D, Khalil A. Monkeypox infection in pregnancy: a systematic review 
and metaanalysis. American journal of obstetrics & gynecology MFM 2023;5(1):100747 
http://dx.doi.org/10.1016/j.ajogmf.2022.100747
  
58. Hobson G., Adamson J., Adler H., Firth R., Gould S., Houlihan C., et al. Family cluster of three 
cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill 
2021;26(32) http://dx.doi.org/10.2807/1560-7917.ES.2021.26.32.2100745
  
59. Mbala PK, Huggins JW, Riu-Rovira T., Ahuka SM, Mulembakani P., Rimoin AW, et al. Maternal 
and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the 
Democratic Republic of Congo. J Infect Dis 2017;216(7):824-828 
http://dx.doi.org/10.1093/infdis/jix260
  
60. Nachega JB. Mpox in pregnancy: Risks, vertical transmission, prevention and treatment. The New 
England Journal of medicine 2024. http://dx.doi.org/10.1056/NEJMp2410045
  
References 
97 
61. Brown SH., Goldfarb IT., Shenoy ES., Kwolek D. Mpox Exposure in Pregnancy. Journal of General 
Internal Medicine 2023. https://link.springer.com/article/10.1007/s11606-023-08226-z  
62. Jamieson DJ, Jernigan DB, Ellis JE, Treadwell TA. Emerging infections and pregnancy: West Nile 
virus, monkeypox, severe acute respiratory syndrome, and bioterrorism. Clin Perinatol 
2005;32(3):765-76 http://dx.doi.org/10.1016/j.clp.2005.04.008
  
63. Hughes C., McCollum A., Pukuta E., Karhemere S., Nguete B., Shongo Lushima R., et al. Ocular 
complications associated with acute monkeypox virus infection, DRC. International Journal of 
Infectious Diseases 2014;21:276-277 http://dx.doi.org/10.1016/j.ijid.2014.03.994
  
64. Centers for Disease Control and Prevention. Science Brief: Detection and Transmission of Mpox 
Virus. 2022. 
https://archive.cdc.gov/%23/details?url=https%3A//www.cdc.gov/poxvirus/mpox/about/science
-behind-transmission.html  
65. Li Z, Li XX, Chen Y, Ruan Q, Huang X, Zhu G, et al. Persistence of monkeypox virus DNA in clinical 
specimens. The Journal of infection 2022;85(6):702-769 
http://dx.doi.org/10.1016/j.jinf.2022.10.013
  
66. Meschi S, Colavita F, Carletti F, Mazzotta V, Matusali G, Specchiarello E, et al. MPXV DNA kinetics 
in bloodstream and other body fluids samples. Scientific reports 2024;14(1):13487 
http://dx.doi.org/10.1038/s41598-024-63044-5
  
67. Kim H, Kwon R, Lee H, Lee SW, Rahmati M, Koyanagi AI, et al. Viral load dynamics and shedding 
kinetics of mpox infection: a systematic review and meta-analysis. Journal of travel medicine 
2023;30(5) http://dx.doi.org/10.1093/jtm/taad111
  
68. Kuehn R, Fox T, Guyatt G, Lutje V, Gould S. Infection prevention and control measures to reduce 
the transmission of mpox: A systematic review. PLOS global public health 2024;4(1):e0002731 
http://dx.doi.org/10.1371/journal.pgph.0002731
  
69. Seang S, Burrel S, Todesco E, Leducq V, Monsel G, Le Pluart D. Evidence of human- to-dog 
transmission of monkeypox virus. The Lancet 2022. 
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01487-8/fulltext
  
70. Islam M, Dutta P, .et al. Pathogenicity and virulence of monkeypox at the human-animal-ecology 
interface. Virulence 2023. http://dx.doi.org/10.1080/21505594.2023.2186357   
71. World Health Organization. Surveillance, case investigation and contact tracing for mpox. 2022. 
https://www.who.int/publications/i/item/WHO-MPX-Surveillance-2022.4
  
72. World Health Organization. Surveillance, case investigation and contact tracing for mpox: 
interim guidance, 27 November 2024. 2024. 
https://iris.who.int/bitstream/handle/10665/379643/B09169-eng.pdf
  
73. Johnson RF, Dyall J., Ragland DR, Huzella L., Byrum R., Jett C., et al. Comparative analysis of 
monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial 
inoculation route. J Virol 2011;85(5):2112-25 http://dx.doi.org/10.1128/JVI.01931-10
  
74. Thy M, Peiffer-Smadja N, Mailhe M, Kramer L, Ferré VM, Houhou N, et al. Breakthrough 
Infections after Postexposure Vaccination against Mpox. The New England journal of medicine 
2022;387(26):2477-2479 http://dx.doi.org/10.1056/NEJMc2211944
  
75. Pittman PR, Martin JW, Kingebeni PM, Tamfum J-JM, Mwema G, Wan Q, et al. Clinical 
characterization and placental pathology of mpox infection in hospitalized patients in the 
Democratic Republic of the Congo. PLoS neglected tropical diseases 2023;17(4):e0010384 
http://dx.doi.org/10.1371/journal.pntd.0010384
    
Clinical management and infection prevention and control for mpox 
98 
76. Mellon G, Rubenstein E, Meghann A, Molina J-M, Delaugerre C, LeGoff J. Air detection of 
monkeypox virus in a dedicated outpatient clinic room for monkeypox infection diagnosis. 
Journal of Infection 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546519/   
77. Gould S, Atkinson B, Onianwa O, Spencer A, Furneaux J, Grieves J, et al. Air and surface sampling 
for monkeypox virus in a UK hospital: an observational study. Lancet Microbe. 2022. 
http://dx.doi.org/10.1016/S2666-5247(22)00257-9
  
78. Kisalu NK, Mokili JL. Toward Understanding the Outcomes of Monkeypox Infection in Human 
Pregnancy. J Infect Dis 2017;216(7):795-797 http://dx.doi.org/10.1093/infdis/jix342
  
79. Salvato RS, Ikeda MLR, Barcellos RB, Godinho FM, Sesterhiem P, Bitencourt LCB, et al. Possible 
Occupational Infection of Healthcare Workers with Monkeypox Virus, Brazil. Emerging Infectious 
Disease 2022. http://dx.doi.org/10.3201/eid2812.221343
  
80. Dominik. Evidence of surface contamination in hospital rooms occupied by patients infected 
with monkeypox, Germany, June 2022. https://icpcovid.com/sites/default/files/2022 -07/Ep 272-7 
A Norz Surface contamination with monkeypox in hospitals Eurosurv-27-26-1.pdf  
81. Muller M, Mishra S, McGeer A, Patel S, Gubbay J, Hasso M, et al. Environmental Testing of 
Surfaces in the Room of a Patient With Mpox. Clinical Infectious Disease 2023. 
https://academic.oup.com/cid/article-abstract/76/1/179/6671583
  
82. Wood JP, Choi YW, Wendling MQ, Rogers JV, Chappie DJ. Environmental persistence of vaccinia 
virus on materials. Lett Appl Microbiol 2013;57(5):399-404 http://dx.doi.org/10.1111/lam.12126   
83. Rheinbaben FV, Gebel J, Exner M, Schmidt A. Environmental resistance, disinfection, and 
sterilization of poxviruses. Mercer AA, Schmidt A, Weber O, (Eds.), Poxviruses, null, Birkhäuser 
Basel 2007;397-405 http://dx.doi.org/10.1007/978-3-7643-7557-7_19   
84. High-Contact Object and Surface Contamination in a Household of Persons with Monkeypox 
Virus Infection — Utah, June 2022. http://www.cdc.gov/mmwr/volumes/71/wr/mm7134e1.htm
  
85. Morgan C, Whitehill F, Doty J, Matheny A, Stringer J, Delaney L, et al. Environmental Persistence 
of Monkeypox Virus on Surfaces in Household of Person with Travel-Associated Infection, Dallas, 
Texas, USA, 2021. Emerging Infectious Disease 2022. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514334/
  
86. Hemati S, Mohammadi-Moghadam F. A systematic review on environmental perspectives of 
monkeypox virus. Reviews on environmental health 2024;39(2):363-370 
http://dx.doi.org/10.1515/reveh-2022-0221  
87. Pan D, Nazareth J, Sze S, Martin CA, Decker J, Fletcher E, et al. Transmission of monkeypox/mpox 
virus: A narrative review of environmental, viral, host, and population factors in relation to the 
2022 international outbreak. Journal of medical virology 2023;95(2):e28534 
http://dx.doi.org/10.1002/jmv.28534
  
88. 2022 Mpox (Monkeypox) Outbreak: Global Trends. 2023. 
https://worldhealthorg.shinyapps.io/mpx_global/  
89. Atkinson. Monkeypox virus contamination in an office-based workplace environment. The 
Journal of Hospital Infection 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428113/   
90. Isabel B, Christophe Van D, Jasmine C, Leen V, Eugene B, Fien V, et al. Pre- and asymptomatic 
viral shedding in high-risk contacts of monkeypox cases: a prospective cohort study. medRxiv 
2022. https://www.medrxiv.org/content/10.1101/2022.11.23.22282505v1  
91. Vaughan A., Aarons E., Astbury J., Brooks T., Chand M., Flegg P., et al. Human-to-Human 
Transmission of Monkeypox Virus, United Kingdom, October 2018. Emerg Infect Dis 
2020;26(4):782-785 http://dx.doi.org/10.3201/eid2604.191164
  
References 
99 
92. Carvalho LB, Casadio LV, Polly M, Nastri AC, Turdo AC, de Araujo Eliodoro R, et al. Monkeypox 
Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil. Emerging Infectious 
Disease journal 2022;28(11):2334 http://dx.doi.org/10.3201/eid2811.221323
  
93. Garia VDR, Palacios J, Morcillo A, Duran-Pla E, Rodriguez BS, Lorusso N. Monkeypox outbreak in 
a piercing and tattoo establishment in Spain. The Lancet Infectious Diseases 2022. 
https://www.sciencedirect.com/science/article/pii/S1473309922006521?via%3Dihub&
!  
94. Ward T, Christie R, Paton R, Cumming F, Overton C. Transmission dynamics of monkeypox in the 
United Kingdom: contact tracing study. BMJ 2022. 
https://www.bmj.com/content/379/bmj-2022-
073153  
95. Fuminari M, Jantien A. B, Gini van R, Roisin B, Stjin R, Mariska P, et al. Time scales of human 
monkeypox transmission in the Netherlands. medRxiv 2022. 
https://www.medrxiv.org/content/10.1101/2022.12.03.22283056v1
  
96. Brosius I, Van Dijck C, Coppens J, Vandenhove L, Bangwen E, Vanroye F, et al. Presymptomatic 
viral shedding in high-risk mpox contacts: A prospective cohort study. Journal of medical 
virology 2023;95(5):e28769 http://dx.doi.org/10.1002/jmv.28769  
97. Hoxha A, Kerr SM, Laurenson-Schafer H, Sklenovská N, Mirembe BB, Nezu IH, et al. Mpox in 
Children and Adolescents during Multicountry Outbreak, 2022-2023. Emerging infectious 
diseases 2023;29(10):2125-2129 http://dx.doi.org/10.3201/eid2910.230516  
98. World Health Organization. Multi-country outbreak of mpox, External situation report #47 13 
February 2025. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--
external-situation-report--47---13-february-2025  
99. Epidemiologic and Clinical Features of Children and Adolescents Aged <18 Years with 
Monkeypox — United States, May 17–September 24, 2022. 
https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a4.htm
  
100. Monkeypox virus infections in children in Spain during the first months of the 2022 outbreak. 
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00250-4/fulltext
  
101. World. Considerations for wastewater and environmental surveillance for monkeypox virus: 
Interim guidance. https://www.who.int/publications/i/item/B09178
  
102. Oghuan J, Chavarria C, Vanderwal SR, Gitter A, Ojaruega AA, Monserrat C, et al. Wastewater 
analysis of Mpox virus in a city with low prevalence of Mpox disease: an environmental 
surveillance study. Lancet regional health. Americas 2023;28:100639 
http://dx.doi.org/10.1016/j.lana.2023.100639
  
103. Wong CH, Zhang Z, Eid W, Plaza-Diaz J, Kabir P, Wan S, et al. Rapidly developed, optimized, and 
applied wastewater surveillance system for real-time monitoring of low-incidence, high-impact 
MPOX outbreak. Journal of Water & Health 2023. 
https://iwaponline.com/jwh/article/21/9/1264/97439/Rapidly-developed-optimized-and-
applied-wastewater  
104. World Health Organization. MPOX. 2024. https://www.who.int/news-room/fact-
sheets/detail/mpox  
105. World Health Organization. Second meeting of the International Health Regulations (2005) 
Emergency Committee regarding the upsurge of mpox 2024. 2024. 
https://www.who.int/news/item/28-11-2024-second-meeting-of-the-international-health-
regulations-%282005%29-emergency-committee-regarding-the-upsurge-of-mpox-2024  
106. Bunge E. The changing epidemiology of human monkeypox—A potential threat? A systematic 
review. Plos Negl Trop Dis 2022. http://dx.doi.org/10.1371/journal.pntd.0010141  
Clinical management and infection prevention and control for mpox 
100 
107. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication.1988;6 . 
https://iris.who.int/bitstream/handle/10665/39485/9241561106.pdf  
108. WHO. Proposed case definition for mpox WHO. 2025. https://cdn.who.int/media/docs/default-
source/documents/emergencies/outbreak-toolkit/who-suggested-outbreak-case-
definition3c9e12f0-d346-4583-b34c-99c3a201aa1c.pdf?sfvrsn=521f7713_1  
109. Adams, John, Bartram, Jamie & Chartier, Yves. (2008). Essential environmental health standards 
for health care / edited by John Adams, Jamie Bartram, Yves Chartier. World Health 
Organization. https://iris.who.int/handle/10665/43767  
110. World Health Organization. Strengthening infection prevention and control in primary care: a 
collection of existing standards, measurement and implementation resources. 2021. 
https://www.who.int/publications/i/item/9789240035249
  
111. World Health Organization. Clinical care for severe acute respiratory infection: toolkit: COVID- 19 
adaptation. 2022. https://apps.who.int/iris/handle/10665/331736  
112. WHO. Diagnostic testing for the monkeypox virus (MPXV): interim guidance, 10 May 2024. 2024. 
https://iris.who.int/handle/10665/379547
  
113. WHO. Consolidated guidelines on differentiated HIV testing services. 2024. 
https://www.who.int/publications/i/item/9789240096394
  
114. World Health Organization. Strengthening the global architecture for health emergency 
prevention, preparedness, response and resilience. 
https://www.who.int/publications/m/item/strengthening-the-global-architecture-for-health-
emergency-prevention--preparedness--response-and-resilience  
115. World Health Organization. Infection prevention and control and water, sanitation and hygiene 
measures for home care and isolation for mpox in resource-limited settings: interim operational 
guide. https://www.who.int/publications/i/item/9789240101654
  
116. Adams V, Song J, Shang J, McDonald M, Dowding D, Ojo M, et al. Infection prevention and 
control practices in the home environment: Examining enablers and barriers to adherence 
among home health care nurses. American journal of infection control 2021;49(6):721-726 
http://dx.doi.org/10.1016/j.ajic.2020.10.021
  
117. Brockhaus L, Lötscher C, Labhardt ND. Infection prevention practice in home healthcare: a 
mixed-method study in two Swiss home healthcare organisations. BMC health services research 
2024;24(1):657 http://dx.doi.org/10.1186/s12913-024-11111-y
  
118. WHO. Risk communication and community engagement (RCCE) for monkeypox outbreaks: 
Interim guidance, 24 June 2022. 2022. https://www.who.int/publications/i/item/WHO -MPX-
RCCE-2022.1 
119. Public advice-mpox. https://www.who.int/news-room/public-advice
  
120. World Health Organization. Home care for patients with suspected or confirmed COVID- 19 and 
management of their contacts: interim guidance, 12 August 2020. 2020. 
https://www.who.int/publications/i/item/home-care-for-patients-with-suspected-novel-
coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts  
121. MacLeod C, Braun L, Caruso BA, Chase C, Chidziwisano K, Chipungu J, et al. Recommendations 
for hand hygiene in community settings: a scoping review of current international guidelines. 
BMJ open 2023;13(6):e068887 http://dx.doi.org/10.1136/bmjopen-2022-068887
  
122. Pitol AK, Richards S, Mirindi P, Mahamed HO, Baller A, Hughes GL, et al. Efficacy of laundry 
practices in eliminating monkeypox virus (MPXV) from fabrics. The Journal of infectious diseases 
2024. http://dx.doi.org/10.1093/infdis/jiae606
  
References 
101 
123. Pitol AK, Richards S, Mirindi P, Mahamed HO, Baller A, Hughes GL, et al. Efficacy of Disinfectants 
for Monkeypox Virus Inactivation on High Touch Surface Materials in Low-Resource Settings. 
Environmental science & technology 2024;58(45):19981-19989 
http://dx.doi.org/10.1021/acs.est.4c09821  
124. Butcher W, Ulaeto D. Contact inactivation of orthopoxviruses by household disinfectants. Journal 
of Applied Microbiology 2005. 
https://ami-
journals.onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2672.2005.02601.x  
125. Gerba CP, Kennedy D. Enteric virus survival during household laundering and impact of 
disinfection with sodium hypochlorite. Appl Environ Microbiol 2007;73(14):4425-8 
http://dx.doi.org/10.1128/AEM.00688-07
  
126. Rutala WA, Weber DJ. Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin 
Microbiol Rev 1997;10(4):597-610 http://dx.doi.org/10.1128/CMR.10.4.597  
127. World Health Organisation . Standard precautions: waste management (OpenWHO). 2022.  
128. Ianache I, Skrzat-Klapaczynska A, Jilich D, Fleischhans L, Gmizic I, Ranin J, et al. Mpox across 
countries from Central and Eastern Europe - 2022 outbreak. Travel medicine and infectious 
disease 2024;59:102719 http://dx.doi.org/10.1016/j.tmaid.2024.102719  
129. Clark AE. Validating tools to detect and Inactivate Monkeypox virus in Human milk. Breastfed 
Med 2023. http://dx.doi.org/10.1089/bfm.2023.0175
  
130. Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, et al. Human monkeypox 
virus infection in women and non- binary individuals during the 2022 outbreaks: a global case 
series. Lancet (London, England) 2022;400(10367):1953-1965 
http://dx.doi.org/10.1016/S0140-
6736(22)02187-0  
131. Bragazzi NL, Woldegerima WA, Wu J, Converti M, Szarpak L, Crapanzano A, et al. 
Epidemiological and Clinical Characteristics of Mpox in Cisgender and Transgender Women and 
Non-Binary Individuals Assigned to the Female Sex at Birth: A Comprehensive, Critical Global 
Perspective. Viruses 2024;16(3) http://dx.doi.org/10.3390/v16030325
  
132. Mirembe BB, Kerr SM, Ndumbi P, Ajong B, Le Polain de Waroux O, Pavlin BI, et al. MPOX 
infections among health workers from global surveillance data, January 2022-May 2023. 
Antimicrobial Resistance and Infection Control Conference: 7th International Confe rence on 
Prevention and Infection Control, ICPIC 2023, 12(Supplement 1). 2023. 
https://aricjournal.biomedcentral.com/articles/supplements/volume-12-supplement-1  
133. World Health Organization. Responding to the global mpox outbreak: ethics issues and 
considerations: a policy brief. 
https://www.who.int/publications/i/item/WHO-Mpox-
Outbreak_response-Ethics-2023.1  
134. UK Health Security Agency . Monkeypox cases confirmed in England – latest updates. 2022. 
https://www.gov.uk/government/news/monkeypox-cases-confirmed-in-england-latest-updates  
135. Nigeria Centre for Disease Control. National monkeypox public health response guidelines. 
2019. https://ncdc.gov.ng/themes/common/docs/protocols/96_1577798337.pdf
  
136. France K., Villa A. Acute Oral Lesions. Dermatol Clin 2020;38(4):441-450 
http://dx.doi.org/10.1016/j.det.2020.05.005   
137. WHO. Care of skin lesions in mpox infection. 2025. https://www.who.int/multi-
media/details/care-of-skin-lesions-in-mpox-infection-poster  
138. Flynn M, Mercer D. Oxford Handbook of Adult Nursing. 2018. 
https://doi.org/10.1093/med/9780198743477.001.0001  
Clinical management and infection prevention and control for mpox 
102 
139. WHO. Guideline: updates on the management of severe acute malnutrition in infants and 
children. 2013. https://www.who.int/publications/i/item/9789241506328  
140. World Health Organization. WHO-ICRC Basic Emergency Care: approach to the acutely ill and 
injured. 2018. https://www.who.int/publications/i/item/basic-emergency-care-approach-to-the-
acutely-ill-and-injured  
141. World Health Organization. Pocket book of hospital care for children: guidelines for the 
management of common childhood illnesses. 2013. 
https://www.who.int/publications/i/item/978-92-4-154837-3
  
142. Zinder R., Cooley R., Vlad LG, Molnar JA. Vitamin A and Wound Healing. Nutr Clin Pract 
2019;34(6):839-849 http://dx.doi.org/10.1002/ncp.10420
  
143. World Health Organization. WHO recommendations on antenatal care for a positive pregnancy 
experience. 2016. https://www.who.int/publications/i/item/9789241549912
  
144. World Health Organization. WHO recommendations on maternal and newborn care for a 
positive postnatal experience. 2022. https://www.who.int/publications/i/item/9789240045989
  
145. World Health Organization. Abortion care guideline. 2022. 
https://www.who.int/publications/i/item/9789240039483
  
146. Reynolds MG, McCollum AM, Nguete B., Shongo Lushima R., Petersen BW. Improving the Care 
and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from 
Contemporary Biomedical and Smallpox Biodefense Research. Viruses 2017;9(12) 
http://dx.doi.org/10.3390/v9120380   
147. World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 
https://www.who.int/publications/i/item/9789240062382?%20utm_source=monthly -
newsletter&utm_medium=email&utm_campaign=Feb-2022  
148. Llor C., Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives 
to reduce the problem. Ther Adv Drug Saf 2014;5(6):229-41 
http://dx.doi.org/10.1177/2042098614554919  
149. Duncan H., Hutchison J., Parshuram CS. The Pediatric Early Warning System score: a severity of 
illness score to predict urgent medical need in hospitalized children. J Crit Care 2006;21(3):271 -8 
http://dx.doi.org/10.1016/j.jcrc.2006.06.007  
150. Médecins Sans Frontières. Clinical guidelines: diagnosis and treatment manual. 2021. 
https://medicalguidelines.msf.org/en/viewport/CG/english/cutaneous-abscess-18482406.html  
151. World Health Organization. Guidelines on core components of infection prevention and control 
programmes at the national and acute health care facility level. 
https://iris.who.int/handle/10665/331750
  
152. Centers of Disease Control and Prevention. Hierarchy of Controls. 2023. 
https://www.cdc.gov/niosh/topics/hierarchy/default.html
  
153. World Health Organization. Minimum requirements for infection prevention and control 
programmes. https://iris.who.int/handle/10665/330080
  
154. World Health Organization. Framework and toolkit for infection prevention and control in 
outbreak preparedness, readiness and response at the national level. 2021. 
https://iris.who.int/handle/10665/345251  
155. World Health Organization. Framework and toolkit for infection prevention and control in 
outbreak preparedness, readiness and response at the health care facility level. 
https://www.who.int/publications/i/item/9789240051027
  
References 
103 
156. World Health Organization. WHO guidelines on hand hygiene in health care . 2009. 
https://iris.who.int/handle/10665/44102  
157. Antimicrobial Resistance and Healthcare Associated Infection Scotland . Standard Infection 
Control Precautions Literature review - Footwear. 2021. 
https://www.nipcm.hps.scot.nhs.uk/media/1901/2021-07-22-ppe-footwear-v30-final.pdf  
158. Hall S., Poller B., Bailey C., Gregory S., Clark R., Roberts P., et al. Use of ultraviolet -fluorescence-
based simulation in evaluation of personal protective equipment worn for first assessment and 
care of a patient with suspected high-consequence infectious disease. J Hosp Infect 
2018;99(2):218-228 http://dx.doi.org/10.1016/j.jhin.2018.01.002
  
159. Poller B., Hall S., Bailey C., Gregory S., Clark R., Roberts P., et al. 'VIOLET': a fluorescence -based 
simulation exercise for training healthcare workers in the use of personal protective equipment. 
J Hosp Infect 2018;99(2):229-235 http://dx.doi.org/10.1016/j.jhin.2018.01.021   
160. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, 
service delivery and monitoring: recommendations for a public health approach. 2021. 
https://www.who.int/publications/i/item/9789240031593
  
161. WHO recommendations on Postnatal care of mother and newborn 2013. 
http://www.who.int/publications/i/item/9789241506649
  
162. WHO. Guidelines on optimal feeding of low birth-weight infants in low- and middle-income 
countries. https://www.who.int/publications/i/item/9789241548366  
163. World Health Organization. WHO recommendations on intrapartum care for a positive childbirth 
experience. 2018. https://www.who.int/publications/i/item/9789241550215
  
164. Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, et al. Monkeypox treatment 
with tecovirimat in the Central African Republic under an Expanded Access Programme. medRxiv 
2022;2022.08.24.22279177 http://dx.doi.org/10.1101/2022.08.24.22279177   
165. O'Laughlin K., Tobolowsky FA, Elmor R., Overton R., O'Connor SM, Damon IK, et al. Clinical Use 
of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol 
- United States, May-August 2022. MMWR Morb Mortal Wkly Rep 2022;71(37):1190-1195 
http://dx.doi.org/10.15585/mmwr.mm7137e1
  
166. SIGA . SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® 
(tecovirimat). 2022. https://investor.siga.com/news-releases/news-release-details/siga-receives-
approval-fda-intravenous-iv-formulation-tpoxxr  
167. Fox T, Gould S, Princy N, Rowland T, Lutje V, Kuehn R. Therapeutics for treating mpox in humans. 
2022. https://www.doi.org/10.1002/14651858.CD015769 
168. European Medicines Agency . EMA Tecovirimat-SIGA assessment report. 2022. 
https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga  
169. GlobalNewswire. SIGA announces health Canada regulatory approval of oral TPOXX® SIGA 
Technologies Inc. 2021. 
https://www.globenewswire.com/news-
release/2021/12/01/2344305/9738/en/SIGA-Announces-Health-Canada-Regulatory-Approval-
of-Oral-TPOXX.html  
170. Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, et al. Monkeypox treatment 
with tecovirimat in the Central African Republic under an Expanded Access Programme. medRxiv 
2022;2022.08.24.22279177 http://dx.doi.org/10.1101/2022.08.24.22279177
  
171. World Health Organisation. WHO recommendations: Induction of labour at or beyond term. 
2018;2018. https://iris.who.int/bitstream/handle/10665/363138/9789240052796-eng.pdf
  
Clinical management and infection prevention and control for mpox 
104 
172. World Health Organization. Guidelines for the management of symptomatic sexually transmitted 
infections. 2021. https://www.who.int/publications/i/item/9789240024168  
173. World Health Organization. Doing what matters in times of stress: an illustrated guide. 2020. 
https://www.who.int/publications/i/item/9789240003927
  
174. World Health Organization. mhGAP Humanitarian Intervention Guide (mhGAP-HIG): clinical 
management of mental, neurological and substance use conditions in humanitarian 
emergencies. 2015. https://www.who.int/publications/i/item/9789241548922
  
175. World Health Organization. mhGAP Intervention Guide - version 2.0. 
https://www.who.int/publications/i/item/9789241549790  
176. World Health Organization. mhGAP training manuals for the mhGAP intervention guide for 
mental, neurological and substance use disorders in non-specialized health settings. 2017. 
https://apps.who.int/iris/handle/10665/259161
  
177. World Health Organization. Psychological first aid: Guide for field workers. 2011. 
https://www.who.int/publications/i/item/9789241548205
  
178. Inter-Agency Standing Committee (IASC) . IASC Guidance on Basic Psychosocial Skills – A Guide 
for COVID-19 Responders. 2020. https://interagencystandingcommittee.org/iasc-reference-
group-mental-health-and-psychosocial-support-emergency-settings/iasc-guidance-basic-
psychosocial-skills-guide-covid-19-responders  
179. World Health Organization. Problem Management Plus (PM+): Individual psychological help for 
adults impaired by distress in communities exposed to adversity. 2016. 
https://www.who.int/publications/i/item/WHO-MSD-MER-16.2
  
180. World Health Organization. Optimized supportive care for Ebola virus disease: clinical 
management standard operating procedures. 2019. 
https://apps.who.int/iris/handle/10665/325000
  
181. WHO handbook for guideline development, 2nd Edition. 2014. 
https://www.who.int/publications/i/item/9789241548960
  
182. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction -
GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology 
2011;64(4):383-94 http://dx.doi.org/10.1016/j.jclinepi.2010.04.026
  
183. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to 
recommendations. BMJ (Clinical research ed.) 2008;336(7652):1049-51 
http://dx.doi.org/10.1136/bmj.39493.646875.AE
  
184. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an 
emerging consensus on rating quality of evidence and strength of recommendations. BMJ 
(Clinical research ed.) 2008;336(7650):924-6 http://dx.doi.org/10.1136/bmj.39489.470347.AD
  
185. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. 
Rating the quality of evidence. Journal of clinical epidemiology 2011;64(4):401 -6 
http://dx.doi.org/10.1016/j.jclinepi.2010.07.015  
186. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE 
guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's 
direction and strength. Journal of clinical epidemiology 2013;66(7):726-35 
http://dx.doi.org/10.1016/j.jclinepi.2013.02.003  
187. World Health Organization. Meeting Report Technical working group (TWG) meeting on infant 
feeding and direct contact in Mpox infection. 2024. 
References 
105 
https://files.magicapp.org/guideline/7a056634-975d-442c-9871-
57d650dd990d/files/TWG_report_infant_feeding_mpox_r817816.pdf.  
188. World Health Organization. Technical meeting report - Initiation of antiretroviral therapy in 
people with HIV and mpox. 2024 https://files.magicapp.org/guideline/7a056634-975d-442c-
9871-57d650dd990d/files/TWG_report_HIV_mpox_r817731.pdf. 
189. The WHO Global Clinical Platform for mpox. https://www.who.int/tools/global-clinical-
platform/monkeypox  
190. WHO. Clinical characterization of mpox including monitoring the use of therapeutic 
interventions. Statistical plan 2023. https://iris.who.int/bitstream/handle/10665/373366/WHO-
MPX-Clinical-Analytic_plan-2023.1-eng.pdf  
191. WHO. Diagnostic testing for the monkeypox virus (MPXV): interim guidance, 10 May 2024. 2024. 
https://www.who.int/publications/i/item/WHO-MPX-Laboratory-2024.1  
192. WHO. The WHO Essential Medicines List Antibiotic Book: improving antibiotic AWaReness. 
2022-11-19. 
https://www.who.int/publications/m/item/the-who-essential-medicines-list-
antibiotic-book-improving-antibiotic-awareness  
193. Altmann S., Brandt CR, Murphy CJ, Patnaikuni R., Takla T., Toomey M., et al. Evaluation of 
therapeutic interventions for vaccinia virus keratitis. J Infect Dis 2011;203(5):683-90 
http://dx.doi.org/10.1093/infdis/jiq103
    
194. Semba RD. The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol 
2003;121(5):715-9 http://dx.doi.org/10.1001/archopht.121.5.715
  
 
 
 
Annex 1. WHO case definitions for 
mpox outbreak in non-endemic 
countries 
Surveillance case definitions 
The case definitions for use in this outbreak may be reviewed as more evidence 
becomes available. 
For further guidance on testing please refer to Laboratory testing for the monkeypox 
virus (MPXV): interim guidance 2024 [191]. 
Suspected case 
i) A person who is a contact of a probable or confirmed mpox case in the 21 
days before the onset of signs or symptoms, and who presents with any of 
the following: acute onset of fever (> 38.5°C), headache, myalgia (muscle 
pain/body aches), back pain, profound weakness or fatigue. 
OR 
ii) A person presenting since 1 January 2022 with an unexplained acute skin 
rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin 
rash may include single or multiple lesions in the ano-genital region or 
elsewhere on the body. Mucosal lesions may include single or multiple oral, 
conjunctival, urethral, penile, vaginal or ano-rectal lesions. Ano-rectal 
lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or 
bleeding. 
AND 
For which the following common causes of acute rash or skin lesions do not fully 
explain the clinical picture: varicella zoster, herpes zoster, measles, herpes simplex, 
bacterial skin infections, disseminated gonococcus infection, primary or secondary 
syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum 
contagiosum, allergic reaction (e.g. to plants); and any other locally relevant 
common causes of papular or vesicular rash. 
NB It is not necessary to obtain negative laboratory results for listed common causes of 
rash illness in order to classify a case as suspected. Further, if suspicion of mpox is high 
due to either history and/or clinical presentation or possible exposure to a case, the 
 
 
identification of an alternate pathogen which causes rash illness should not preclude 
testing for MPXV, as co-infections have been identified. 
Probable case 
A person presenting with an unexplained acute skin rash, mucosal lesions or 
lymphadenopathy (swollen lymph nodes). The skin rash may include single or 
multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions 
may include single or multiple oral, conjunctival, urethral, penile, vaginal or ano-rectal 
lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), 
pain and/or bleeding. 
AND 
One or more of the following: 
• Has an epidemiological link to a probable or confirmed case of mpox in the 21 
days before symptom onset. 
• Identifies as gay, bisexual or other cis or trans man who has sex with men. 
• Has had multiple and/or casual sexual partners in the 21 days before symptom 
onset. 
• Has detectable levels of anti-orthopoxvirus (OPXV) IgM antibody (during the 
period of 4–56 days after rash onset); or a four-fold rise in IgG antibody titer 
based on acute (up to day 5–7) and convalescent (day 21 onwards) samples; in the 
absence of a recent smallpox/ mpox vaccination or other known exposure to 
OPXV. 
• Has a positive test result for orthopoxviral infection (e.g. OPXV-specific PCR 
without MPXV-specific PCR or sequencing) . 
Confirmed case 
A person with laboratory-confirmed mpox virus infection by detection of unique 
sequences of viral DNA by real-time polymerase chain reaction (PCR) and/or 
sequencing. 
Discarded case 
A suspected or probable case for which laboratory testing of lesion fluid, skin 
specimens or crusts by PCR and/or sequencing is negative for mpox virus. Conversely, 
a retrospectively detected probable case for which lesion testing can no longer be 
adequately performed (i.e. after the crusts fall off) and no other specimen is found 
PCR-positive, would remain classified as a probable case. A suspected or probable 
 
 
case should not be discarded based on a negative result from an oropharyngeal, anal 
or rectal swab or from a blood test alone. 
1) The person has been exposed to a probable or confirmed mpox case. Please see 
below definition of a contact. 
2) Serology can be used for retrospective case classification for a probable case in 
specific circumstances such as when diagnostic testing through PCR of skin lesion 
specimens has not been possible, or in the context of research with standardized 
data collection. The primary diagnostic test for mpox is PCR of skin lesion material 
or other specimen such as an oral or nasopharyngeal swab as appropriate. 
Serology should not be used as a first-line diagnostic test. 
3) PCR on a blood specimen may be unreliable and should also not be used alone as 
a first-line diagnostic test. If blood PCR is negative and was the only test done, 
this is not sufficient to discard a case that otherwise meets the definition of a 
suspected for probable case. This applies regardless of whether the blood PCR 
was for orthopox viruses or was mpox virus-specific. 
 
 
 
 
Annex 2. Medications and dosages for 
symptomatic care 
Fever – paracetamol 
Adults: 1 g PO/IV every 6–8 hours. Maximum dose 4 g every 24 hours or (max 2 g/24 h if history of 
chronic liver disease). 
Neonates: Oral dose 10–15 mg/kg every 6 hours. Maximum dose 40 mg/kg/day; IV dose 7.5 mg/kg 
every 6 hours, maximum dose 30 mg/kg day. 
All other children: 10–15 mg/kg every 6 hours, maximum dose 60 mg/kg /day. 
Mild pain control – paracetamol 
Adults: 1 g PO/IV every 6–8 hours. Maximum dose 4 g every 24 hours or (max 2 g/24 h if history of 
chronic liver disease). 
Children: Orally or IV 10–15 mg/kg/dose every 4–6 hours as required, maximum usual dose 60 
mg/kg/day, but 90 mg/kg/day can be given for short period with medical supervision. 
Severe pain control – consider to add tramadol (PO or IV) 
Adults: 50–100 mg PO/IV every 4–6 hours as needed, daily maximum 400 mg/day. 
Children > 6 months: 1–2 mg/kg every 4–6 hours, maximum 400 mg/day. 
Severe pain control – consider replacing tramadol for morphine (PO, IV, SC) (oral dose preferred if 
patient can tolerate; only use immediate release tablets for acute pain) 
Adults: Oral dose is 10 mg every 4 hours as needed; maximum dose is 60 mg/day. IV dose is 1–4 mg 
SQ/IV every 4 hours as needed – monitor SBP and RR prior to administration of morphine (hold for 
low SBP or respiratory rate). 
Children: Oral dose is 0.2–0.4 mg/kg/dose every 4 hours. Titrate dose to pain. IV dose is 0.05–0.1 
mg/kg/dose every 4–6 hours as required. 
Antihistaminic for itching 
Adults: Loratadine 10 mg PO once daily. 
Children (> 30 kg): Loratadine 10 mg PO once daily. 
Nausea and vomiting 
Ondansetron (associated with QT prolongation, thus it is important to note other medications that 
may also prolong the QT interval and to monitor regularly with ECGs if available). 
Adults: 8 mg PO every 12 hours or 4 mg IV every 8 hours as needed. 
Children: 0.15 mg/kg orally or IV 0.15 mg/kg every 12 hours, maximum dose 8 mg. 
Promethazine 
Only for adults: 12.5–25 mg orally every 4–6 hours as needed (can prolong QT interval). 
Dyspepsia 
Adult: Omeprazole 40 mg PO/IV every 24 hours. 
Child: Omeprazole: 5–10 kg: 5 mg once daily; 10–20 kg: 10 mg once daily; ≥ 20 kg: 20 mg once daily. 
Diarrhoea 
Diarrhoea should be managed conservatively. The use of anti-motility agents is not generally 
recommended given the potential for ileus. 
 
 
Anxiety 
This may be a symptom patients experience particularly related to being in isolation or due to 
worsening symptoms. 
First-line therapy is to talk with a mental health counsellor. 
For moderate to severe anxiety, diazepam can be considered, but an evaluation of the patient’s 
mental status should precede its use. 
Benzodiazepines should not be given to patients with altered mentation. 
Adults: Diazepam 5–10 mg PO every 8 hours as needed as long as mentation is unaffected. 
Children: Diazepam 0.05–0.1 mg/kg PO every 6 hours as needed. Continual supervision by a health 
aid is indicated to keep the child calm. Sedatives should only be used if necessary to perform 
procedures and give interventions. 
Agitation 
If patient is agitated and becomes a danger to self, health care providers or other patients, consider 
pharmacotherapy. 
Adults: Diazepam 2–10 mg PO/IV every 6–8 hours as needed as long as patient can protect their 
airway. 
Adults: Haloperidol 0.5–5 mg every 4–6 hours, as needed. 
Children > 6 years: Haloperidol IM 1–3 mg every 4–8 hours, as needed. 
Children 3–6 years: Haloperidol PO 0.01–0.03 mg/kg once daily. 
Haloperidol is associated with QT prolongation, thus it is important to note other medications that 
may also prolong the QT interval and to monitor with ECG regularly if available. 
Note: Avoid the use of salicylates (e.g. aspirin) in children and adolescents < 18 years of age to avoid 
the development of Reye’s Syndrome. 
  
 
 
Annex 3. Antimicrobial 
recommendations and dosages for 
secondary bacterial skin infection 
This is for the treatment of impetigo, erysipelas or cellulitis caused by a bacterial 
pathogen. It excludes skin infections caused by viral, fungal or parasitic pathogens, 
necrotizing fasciitis, pyomyositis, severe infections with sepsis and surgical site 
infections. 
For further guidance on WHO recommendations for antimicrobial therapy please 
consult The WHO Essential Medicines List antibiotic 
book: improving antibiotic 
AWaReness [147]and The WHO Essential Medicines List antibiotic book: infographics. 
[192] 
Adults 
Antibiotic Dose 
Cloxacillin (flucloxacillin)  500 mg orally every 8 hours 
Cephalexin 500 mg orally every 8 hours 
Amoxicillin-clavulanic acid 500–125 mg orally every 8 hours 
  
If concern for community acquired MRSA consider following treatment: 
Clindamycin 600 mg orally every 8 hours 
Trimethoprim-sulfamethoxazole 800–160 mg orally every 12 hours 
Doxycycline 100 mg orally every 12 hours 
Note: In the case of penicillin or beta-lactam allergy: use clindamycin or trimethoprim-sulfamethoxazole.  
Children 
Weight Amoxicillin-clavulanic acid Cefalexin Cloxacillin (flucloxacillin) 
 40–50 mg/kg/dose of 
amoxicillin component 
every 12 hours OR 
30 mg/kg/dose every 8 hours 
orally 
25 mg/kg/dose 
every 12 hours orally 
in neonates: 25–50 
mg/kg/dose twice daily; 
in children: 25 mg/kg/dose 
every 6 hours 
3 < 6 kg 250 mg of amoxicillin/dose 
twice daily 
125 mg every 12 hours 125 mg every 6 hours 
6 < 10 kg 375 mg of amoxicillin/dose 
twice daily 
250 mg every 12 hours 250 mg every 6 hours 
 
 
10 < 15 kg 500 mg of amoxicillin/dose 
twice daily 
375 mg every 12 hours 375 mg every 6 hours 
15 < 20 kg 750 mg of amoxicillin/dose 
twice daily 
500 mg every 12 hours 500 mg every 6 hours 
20 < 30 kg 1000 mg of amoxicillin/dose 
twice daily 
625 mg every 12 hours 750 mg every 6 hours 
> 30 kg Use adult dose Use adult dose Use adult dose 
Note: If concern for community-acquired MRSA consider clindamycin: neonates 5 mg/kg/dose every 8 
hours; children 10 mg/kg/dose every 8 hours. 
  
 
 
Annex 4. Mpox care pathway 
 
  

 
 
Annex 5. Search strategy and 
terminology for reported routes of 
MPXV infection 
A commissioned systematic in 2024 review underpins the current guideline and is an 
update of a previously published review. It synthesized and updated evidence for the 
three research questions. The review occurred in two stages. The first stage appraised 
available evidence from comparative interventional trials, which yielded no evidence. 
In the absence of such data, the second stage was preformed to synthesize evidence 
on the reported routes of MPXV infection using non-comparative study designs to 
indirectly inform the three IPC intervention review questions. 
Literature search strategy 
The search was done at the end of September 2024 using broad search terms 
including terms for mpox-like viruses. The search included the following databases: 
MEDLINE (OVID), Embase (OVID), Biosis previews (Web of Science), CAB Abstracts 
(Web of Science) and Global Index Medicus. 
Inclusion and exclusion criteria 
All studies published in English and French between September 2022 and September 
2024 that presented data on the mpox mode of transmission were eligible to be 
included. Both comparative and non-comparative studies in different settings (health 
care, households, congregate-living/community settings) were included. The 
following mpox studies were excluded; studies without transmission data, studies 
solely concerning animal-to-animal or animal-to-human transmission, studies solely 
examining laboratory transmission, non-original studies, and studies that published in 
a language other than English and French. 
Given the potential for varying interpretations of key terminology, the following 
descriptions were used for the purpose of the systematic review: 
i) Fully healed: mpox lesions have crusted, scabs have fallen off and a fresh layer of 
skin has formed underneath. 
ii) Infectious period: until mpox lesions have crusted, scabs have fallen off and a 
fresh layer of skin has formed underneath. 
 
 
iii) Isolation: the separation of infected people with a contagious disease from people 
who are not infected by keeping to a separate room or area within the home. 
iv) Adequate ventilation in a single patient room: may be achieved by mechanical, 
natural or hybrid ventilation. 
• Mechanical ventilation rate: six air changes per hour in room. 
• Natural ventilation rate: 60 L/sec per patient. 
• Hybrid (mixed mode) ventilation is a combination of both mechanical and 
natural ventilation. It relies on natural driving forces to provide the desired 
(design) flow rate. Mechanical ventilation can be used when the natural 
ventilation flow rate is too low. 
v) Airborne isolation room ventilation: mechanical ventilation to meet criteria for an 
airborne precaution room: negative pressure is created to control the direction of 
airflow. The ventilation rate should be at least 12 ACH. 
Natural ventilation to meet criteria for an airborne precaution room: the airflow 
should be directed to areas free of transit or should permit the rapid dilution of 
contaminated air into the surrounding areas and the open air. The average ventilation 
rate should be 160 litres/second per patient. 
From the data collected from stage two, several subgroup analyses were conducted 
based on different contexts: 
• Setting: Review considered: household, congregate living, or health care settings 
community settings. 
• Clade (where known or presumed): The analysis included Clade I, Clade II, and its 
subtypes Clade IIa and Clade IIb (and all sub lineages, including but not limited to 
IIb.lineage A, IIb.lineage B, and IIb.lineage C). 
• Route of transmission: Transmission routes were analysed based on the 
information detailed in the paper(s). 
• Region and/or country: Data were categorized by WHO regions, including the 
African Region, Region of the Americas, South-East Asia Region, European Region, 
Eastern Mediterranean Region and the Western Pacific Region. 
• Context: Cases reported in the global mpox outbreak since 2022, categorized as 
the West African clade, were classified as likely Clade IIb unless evidence emerged 
to the contrary. 
The review conducted in 2024 followed a similar search strategy as the one in 2023, 
the main difference being the extended timeframe. 
 
 
 
 
Annex 6. Optimized supportive care 
measures 
Complication Treatment 
Skin exfoliation • Patients with heavy rash burden may develop exfoliation (in severe cases similar to 
partial thickness burns), which can be significant leading to dehydration and 
protein loss [146]. 
• Estimate percentage skin affected and consider treatment like burns. 
• Minimize insensible fluid loss and promote skin healing. 
• Ensure adequate hydration and nutrition. 
• Obtain consultation with appropriate consultants such as surgeon, dermatologist 
and/or wound care specialists. 
• Bedside or surgical debridement as needed. 
• Skin grafting in rare and severe cases 
Necrotizing soft 
tissue infection 
• This is a life-threatening condition of the deep soft tissue that affects the muscle 
fascia which causes necrosis, tissue destruction and systemic toxicity. Suspect if 
patient develops oedema, crepitus, malodorous discharge or pain out of 
proportion to appearance of infection. Though can be caused by mpox virus, 
consider bacterial pathogens as well. Start broad spectrum antibiotics to cover 
Staphylococcus sp. and Streptococcus sp. Consult surgeon for further 
management. 
• See the WHO Essential Medicines List antibiotic book for guidance on correct 
antimicrobial selection and appropriate use [192]. 
Pyomyositis • This occurs when pus develops within the muscle and should be suspected when 
the patient has muscle tenderness. Though this can be caused by mpox virus, it 
may also commonly be caused by skin flora such as Staphylococcus sp. or 
Streptococcus sp. [141,192]. Ultrasound can assist in diagnosis. Collect blood 
cultures, start broad spectrum antibiotics, and proceed to surgical incision and 
drainage. Send sample for microbiology and culture to support antimicrobial 
therapy selection. 
• See the WHO Essential Medicines List antibiotic book for guidance on correct 
antimicrobial selection and appropriate use [192]. 
Cervical 
adenopathy 
• Can occur in up to 85% of cases with lymphadenopathy [33]. 
• When large cervical adenopathy is combined with multiple oropharyngeal lesions 
patients may be at risk for complications such as respiratory compromise and 
retropharyngeal abscesses. Patients are also at risk for dehydration due to 
decreased food and water intake [33,146]. 
• Obtain consultation with appropriate specialists, such as surgeon, ENT, 
anesthesiologist and infectious disease clinicians. Under their care, in severe cases, 
steroids may be used [33]. 
Ocular lesions • One of the most significant sequelae of mpox is corneal scarring and loss of vision 
[29,85,146,63,135]. 
• Patients may present with non-specific ocular symptoms such as conjunctivitis. 
• Eye care with ophthalmologist evaluation [135]. 
• Ophthalmic antibiotics/antivirals if indicated for co-infection. 
 
 
• Vitamin A supplementation, especially to malnourished children [141]. 
• Good eye care that includes eye lubrication and saline-soaked protective eye pads 
[141]. 
• Avoid steroid ointments (may prolong presence of mpox virus in ocular tissue) 
[146,193]. 
• Trifluridine eye drops (sometimes used for other orthopoxviruses or herpetic eye 
infections) may be considered to hasten resolution of symptoms and prevent 
long-term damage from scarring, where available [146,63,193,194]. 
Pneumonia • Manage according to the WHO Clinical care for severe acute respiratory infection 
toolkit [ 111] . 
• See the WHO Essential Medicines List antibiotic book for guidance on correct 
antimicrobial selection and appropriate use [192]. 
Acute respiratory 
distress syndrome 
(ARDS) 
• Oxygen, non-invasive ventilation, mechanical ventilation. 
• Manage according to the WHO Clinical care for severe acute respiratory infection 
toolkit [111]. 
Severe 
dehydration 
• Severe dehydration and hypovolemic shock can be seen in patients with mpox 
due to intravascular volume loss due to extensive rash and/or gastrointestinal 
losses due to diarrhoea and vomiting accompanied by poor oral intake. 
• The treatment for severe dehydration is resuscitation with intravenous or 
intraosseous (IV/IO) fluid, given as one or multiple boluses with close monitoring 
of fluid responsiveness. Adequate IV fluid intake refers to the volume that will 
correct signs of hypovolemia. See Pocket book of hospital care for children 
[146,141]. 
Sepsis and septic 
shock 
• Sepsis and septic shock differ from severe dehydration as it results from an 
immune response to an infection. Management of sepsis requires early 
identification, management of infection and supportive care, including fluid 
resuscitation to maintain organ perfusion to reduce and prevent further organ 
injury; and may also require vasopressors as well as control of infection [146]. 
• See the WHO Clinical care for severe acute respiratory infection toolkit for more 
information about sepsis [111]. 
• See the WHO Essential Medicines List antibiotic book for guidance on correct 
antimicrobial selection and appropriate use [192]. 
Encephalitis • Consider lumbar puncture for cerebrospinal fluid (CSF) evaluation to evaluate for 
other treatable conditions. 
• Monitor and assess airway, breathing, circulation, disability (ABCD) and give 
emergency treatments. 
• Monitor neurological status (AVPU). 
• Control seizures with anti-epileptics [135]. 
• Antibiotics/antivirals if indicated for co-infections. 
• See WHO Essential Medicines List antibiotic book for guidance on correct 
antimicrobial selection and appropriate use [192]. 
 
 
Nutritional 
considerations 
• Assess the nutritional status of all patients. If food intake is limited due to 
weakness, the patient should be assisted with feeding by a health care provider. If 
the patient is unable to tolerate oral nutrition, consider enteral nutrition. The 
placement of a nasogastric tube by an experienced provider could be considered 
along with nasogastric feeding. Always ensure proper placement of nasogastric 
tube before administering feeds to avoid risk of aspiration. 
Paediatric mpox patients diagnosed with severe acute malnutrition should be treated 
according to the national protocol on management of severe acute malnutrition.  
• Take special care with patients at risk for refeeding (critically unwell, low BMI, 
reduced food intake for > 5 days, a history of alcohol abuse or receiving the 
following drugs: insulin, chemotherapy, antacids or diuretics) and start enteral 
feeding slowly with close monitoring. 
• Patients with reduced levels of consciousness are at risk for aspiration and should 
not be forced to eat. If severe malnutrition is present, refer to 
WHO published 
guidelines [135,141]. 
Clinical management of complications and severe forms of mpox  
 
 
Annex 7. Systematic monitoring of 
patients 
Vital signs and 
pain assessment 
Temperature, heart rate, blood pressure, respiratory rate, peripheral oxygen 
saturation, level of consciousness using the alert, voice, pain, unresponsive 
scale (AVPU), point of care glucose, and body weight and height to calculate 
BMI and children’s mid-upper arm circumference (MUAC) 
Pain scale 
General 
condition 
• Is the patient able to eat and drink without support? 
• Is the patient able to sit and walk independently? 
• Has the patient had recent weight loss since onset of symptoms? 
Rash 
characterization 
• Stage of rash: macules, papules, vesicles, pustules, crusted over, exfoliation 
• Location of the rash (face, arms, torso, genitals, legs, mucosa) 
• Number of lesions [59,107]: 
• Mild (< 25 skin lesions) 
• Moderate (25–99 skin lesions) 
• Severe (100–250 skin lesions) 
• Very severe (> 250 skin lesions) 
• If exfoliation present: % body affected (> 10% is concerning) 
Presence of 
bacterial 
secondary 
infection 
• Cellulitis, abscess, pyomyositis, necrotizing soft tissue infection 
Neurologic status • AVPU, seizures, coma 
Volume status • Presence of dehydration: mild, moderate, or severe 
Signs of 
perfusion 
• Pulse rate, strength, capillary refill 
• Urine output (> 0.5 mL/kg/h = good in adults; 1.0 mL/kg/h in children) 
• Mottling of skin 
Respiratory 
system 
• Respiratory rate, SpO2, signs of respiratory distress 
Nutritional 
assessment 
• Change in appetite, weight loss, body weight, height, calculation of BMI, MUAC 
in children 
• Signs of malnutrition – use standardized tool (e.g. Malnutrition Universal 
Screening Tool) 
Ophthalmologica
l examination 
• One of the most frequent complications, for early diagnosis and management 
Laboratory tests • Hematology: white blood count, haemoglobin, platelet. Biochemistry: urea, 
creatinine, ALT, AST, glucose, albumin. Electrolytes: sodium, potassium, 
bicarbonate, calcium, chloride. Coagulation: prothrombin time/INR. 
Vital signs and clinical features to monitor systematically (Source: This table is modified from the 
WHO Optimized supportive care for Ebola virus disease [180] and includes information from the 
WHO Pocket book of hospital care for children [141]). 
 
 
 
 
121 
 Clinical practice guidelines for influenza 
 
 
World Health Organization 
Avenue Appia 20 
1211 Geneva 27 
Switzerland 
 
cmtm@who.int 
